poor AND prognosis prognosis AND brain brain AND tumor
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: Brain metastases (BMs) from colorectal cancer are rare (2-3%). They usually occur in advanced stages of the disease and their prognosis is poor. The aim of this study was to assess the impact of surgical resection of BMs from colorectal cancer in terms of overall survival. PATIENTS AND METHODS: A retrospective bi-centric study included all patients with resected BMs from primary colorectal adenocarcinoma from 1998 to 2009. RESULTS: Twenty-eight patients [13 males, median: 62 (range: 44-86) years old) were included. Fifteen patients presented with other metastatic sites (lung, liver). BMs were metachronous in 16/28 (57%) of patients [median: 19 months (range: 7-97)]. Median overall survival reached 12 months. Brain recurrences occurred in 32% of patients and were treated by curative intent in 5/9 cases. CONCLUSION: When indicated, an aggressive management based on surgical resection of BMs from colorectal cancer, must be performed, in order to improve overall survival to at least 12 months.","fulltextAvailable":false,"journal":"Anticancer research","meshAnnotations":{"@type":"java.util.ArrayList"},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adult","Aged","Aged, 80 and over","Brain Neoplasms","Colorectal Neoplasms","Female","Humans","Male","Middle Aged","Retrospective Studies","Survival Analysis"]},"pmid":"24324111","title":"Patients with brain metastases from colorectal cancer are not condemned.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: Colorectal cancer infrequently causes brain metastasis, and the prognosis is poor. OBJECTIVE: The aim of this study was to identify the prognostic factors associated with survival and outcome of treatment for patients with brain metastasis from colorectal cancer. DESIGN: This is a retrospective study from a prospectively collected database. SETTINGS: The investigation took place in a high-volume multidisciplinary tertiary cancer center in Japan. PATIENTS: From 1979 to 2010, 113 consecutive patients who were treated for brain metastasis from colorectal cancer were identified. MAIN OUTCOME MEASURES: The primary outcome measure was overall survival. RESULTS: Sixty-three patients had neurosurgical resection (including curative resection for 46 patients) followed by whole brain radiotherapy, 9 had stereotactic radiosurgery, 30 had whole brain radiotherapy, and 11 had steroid and palliative care. As a whole, the overall median survival time from diagnosis of brain metastasis was 5.4 months (95% CI, 4.3-7.6 months), and the 1-year survival rate was 29% (95% CI, 22%-38%). In the group of patients who underwent curative neurosurgical resection, the overall median survival time was 15.2 months (95% CI, 9.2-17.8 months), and the 1-year survival rate was 57% (95% CI, 43%-71%). On multivariate analysis, 1 or 2 brain metastatic lesions, no extracranial metastatic lesions, and neurosurgical resection were independent favorable prognostic factors overall (p = 0.0057, 0.0197, and <0.0001), and 1 or 2 brain metastatic lesions, no extracranial metastatic lesion, and no emergence of secondary brain metastatic lesions were independent favorable prognostic factors in the group of patients who underwent curative neurosurgical resection (p = 0.0137, 0.0081, and 0.0010). LIMITATIONS: This study was limited by its single-institute, retrospective, nonrandomized design and selection bias. CONCLUSIONS: Neurosurgical resection in select patients is a reasonable option for brain metastasis from colorectal cancer, although it is not associated with long-term (5-year) survival. (see Video, Supplemental Digital Content 1, http://links.lww.com/DCR/A121 ).","fulltextAvailable":false,"journal":"Diseases of the colon and rectum","meshAnnotations":{"@type":"java.util.ArrayList"},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adult","Aged","Aged, 80 and over","Brain Neoplasms","Colorectal Neoplasms","Female","Follow-Up Studies","Humans","Male","Middle Aged","Neurosurgical Procedures","Prognosis","Retrospective Studies","Survival Analysis","Treatment Outcome"]},"pmid":"24316946","title":"Prognostic factors and treatment effects in patients with curatively resected brain metastasis from colorectal cancer.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Despite therapeutic advances, the development of breast cancer brain metastases (BCBM) is still the harbinger of a dismal prognosis. Patient outcomes vary depending on factors, including tumor phenotype, extent of disease within and outside the brain, as well as patient performance status. Treatment includes surgery, radiation therapy and systemic therapy determined by patient and tumor characteristics. Despite these approaches, novel treatments are needed and there is growing interest in systemic therapies. However, the efficacy of pharmacologic agents is hampered by poor penetration of drugs across the blood-brain barrier. Therefore, there is a pressing need for a greater understanding of the natural history of BCBM to guide the development of further therapies. This review analyzes prognosis and treatment of BCBM by tumor phenotype and discusses ongoing research into new therapies.","fulltextAvailable":false,"journal":"Expert review of anticancer therapy","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Breast Neoplasms","uri":{"id":"D001943","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blood-Brain Barrier","uri":{"id":"D001812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Natural History","uri":{"id":"D019021","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"History","uri":{"id":"D006664","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Metastasis","uri":{"id":"D009362","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phenotype","uri":{"id":"D010641","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiation","uri":{"id":"D011827","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"General Surgery","uri":{"id":"D013502","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nature","uri":{"id":"D019368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Penetrance","uri":{"id":"D019683","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antineoplastic Agents","uri":{"id":"D000970","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Treatment Outcome","uri":{"id":"D016896","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blood-Brain Barrier","uri":{"id":"D001812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Breast Neoplasms","uri":{"id":"D001943","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Antineoplastic Agents","Blood-Brain Barrier","Brain Neoplasms","Breast Neoplasms","Female","Humans","Prognosis","Treatment Outcome"]},"pmid":"24308683","title":"Brain metastases in breast cancer.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: Malignant brain tumors in children generally have a very poor prognosis when they relapse and improvements are required in their management. It can be difficult to accurately diagnose abnormalities detected during tumor surveillance, and new techniques are required to aid this process. This study investigates how metabolite profiles measured noninvasively by (1)H magnetic resonance spectroscopy (MRS) at relapse reflect those at diagnosis and may be used in this monitoring process. METHODS: Single-voxel MRS (1.5 T, point-resolved spectroscopy, echo time 30 ms, repetition time 1500 ms was performed on 19 children with grades II-IV brain tumors during routine MRI scans prior to treatment for a suspected brain tumor and at suspected first relapse. MRS was analyzed using TARQUIN software to provide metabolite concentrations. Paired Student's t-tests were performed between metabolite profiles at diagnosis and at first relapse. RESULTS: There was no significant difference (P > .05) in the level of any metabolite, lipid, or macromolecule from tumors prior to treatment and at first relapse. This was true for the whole group (n = 19), those with a local relapse (n = 12), and those with a distant relapse (n = 7). Lipids at 1.3 ppm were close to significance when comparing the level at diagnosis with that at distant first relapse (P = .07, 6.5 vs 12.9). In 5 cases the MRS indicative of tumor preceded a formal diagnosis of relapse. CONCLUSIONS: Tumor metabolite profiles, measured by MRS, do not change greatly from diagnosis to first relapse, and this can aid the confirmation of the presence of tumor.","fulltextAvailable":false,"journal":"Neuro-oncology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Magnetic Resonance Imaging","uri":{"id":"D008279","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Magnetic Resonance Spectroscopy","uri":{"id":"D009682","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Child","uri":{"id":"D002648","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lipids","uri":{"id":"D008055","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Recurrence","uri":{"id":"D012008","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Software","uri":{"id":"D012984","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Spectrum Analysis","uri":{"id":"D013057","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Students","uri":{"id":"D013334","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adolescent","uri":{"id":"D000293","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Child","uri":{"id":"D002648","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Child, Preschool","uri":{"id":"D002675","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Follow-Up Studies","uri":{"id":"D005500","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Infant","uri":{"id":"D007223","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Infant, Newborn","uri":{"id":"D007231","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Recurrence, Local","uri":{"id":"D009364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Retrospective Studies","uri":{"id":"D012189","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Magnetic Resonance Spectroscopy","uri":{"id":"D009682","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Metabolomics","uri":{"id":"D055432","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Grading","uri":{"id":"D060787","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adolescent","Brain Neoplasms","Child","Child, Preschool","Female","Follow-Up Studies","Humans","Infant","Infant, Newborn","Magnetic Resonance Spectroscopy","Male","Metabolomics","Neoplasm Grading","Neoplasm Recurrence, Local","Prognosis","Retrospective Studies"]},"pmid":"24305716","title":"Diagnosing relapse in children's brain tumors using metabolite profiles.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVE: To evaluate the outcome of management of intraventricular lesions operated by an open transcortical (nonendoscopic) approach. STUDY DESIGN: Case series. PLACE AND DURATION OF STUDY: Department of Neurosurgery, Dow University of Health Sciences and Civil Hospital, Karachi, from January 2009 to December 2011, with six months follow-up. METHODOLOGY: All cases with lesions in the lateral ventricle and anterior third ventricle operated by open transcortical approach, were included after informed consent. Total excision of the lesion was attempted in all cases. Patients were analyzed for outcome in terms of establishment of diagnosis, completeness of resection, morbidity and mortality. RESULTS: A total of 33 patients were operated. Twenty three were males and 10 were females. Colloid cyst was diagnosed in 14 patients (42%), giant cell astrocytoma and choroid plexus papilloma in 4 cases each and subependymoma and central neurocytoma in 2 cases each, epidermoid, choroid plexus carcinoma, oligodendroglioma, metastasis, meningioma, ependymoma and cavernous hemangioma in one patient each. The overall outcome could be labeled as good in 24 out of 33 cases (73%) and in 8 cases (24%) it was fair. One patient died due to ventriculitis and was categorized as poor outcome (3%). Postoperative complications included meningitis, seizures, intraventicular haemorrhage, subdural collection and transient hemiparesis. Nine patients had persistent hydrocephalus requiring ventriculoperitoneal shunt. CONCLUSION: Conventional open transcortical approach is still effective in getting conclusive biopsy or near total excision of the lesion with minimum morbidity.","fulltextAvailable":false,"journal":"Journal of the College of Physicians and Surgeons--Pakistan : JCPSP","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Postoperative Complications","uri":{"id":"D011183","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Giant Cells","uri":{"id":"D015726","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Choroid Plexus","uri":{"id":"D002831","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemangioma, Cavernous","uri":{"id":"D006392","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Informed Consent","uri":{"id":"D007258","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ventriculoperitoneal Shunt","uri":{"id":"D017287","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neurocytoma","uri":{"id":"D018306","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Papilloma, Choroid Plexus","uri":{"id":"D020288","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Third Ventricle","uri":{"id":"D020542","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lateral Ventricles","uri":{"id":"D020547","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Colloid Cysts","uri":{"id":"D056364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biopsy","uri":{"id":"D001706","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carcinoma","uri":{"id":"D002277","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Choroid","uri":{"id":"D002829","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Choroiditis","uri":{"id":"D002833","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Civilization","uri":{"id":"D002962","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Colloids","uri":{"id":"D003102","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitalization","uri":{"id":"D006760","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals","uri":{"id":"D006761","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Meninges","uri":{"id":"D008578","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Meningioma","uri":{"id":"D008579","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Meningism","uri":{"id":"D008580","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Meningitis","uri":{"id":"D008581","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Morbidity","uri":{"id":"D009017","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mortality","uri":{"id":"D009026","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Metastasis","uri":{"id":"D009362","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oligodendroglioma","uri":{"id":"D009837","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Science","uri":{"id":"D012586","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Seizures","uri":{"id":"D012640","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Universities","uri":{"id":"D014495","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Complicity","uri":{"id":"D028661","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Astrocytoma","uri":{"id":"D001254","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ependymoma","uri":{"id":"D004806","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemangioma","uri":{"id":"D006391","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hydrocephalus","uri":{"id":"D006849","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neurosurgery","uri":{"id":"D009493","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Papilloma","uri":{"id":"D010212","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Paresis","uri":{"id":"D010291","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neurocytoma","uri":{"id":"D018306","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma, Subependymal","uri":{"id":"D018315","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Caves","uri":{"id":"D059552","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Postoperative Complications","uri":{"id":"D011183","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prospective Studies","uri":{"id":"D011446","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Time Factors","uri":{"id":"D013997","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Treatment Outcome","uri":{"id":"D016896","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biopsy","uri":{"id":"D001706","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cerebral Ventricle Neoplasms","uri":{"id":"D002551","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cysts","uri":{"id":"D003560","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neurosurgical Procedures","uri":{"id":"D019635","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Third Ventricle","uri":{"id":"D020542","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Colloid Cysts","uri":{"id":"D056364","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adult","Biopsy","Cerebral Ventricle Neoplasms","Colloid Cysts","Cysts","Female","Humans","Male","Middle Aged","Neurosurgical Procedures","Postoperative Complications","Prospective Studies","Third Ventricle","Time Factors","Treatment Outcome"]},"pmid":"24304988","title":"Outcome of open transcortical approach in the management of intraventricular lesions.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND & AIM: Brain metastases are frequent in patients with metastatic melanoma, indicating poor prognosis. We investigated the BRAF kinase inhibitor vemurafenib in patients with advanced melanoma with symptomatic brain metastases. METHODS: This open-label trial assessed vemurafenib (960mg twice a day) in patients with BRAF(V600) mutation-positive metastatic melanoma with non-resectable, previously treated brain metastases. The primary end-point was safety. Secondary end-points included best overall response rate, and progression-free and overall survival. RESULTS: Twenty-four patients received vemurafenib for a median treatment duration of 3.8 (0.1-11.3) months. The majority of discontinuations were due to disease progression (n=22). Twenty-three of 24 patients reported at least one adverse event (AE). Grade 3 AEs were reported in four (17%; 95% confidence interval [CI], 4.7-37.4%) patients and included cutaneous squamous cell carcinoma in four patients. Median progression-free survival was 3.9 (95% CI, 3.0-5.5) months, and median survival was 5.3 (95% CI, 3.9-6.6) months. An overall partial response (PR) at both intracranial and extracranial sites was achieved in 10 of 24 (42%; 95% CI, 22.1-63.4) evaluable patients, with stable disease in nine (38%; 95% CI, 18.8-59.4) patients. Of 19 patients with measurable intracranial disease, seven (37%) achieved >30% intracranial tumour regression, and three (16%; 95% CI, 3.4-39.6%) achieved a confirmed PR. Other signs of improvement included reduced need for corticosteroids and enhanced performance status. CONCLUSIONS: Vemurafenib can be safely used in patients with advanced symptomatic melanoma that has metastasised to the brain and can result in meaningful tumour regression.","fulltextAvailable":false,"journal":"European journal of cancer (Oxford, England : 1990)","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carcinoma, Squamous Cell","uri":{"id":"D002294","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carcinoma, Squamous Cell","uri":{"id":"D002294","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pilot Projects","uri":{"id":"D010865","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Confidence Intervals","uri":{"id":"D016001","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Disease Progression","uri":{"id":"D018450","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Disease-Free Survival","uri":{"id":"D018572","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proto-Oncogene Proteins B-raf","uri":{"id":"D048493","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carcinoma","uri":{"id":"D002277","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Melanoma","uri":{"id":"D008545","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Metastasis","uri":{"id":"D009362","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phosphotransferases","uri":{"id":"D010770","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Safety","uri":{"id":"D012449","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adrenal Cortex Hormones","uri":{"id":"D000305","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Indoles","uri":{"id":"D007211","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Melanoma","uri":{"id":"D008545","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mutation","uri":{"id":"D009154","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pilot Projects","uri":{"id":"D010865","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Skin Neoplasms","uri":{"id":"D012878","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sulfonamides","uri":{"id":"D013449","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Treatment Outcome","uri":{"id":"D016896","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Disease Progression","uri":{"id":"D018450","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Young Adult","uri":{"id":"D055815","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Metastasis","uri":{"id":"D009362","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Protein Kinase Inhibitors","uri":{"id":"D047428","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proto-Oncogene Proteins B-raf","uri":{"id":"D048493","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adult","Aged","Brain Neoplasms","Disease Progression","Female","Humans","Indoles","Male","Melanoma","Middle Aged","Mutation","Neoplasm Metastasis","Pilot Projects","Protein Kinase Inhibitors","Proto-Oncogene Proteins B-raf","Skin Neoplasms","Sulfonamides","Treatment Outcome","Young Adult"]},"pmid":"24295639","title":"Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVE: Brain metastases in primary breast cancer patients are considerable sources of morbidity and mortality. Gamma knife radiosurgery (GKRS) has gained popularity as an up-front therapy in treating such metastases over traditional radiation therapy due to better neurocognitive function preservation. The aim of this study was to clarify the prognostic factors for local tumor control and survival in radiosurgery for brain metastases from primary breast cancer. METHODS: From March 2001 to May 2011, 124 women with metastatic brain lesions originating from a primary breast cancer underwent GKRS at a tertiary medical center in Seoul, Korea. All patients had radiosurgery as a primary treatment or salvage therapy. We retrospectively reviewed their clinical outcomes and radiological responses. The end point of this study was the date of patient's death or the last follow-up examination. RESULTS: In total, 106 patients (268 lesions) were available for follow-up imaging. The median follow-up time was 7.5 months. The mean treated tumor volume at the time of GKRS was 6273 mm(3) (range, 4.5-27745 mm(3)) and the median dose delivered to the tumor margin was 22 Gy (range, 20-25 Gy). Local recurrence was assessed in 86 patients (216 lesions) and found to have occurred in 36 patients (83 lesions, 38.6%) with a median time of 6 months (range, 4-16 months). A treated tumor volume >5000 mm(3) was significantly correlated with poor local tumor control through a multivariate analysis (hazard risk=7.091, p=0.01). Overall survival was 79.9%, 48.3%, and 15.3% at 6, 12, and 24 months, respectively. The median overall survival was 11 months after GKRS (range, 6 days-113 months). Multivariate analysis showed that the pre-GKRS Karnofsky performance status, leptomeningeal seeding prior to initial GKRS, and multiple metastatic lesions were significant prognostic factors for reduced overall survival (hazard risk=1.94, p=0.001, hazard risk=7.13, p<0.001, and hazard risk=1.46, p=0.046, respectively). CONCLUSION: GKRS has shown to be an effective and safe treatment modality for treating brain metastases of primary breast cancer. Most metastatic brain lesions initially respond to GKRS, though, many patients have further CNS progression in subsequent periods. Patients with poor Karnofsky performance status and multiple metastatic lesions are at risk of CNS progression and poor survival, and a more frequent and strict surveillance protocol is suggested in such high-risk groups.","fulltextAvailable":false,"journal":"Journal of Korean Neurosurgical Society","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Breast Neoplasms","uri":{"id":"D001943","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Multivariate Analysis","uri":{"id":"D015999","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiosurgery","uri":{"id":"D016634","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Salvage Therapy","uri":{"id":"D016879","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Treatment Failure","uri":{"id":"D017211","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Karnofsky Performance Status","uri":{"id":"D017567","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tumor Burden","uri":{"id":"D047368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Data Collection","uri":{"id":"D003625","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Korea","uri":{"id":"D007723","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Morbidity","uri":{"id":"D009017","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mortality","uri":{"id":"D009026","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Metastasis","uri":{"id":"D009362","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiation","uri":{"id":"D011827","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Recurrence","uri":{"id":"D012008","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Women","uri":{"id":"D014930","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiosurgery","uri":{"id":"D016634","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24294457","title":"Clinical outcome in gamma knife radiosurgery for metastatic brain tumors from the primary breast cancer : prognostic factors in local treatment failure and survival.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: The development of brain metastases (BMs) was associated with poor prognosis in melanoma patients. Patients with BMs have a median survival of <6 months. Melanoma is the third most common tumor to metastasize to the brain with a reported incidence of 10-40 %. Our aim was to identify factors predicting development of BMs and survival. PATIENTS AND METHODS: We performed a retrospective analysis of 470 melanoma patients between 2000 and 2012. The logistic regression analyses were used to identify the clinicopathological features of primary melanoma that are predictive of BMs development and survival after a diagnosis of brain metastases. RESULTS: There were 52 patients (11.1 %) who developed melanoma BMs during the study period. The analysis of post-BMs with Kaplan-Meier curves has resulted in a median survival rate of 4.1 months (range 2.9-5.1 months). On logistic regression analysis site of the primary tumor on the head and neck (p = 0.002), primary tumor thickness (Breslow >4 mm) (p = 0.008), ulceration (p = 0.007), and pathologically N2 and N3 diseases (p = 0.001) were found to be significantly associated with the development of BMs. In univariate analysis, tumor thickness and performance status had a significant influence on post-BMs survival. In multivariate analysis, these clinicopathologic factors were not remained as significant predictive factors. CONCLUSIONS: Our results revealed the importance of primary tumor characteristics associated with the development of BMs. Ulceration, primary tumor thickness, anatomic site, and pathologic ≥N2 disease were found to be significant predictors of BMs development.","fulltextAvailable":false,"journal":"Journal of cancer research and clinical oncology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Societies, Medical","uri":{"id":"D012955","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Melanoma","uri":{"id":"D008545","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Regression Analysis","uri":{"id":"D012044","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival Rate","uri":{"id":"D015996","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Multivariate Analysis","uri":{"id":"D015999","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Logistic Models","uri":{"id":"D016015","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medical Oncology","uri":{"id":"D008495","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Melanoma","uri":{"id":"D008545","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Metastasis","uri":{"id":"D009362","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Organization and Administration","uri":{"id":"D009934","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Societies","uri":{"id":"D012952","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ulcer","uri":{"id":"D014456","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Incidence","uri":{"id":"D015994","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged, 80 and over","uri":{"id":"D000369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Melanoma","uri":{"id":"D008545","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Staging","uri":{"id":"D009367","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Predictive Value of Tests","uri":{"id":"D011237","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Retrospective Studies","uri":{"id":"D012189","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Logistic Models","uri":{"id":"D016015","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adult","Aged","Aged, 80 and over","Brain Neoplasms","Female","Humans","Logistic Models","Male","Melanoma","Middle Aged","Neoplasm Staging","Predictive Value of Tests","Retrospective Studies"]},"pmid":"24292400","title":"Predictive factors for the development of brain metastases in patients with malignant melanoma: a study by the Anatolian society of medical oncology.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: New treatment strategies for malignant gliomas are indispensible, due to the poor prognosis for patients. Fluorescence diagnosis (FD) and photodynamic therapy (PDT) are currently under intensive investigation and seem to improve the prognosis. Especially for deep seated malignant brain lesions and in order to optimize therapy new diagnostic tools are needed. METHODS: In a syngeneic subcutaneous glioma mouse model we investigated the time dependent hypericin (HYP) uptake in malignant tumor tissue by microendoscopically fluorescence measurements. The HYP fluorescence in tumor was also detected by fluorescence microscopy (FM) and was compared to endoscopic data. RESULTS: Both methods, microendoscopy and FM, demonstrated time dependent HYP uptake in subcutaneously implanted mouse glioma. Maximum of HYP uptake was achieved after 6h, measured with both methods. FM reached a 10-fold increase in fluorescence intensity compared to the autofluorescence. Measured by microendoscopy a 2.2-fold HYP fluorescence intensity compared to the autofluorescence was detected. Microendoscopy enables visualization of small vessels even in healthy brain tissue by intravascular HYP fluorescence. CONCLUSION: The new developed microendoscope enables not only fluorescence based discrimination of tumor and healthy tissue, but also semiquantitative measurements of fluorescence intensities in vivo. Individual repetitive fluorescence diagnosis will become possible by this method and opens up new possibilities for determining optimal settings of light applications for PDT.","fulltextAvailable":false,"journal":"Photodiagnosis and photodynamic therapy","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microscopy, Fluorescence","uri":{"id":"D008856","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Photochemotherapy","uri":{"id":"D010778","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Discrimination (Psychology)","uri":{"id":"D004192","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Fluorescence","uri":{"id":"D005453","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microscopy","uri":{"id":"D008853","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissues","uri":{"id":"D014024","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Endoscopes","uri":{"id":"D019723","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice","uri":{"id":"D051379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Disease Models, Animal","uri":{"id":"D004195","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sensitivity and Specificity","uri":{"id":"D012680","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Skin Neoplasms","uri":{"id":"D012878","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissue Distribution","uri":{"id":"D014018","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Reproducibility of Results","uri":{"id":"D015203","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Line, Tumor","uri":{"id":"D045744","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice","uri":{"id":"D051379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Endoscopy","uri":{"id":"D004724","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Metabolic Clearance Rate","uri":{"id":"D008657","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Perylene","uri":{"id":"D010569","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Spectrometry, Fluorescence","uri":{"id":"D013050","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Photosensitizing Agents","uri":{"id":"D017319","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Animals","Brain Neoplasms","Cell Line, Tumor","Disease Models, Animal","Endoscopy","Glioma","Metabolic Clearance Rate","Mice","Perylene","Photosensitizing Agents","Reproducibility of Results","Sensitivity and Specificity","Skin Neoplasms","Spectrometry, Fluorescence","Tissue Distribution"]},"pmid":"24284111","title":"Microendoscopy for hypericin fluorescence tumor diagnosis in a subcutaneous glioma mouse model.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"INTRODUCTION: MBT carry poor prognosis and more than 80% of MBT recur locally within 2 cm of the resection margin because of inadequate surgical removal. A number of techniques have been implemented in recent years to improve surgical removal of MBT with variable success. We examined two methods commonly used to resect MBT to establish which one offered the best chances of gross total removal; MRI guided technology and ALA-induced fluorescence. PATIENTS AND METHODS: Twenty consecutive patients diagnosed with MBT were included in this study. They were given 20mg ALA per kg body weight 3h before anaesthesia orally mixed in water. Surgery was planned using preoperative enhanced MPR age images. Surgery was executed using the Stealth Station image guidance system and ALA-induced fluorescence microsurgical techniques. During surgery the intensity of fluorescence was graded into red, pink or blue. The intensity of fluorescence was also measured using pulsed 405 nm laser and a compact spectrometer using a touch probe directly placed on the tissue. The extent of tumour invasion was assessed intraoperatively using standard white light, blue light and spectroscopic measurements. Postoperative enhanced MRI was used to assess the extent of resection and the volume of residual tumour was measured. RESULTS: There were six newly diagnosed GBM, eight recurrent GBM, one oligodendroglioma (ODG) and five metastases (MET). On enhanced MRI, the mean diameter of new GBM, recurrent GBM, ODG and MET was 2.3 cm, 2.3 cm, 1.5 cm, and 2.3 cm respectively. Under the blue light, the mean diameter of new GBM, recurrent GBM, ODG and MET was 2.9 cm, 3 cm, 1.5 cm and 2.3 cm respectively. The results of quantitative measurements of fluorescence ratios revealed that red fluorescence corresponded to 5.9-11.6 (solid tumour on histology), and pink fluorescence measured 0.8-1.9 (infiltrating edge of tumour on histology). When we compared the maximum tumour diameter of GBM we found on average it was 10mm wider on spectroscopy compared to standard white light microscopy and 6mm wider than what the enhanced MRI demonstrated. CONCLUSIONS: Fluorescence technology revealed that GBMs are wider than the enhanced MRI had demonstrated, while MET enhanced MRI was similar in size to fluorescence. Furthermore, solid tumour can be identified intraoperatively and can be measured using fluorescence and spectroscopy techniques and it can be removed safely. Infiltrating tumour can also be identified intraoperatively using this technology and can be removed in non-eloquent areas to maximise surgical resection.","fulltextAvailable":false,"journal":"Photodiagnosis and photodynamic therapy","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prospective Studies","uri":{"id":"D011446","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Residual Volume","uri":{"id":"D012115","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Spectrometry, Fluorescence","uri":{"id":"D013050","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Body Weight","uri":{"id":"D001835","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Fluorescence","uri":{"id":"D005453","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Histology","uri":{"id":"D006653","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lasers","uri":{"id":"D007834","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microscopy","uri":{"id":"D008853","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Metastasis","uri":{"id":"D009362","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oligodendroglioma","uri":{"id":"D009837","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pulse","uri":{"id":"D011674","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Recurrence","uri":{"id":"D012008","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Spectrum Analysis","uri":{"id":"D013057","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"General Surgery","uri":{"id":"D013502","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Technology","uri":{"id":"D013672","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissues","uri":{"id":"D014024","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"European Continental Ancestry Group","uri":{"id":"D044465","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neuronavigation","uri":{"id":"D038361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Magnetic Resonance Imaging","uri":{"id":"D008279","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microscopy, Fluorescence","uri":{"id":"D008856","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sensitivity and Specificity","uri":{"id":"D012680","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Reproducibility of Results","uri":{"id":"D015203","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Treatment Outcome","uri":{"id":"D016896","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Surgery, Computer-Assisted","uri":{"id":"D025321","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiation-Sensitizing Agents","uri":{"id":"D011838","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Amino Acids, Neutral","uri":{"id":"D021542","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adult","Aged","Amino Acids, Neutral","Brain Neoplasms","Female","Humans","Magnetic Resonance Imaging","Male","Microscopy, Fluorescence","Middle Aged","Radiation-Sensitizing Agents","Reproducibility of Results","Sensitivity and Specificity","Surgery, Computer-Assisted","Treatment Outcome"]},"pmid":"24284085","title":"Comparison of intraoperative fluorescence and MRI image guided neuronavigation in malignant brain tumours, a prospective controlled study.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"INTRODUCTION: Gliomas are the most common primary brain tumors in adults and a significant cause of cancer-related mortality. A 9-gene signature was identified as a novel prognostic model reflecting survival situation obviously in gliomas. AIMS: To identify an mRNA expression signature to improve outcome prediction for patients with different glioma grades. RESULTS: We used whole-genome mRNA expression microarray data of 220 glioma samples of all grades from the Chinese Glioma Genome Atlas (CGGA) database (http://www.cgga.org.cn) as a discovery set and data from Rembrandt and GSE16011 for validation sets. Data from every single grade were analyzed by the Kaplan-Meier method with a two-sided log-rank test. Univariate Cox regression and linear risk score formula were applied to derive a gene signature with better prognostic performance. We found that patients who had high risk score according to the signature had poor overall survival compared with patients who had low risk score. Highly expressed genes in the high-risk group were analyzed by gene ontology (GO) and gene set variation analysis (GSVA). As a result, the reason for the divisibility of gliomas was likely due to cell life processes and adhesion. CONCLUSION: This 9-gene-signature prediction model provided a more accurate predictor of prognosis that denoted patients with high risk score have poor outcome. Moreover, these risk models based on defined molecular profiles showed the considerable prospect in personalized cancer management.","fulltextAvailable":false,"journal":"CNS neuroscience & therapeutics","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Linear Models","uri":{"id":"D016014","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Ontology","uri":{"id":"D063990","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes","uri":{"id":"D005796","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mortality","uri":{"id":"D009026","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RNA, Messenger","uri":{"id":"D012333","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genome","uri":{"id":"D016678","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Life","uri":{"id":"D019369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genomics","uri":{"id":"D023281","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Asian Continental Ancestry Group","uri":{"id":"D044466","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Membrane Proteins","uri":{"id":"D008565","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microtubule-Associated Proteins","uri":{"id":"D008869","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nuclear Proteins","uri":{"id":"D009687","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RNA, Messenger","uri":{"id":"D012333","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genetic Variation","uri":{"id":"D014644","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Expression Regulation, Neoplastic","uri":{"id":"D015972","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Expression Profiling","uri":{"id":"D020869","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microarray Analysis","uri":{"id":"D046228","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"DNA-Binding Proteins","uri":{"id":"D004268","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Histone Deacetylases","uri":{"id":"D006655","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Metallothionein","uri":{"id":"D008668","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Repressor Proteins","uri":{"id":"D012097","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Transcription Factors","uri":{"id":"D014157","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tubulin","uri":{"id":"D014404","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genomic Library","uri":{"id":"D015698","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Cycle Proteins","uri":{"id":"D018797","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"rab1 GTP-Binding Proteins","uri":{"id":"D020761","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Inhibitor of Apoptosis Proteins","uri":{"id":"D051034","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Kaplan-Meier Estimate","uri":{"id":"D053208","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Endosomal Sorting Complexes Required for Transport","uri":{"id":"D056827","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Brain Neoplasms","Cell Cycle Proteins","DNA-Binding Proteins","Endosomal Sorting Complexes Required for Transport","Gene Expression Profiling","Gene Expression Regulation, Neoplastic","Genetic Variation","Genomic Library","Glioma","Histone Deacetylases","Humans","Inhibitor of Apoptosis Proteins","Kaplan-Meier Estimate","Membrane Proteins","Metallothionein","Microarray Analysis","Microtubule-Associated Proteins","Nuclear Proteins","RNA, Messenger","Repressor Proteins","Transcription Factors","Tubulin","rab1 GTP-Binding Proteins"]},"pmid":"24279471","title":"Prognostic value of a nine-gene signature in glioma patients based on mRNA expression profiling.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Secondary hypoxia is a known contributor to adverse outcomes in patients with traumatic brain injury (TBI). Based on the evidence that hypoxia and TBI in isolation induce neuroinflammation, we investigated whether TBI combined with hypoxia enhances cerebral cytokine production. We also explored whether increased concentrations of injury biomarkers discriminate between hypoxic (Hx) and normoxic (Nx) patients, correlate to worse outcome, and depend on blood-brain barrier (BBB) dysfunction. Forty-two TBI patients with Glasgow Coma Scale ≤8 were recruited. Cerebrospinal fluid (CSF) and serum were collected over 6 days. Patients were divided into Hx (n=22) and Nx (n=20) groups. Eight cytokines were measured in the CSF; albumin, S100, myelin basic protein (MBP) and neuronal specific enolase (NSE) were quantified in serum. CSF/serum albumin quotient was calculated for BBB function. Glasgow Outcome Scale Extended (GOSE) was assessed at 6 months post-TBI. Production of granulocye macrophage-colony stimulating factor (GM-CSF) was higher, and profiles of GM-CSF, interferon (IFN)-γ and, to a lesser extent, tumor necrosis factor (TNF), were prolonged in the CSF of Hx but not Nx patients at 4-5 days post-TBI. Interleukin (IL)-2, IL-4, IL-6, and IL-10 increased similarly in both Hx and Nx groups. S100, MBP, and NSE were significantly higher in Hx patients with unfavorable outcome. Among these three biomarkers, S100 showed the strongest correlations to GOSE after TBI-Hx. Elevated CSF/serum albumin quotients lasted for 5 days post-TBI and displayed similar profiles in Hx and Nx patients. We demonstrate for the first time that post-TBI hypoxia is associated with prolonged neuroinflammation, amplified extravasation of biomarkers, and poor outcome. S100 and MBP could be implemented to track the occurrence of post-TBI hypoxia, and prompt adequate treatment.","fulltextAvailable":false,"journal":"Journal of neurotrauma","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Myelin Proteins","uri":{"id":"D009185","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hypoxia, Brain","uri":{"id":"D002534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Interleukin-2","uri":{"id":"D007376","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Injuries","uri":{"id":"D001930","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cerebrospinal Fluid","uri":{"id":"D002555","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Myelin Basic Protein","uri":{"id":"D004676","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tumor Necrosis Factor-alpha","uri":{"id":"D014409","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tumor Necrosis Factors","uri":{"id":"D048069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blood-Brain Barrier","uri":{"id":"D001812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phosphopyruvate Hydratase","uri":{"id":"D010751","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Serum Albumin","uri":{"id":"D012709","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glasgow Coma Scale","uri":{"id":"D015600","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glasgow Outcome Scale","uri":{"id":"D023261","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Albumins","uri":{"id":"D000418","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anoxia","uri":{"id":"D000860","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Discrimination (Psychology)","uri":{"id":"D004192","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Interferons","uri":{"id":"D007372","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Interleukins","uri":{"id":"D007378","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Myelin Sheath","uri":{"id":"D009186","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Necrosis","uri":{"id":"D009336","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neurons","uri":{"id":"D009474","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteins","uri":{"id":"D011506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Track and Field","uri":{"id":"D014142","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Wounds and Injuries","uri":{"id":"D014947","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biological Markers","uri":{"id":"D015415","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cytokines","uri":{"id":"D016207","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Interleukin-10","uri":{"id":"D016753","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Serum","uri":{"id":"D044967","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phosphopyruvate Hydratase","uri":{"id":"D010751","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Interleukin-4","uri":{"id":"D015847","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Interleukin-6","uri":{"id":"D015850","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Granulocyte-Macrophage Colony-Stimulating Factor","uri":{"id":"D016178","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adolescent","uri":{"id":"D000293","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Injuries","uri":{"id":"D001930","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Enzyme-Linked Immunosorbent Assay","uri":{"id":"D004797","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biological Markers","uri":{"id":"D015415","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glasgow Coma Scale","uri":{"id":"D015600","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cytokines","uri":{"id":"D016207","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Recovery of Function","uri":{"id":"D020127","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Young Adult","uri":{"id":"D055815","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blood-Brain Barrier","uri":{"id":"D001812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hypoxia, Brain","uri":{"id":"D002534","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adolescent","Adult","Biological Markers","Blood-Brain Barrier","Brain Injuries","Cytokines","Enzyme-Linked Immunosorbent Assay","Female","Glasgow Coma Scale","Humans","Hypoxia, Brain","Male","Middle Aged","Prognosis","Recovery of Function","Young Adult"]},"pmid":"24279428","title":"Post-traumatic hypoxia is associated with prolonged cerebral cytokine production, higher serum biomarker levels, and poor outcome in patients with severe traumatic brain injury.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVES: To study the expression pattern and prognostic significance of SAMSN1 in glioma. METHODS: Affymetrix and Arrystar gene microarray data in the setting of glioma was analyzed to preliminarily study the expression pattern of SAMSN1 in glioma tissues, and Hieratical clustering of gene microarray data was performed to filter out genes that have prognostic value in malignant glioma. Survival analysis by Kaplan-Meier estimates stratified by SAMSN1 expression was then made based on the data of more than 500 GBM cases provided by The Cancer Genome Atlas (TCGA) project. At last, we detected the expression of SAMSN1 in large numbers of glioma and normal brain tissue samples using Tissue Microarray (TMA). Survival analysis by Kaplan-Meier estimates in each grade of glioma was stratified by SAMSN1 expression. Multivariate survival analysis was made by Cox proportional hazards regression models in corresponding groups of glioma. RESULTS: With the expression data of SAMSN1 and 68 other genes, high-grade glioma could be classified into two groups with clearly different prognoses. Gene and large sample tissue microarrays showed high expression of SAMSN1 in glioma particularly in GBM. Survival analysis based on the TCGA GBM data matrix and TMA multi-grade glioma dataset found that SAMSN1 expression was closely related to the prognosis of GBM, either PFS or OS (P<0.05). Multivariate survival analysis with Cox proportional hazards regression models confirmed that high expression of SAMSN1 was a strong risk factor for PFS and OS of GBM patients. CONCLUSION: SAMSN1 is over-expressed in glioma as compared with that found in normal brains, especially in GBM. High expression of SAMSN1 is a significant risk factor for the progression free and overall survival of GBM.","fulltextAvailable":false,"journal":"PloS one","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Multivariate Analysis","uri":{"id":"D015999","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Multigene Family","uri":{"id":"D005810","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proportional Hazards Models","uri":{"id":"D016016","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Kaplan-Meier Estimate","uri":{"id":"D053208","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Risk Factors","uri":{"id":"D012307","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival Analysis","uri":{"id":"D016019","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Kaplan-Meier Estimate","uri":{"id":"D053208","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes","uri":{"id":"D005796","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissues","uri":{"id":"D014024","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cluster Analysis","uri":{"id":"D016000","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genome","uri":{"id":"D016678","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genomics","uri":{"id":"D023281","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Personal Autonomy","uri":{"id":"D026684","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Risk Factors","uri":{"id":"D012307","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Expression Regulation, Neoplastic","uri":{"id":"D015972","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proportional Hazards Models","uri":{"id":"D016016","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival Analysis","uri":{"id":"D016019","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Line, Tumor","uri":{"id":"D045744","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oligonucleotide Array Sequence Analysis","uri":{"id":"D020411","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adaptor Proteins, Vesicular Transport","uri":{"id":"D033942","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissue Array Analysis","uri":{"id":"D046888","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adaptor Proteins, Vesicular Transport","Brain Neoplasms","Cell Line, Tumor","Gene Expression Regulation, Neoplastic","Glioblastoma","Humans","Oligonucleotide Array Sequence Analysis","Prognosis","Proportional Hazards Models","Risk Factors","Survival Analysis","Tissue Array Analysis"]},"pmid":"24278465","title":"SAMSN1 is highly expressed and associated with a poor survival in glioblastoma multiforme.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"MicroRNA-214 (miR-214) plays an important role in tumor cell proliferation, migration and invasion, as well as tumor angiogenesis. Ubiquitin-conjugating enzyme 9 (UBC9) is implicated in regulating several critical cancer-related pathways. Recent study has demonstrated that miR-214 reduction may facilitate UBC9 expression and may be involved in the regulation of glioma cell proliferation. The aim of this study was to clarify the clinical significance of miR-214 and UBC9 in human glioma, which has not been fully elucidated. Quantitative real-time polymerase chain reaction analysis was used to characterize the expression patterns of miR-214 and UBC9 mRNA in 108 glioma and 20 normal brain tissues. The associations of miR-214 and UBC9 mRNA expressions with clinicopathological factors and prognosis of glioma patients were also statistically analyzed. Compared with normal brain tissues, the expression levels of miR-214 and UBC9 mRNA in glioma tissues were significantly downregulated and upregulated, respectively (both P < 0.001). There was a negative correlation between miR-214 and UBC9 mRNA expression in glioma tissues (r = -0.61, P = 0.01). Additionally, the combined miR-214 downregulation and UBC9 upregulation (miR-214-low/UBC9-high) was significantly associated with advanced pathological grade (P = 0.008). Moreover, Kaplan-Meier survival and Cox regression analyses showed that the glioma patients with miR-214-low/UBC9-high expression had poorest overall survival (P < 0.001) and conjoined expression of miR-214-low/UBC9-high was an independent prognostic indicator of glioma (P = 0.01). Furthermore, subgroup analyses showed that miR-214-low/UBC9-high expression was significantly associated with poor overall survival in glioma patients with high pathological grades (for grade III-IV: P < 0.001). This prospective study offers the convincing evidence for the first time that miR-214 and its target gene UBC9 may contribute to the development and the clinical outcome of glioma, and are valuable prognostic factors for glioma patients. A combined detection of miR-214/UBC9 expression may benefit us in predicting the prognosis of patients with advanced gliomas.","fulltextAvailable":false,"journal":"Medical oncology (Northwood, London, England)","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Movement","uri":{"id":"D002465","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Critical Pathways","uri":{"id":"D019091","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prospective Studies","uri":{"id":"D011446","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Regression Analysis","uri":{"id":"D012044","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Polymerase Chain Reaction","uri":{"id":"D016133","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Targeting","uri":{"id":"D018390","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Proliferation","uri":{"id":"D049109","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Real-Time Polymerase Chain Reaction","uri":{"id":"D060888","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ubiquitin-Conjugating Enzymes","uri":{"id":"D044763","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Emigration and Immigration","uri":{"id":"D004641","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Enzymes","uri":{"id":"D004798","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes","uri":{"id":"D005796","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RNA, Messenger","uri":{"id":"D012333","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissues","uri":{"id":"D014024","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Down-Regulation","uri":{"id":"D015536","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Up-Regulation","uri":{"id":"D015854","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adolescent","uri":{"id":"D000293","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain","uri":{"id":"D001921","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prospective Studies","uri":{"id":"D011446","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tumor Markers, Biological","uri":{"id":"D014408","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Expression Regulation, Neoplastic","uri":{"id":"D015972","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Multivariate Analysis","uri":{"id":"D015999","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Treatment Outcome","uri":{"id":"D016896","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Expression Profiling","uri":{"id":"D020869","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"MicroRNAs","uri":{"id":"D035683","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Proliferation","uri":{"id":"D049109","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Young Adult","uri":{"id":"D055815","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ubiquitin-Conjugating Enzymes","uri":{"id":"D044763","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Kaplan-Meier Estimate","uri":{"id":"D053208","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adolescent","Adult","Aged","Brain","Brain Neoplasms","Cell Proliferation","Female","Gene Expression Profiling","Gene Expression Regulation, Neoplastic","Glioma","Humans","Kaplan-Meier Estimate","Male","MicroRNAs","Middle Aged","Multivariate Analysis","Prognosis","Prospective Studies","Treatment Outcome","Tumor Markers, Biological","Ubiquitin-Conjugating Enzymes","Young Adult"]},"pmid":"24277415","title":"Combined aberrant expression of microRNA-214 and UBC9 is an independent unfavorable prognostic factor for patients with gliomas.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Glioblastomas are the most aggressive brain tumors. Glioblastoma stem cells (GSCs) are thought to be responsible for the recurrence, chemoresistance, and poor prognosis of glioblastoma. Fatty acid binding protein 7 (FABP7), which is a cellular chaperone for a variety of omega-3 fatty acids, is a known marker for neural stem cells. In this study, using a newly developed anti-FABP7 antibody and patient-derived GSC lines, we evaluated the expression of FABP7 in GSCs. Using immunocytochemistry, Western blotting, and qPCR analyses, FABP7 was found to be highly enriched in GSCs and its localization was found in cytosol and nuclei. FABP7 expression was significantly downregulated in differentiated GSCs induced by the addition of serum. In the glioma surgical specimens, FABP7 was highly expressed in the majority of glioblastoma. Double immunostaining for FABP7 and Sox2 showed that FABP7(+) Sox2(+) tumor cells were significantly increased in glioblastoma (grade IV) compared with diffuse astrocytoma (grade II) and anaplastic astrocytoma (grade III). Our data introduces FABP7 as a marker for GSCs and further highlights its possible significance for glioma diagnosis and treatment.","fulltextAvailable":false,"journal":"Pathology international","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Endoplasmic Reticulum","uri":{"id":"D004721","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microscopy, Electron","uri":{"id":"D008854","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Giant Cells","uri":{"id":"D015726","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lower Extremity","uri":{"id":"D035002","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Muscle, Smooth","uri":{"id":"D009130","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Endoplasmic Reticulum, Rough","uri":{"id":"D018870","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Upper Extremity","uri":{"id":"D034941","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Actins","uri":{"id":"D000199","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adolescent","uri":{"id":"D000293","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Child","uri":{"id":"D002648","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Collagen","uri":{"id":"D003094","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Curettage","uri":{"id":"D003475","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Electronics","uri":{"id":"D004581","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Electrons","uri":{"id":"D004583","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Extremities","uri":{"id":"D005121","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Fibroblasts","uri":{"id":"D005347","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Histiocytes","uri":{"id":"D006644","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitalization","uri":{"id":"D006760","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals","uri":{"id":"D006761","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microscopy","uri":{"id":"D008853","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Muscles","uri":{"id":"D009132","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Metastasis","uri":{"id":"D009362","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Recurrence","uri":{"id":"D012008","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissues","uri":{"id":"D014024","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Fibula","uri":{"id":"D005360","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lysosomes","uri":{"id":"D008247","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Bone Neoplasms","uri":{"id":"D001859","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Treatment Outcome","uri":{"id":"D016896","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Young Adult","uri":{"id":"D055815","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Histiocytoma, Benign Fibrous","uri":{"id":"D018219","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adolescent","Adult","Aged","Aged, 80 and over","Brain Neoplasms","Carrier Proteins","Cell Line, Tumor","Female","Gene Expression Regulation, Neoplastic","Glioma","Humans","Male","Middle Aged","Neoplastic Stem Cells","Tumor Markers, Biological","Tumor Suppressor Proteins"]},"pmid":"24274717","title":"Fatty acid binding protein 7 as a marker of glioma stem cells.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"PURPOSE: Lung cancer is the leading cause of cancer-related death in North America. It is often diagnosed at an advanced stage, lending to a poor prognosis. Symptoms of lung cancer often do not present until more advanced stages. Common sites of lung cancer metastasis are the bones, liver, and brain. The etiology of eye masses ranges from the relatively benign to those with tremendous risk of morbidity, and the differentiation is often difficult clinically. This case highlights the importance of more detailed workup, including biopsy, to determine the exact nature of the lesion. CASE REPORT: A 50-year-old white man was referred for evaluation of a \"bump\" on his right upper eyelid. He had noticed it for 1 month and noted enlargement during the past 2 weeks. He also reported that he had been smoking about one pack per day since 1969. External examination was remarkable for a 1.5-cm nodule pushing up from under the right upper lid. When the lid was everted, there was a 0.9-cm red and black vascularized sessile lesion on the palpebral conjunctiva. The patient was referred to an oculoplastics specialist to rule out a malignant or metastatic conjunctival neoplasm. The oculoplastics service performed an excisional biopsy, and the pathologic examination showed a poorly differentiated and highly aggressive non-small-cell lung cancer (NSCLC). After systemic evaluation, he was diagnosed as having stage IV NSCLC, with metastases to the right eyelid, brain, liver, and right lung. He underwent multiple radiotherapy sessions. He died 5 months after our initial examination. CONCLUSIONS: Stage IV NSCLC is incurable, and its treatment is often palliative. Conjunctival metastasis of stage IV NSCLC is rare, and it is clinically difficult to differentiate eyelid tumors as benign or concerning by examination alone. This case highlights the importance of a thorough history, referral, proper imaging, and biopsy to diagnose a metastatic neoplasm in a patient at high risk for cancer.","fulltextAvailable":false,"journal":"Optometry and vision science : official publication of the American Academy of Optometry","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cause of Death","uri":{"id":"D002423","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Conjunctiva","uri":{"id":"D003228","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lung Neoplasms","uri":{"id":"D008175","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"North America","uri":{"id":"D009656","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Conjunctival Neoplasms","uri":{"id":"D003230","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Americas","uri":{"id":"D000569","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biopsy","uri":{"id":"D001706","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Conjunctiva","uri":{"id":"D003228","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Eyelids","uri":{"id":"D005143","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"History","uri":{"id":"D006664","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lung","uri":{"id":"D008168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Morbidity","uri":{"id":"D009017","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Metastasis","uri":{"id":"D009362","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiotherapy","uri":{"id":"D011878","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Referral and Consultation","uri":{"id":"D012017","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nature","uri":{"id":"D019368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"African Continental Ancestry Group","uri":{"id":"D044383","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"European Continental Ancestry Group","uri":{"id":"D044465","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Staging","uri":{"id":"D009367","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biopsy","uri":{"id":"D001706","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carcinoma, Non-Small-Cell Lung","uri":{"id":"D002289","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Conjunctival Neoplasms","uri":{"id":"D003230","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Eyelid Neoplasms","uri":{"id":"D005142","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lung Neoplasms","uri":{"id":"D008175","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Fatal Outcome","uri":{"id":"D017809","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Aged","Biopsy","Carcinoma, Non-Small-Cell Lung","Conjunctival Neoplasms","Eyelid Neoplasms","Fatal Outcome","Humans","Lung Neoplasms","Male","Neoplasm Staging"]},"pmid":"24270639","title":"Conjunctival metastasis as the presenting sign for stage IV lung cancer.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Metastasis to the central nervous system, either through a hematogenous route or through the cerebrospinal fluid, is extremely rare in nasopharynx cancer. We aim to expose clinical aspects, therapeutic features and prognosis of nasopharyngeal carcinoma with brain metastases. We retrospectively reviewed the medical history of about 420 patients with nasopharyngeal carcinoma treated during 17 years at the university hospital of Sfax (Tunisia). Among them, three patients had brain metastasis. We excluded patients with direct extension to the brain. Tumours of the nasopharynx were locally advanced. The first patient had brain metastases at the initial diagnosis. The two other patients had brain metastases at 10 and 16 months during the follow-up. Ocular signs were the symptoms. Lesions were unique in two patients. Synchronous bone metastases were recorded in the three cases. All patients had whole brain radiation therapy and palliative chemotherapy. All patients had a progression of the disease and died. Brain metastases in nasopharynx cancer represent a rare event. Prognosis is poor, depending on age, surgical excision and synchronous metastases. Survival does not exceed 6 months.","fulltextAvailable":false,"journal":"Cancer radiothérapie : journal de la Société française de radiothérapie oncologique","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Palliative Care","uri":{"id":"D010166","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Signs and Symptoms","uri":{"id":"D012816","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Central Nervous System","uri":{"id":"D002490","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cerebrospinal Fluid","uri":{"id":"D002555","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals, University","uri":{"id":"D006785","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nervous System","uri":{"id":"D009420","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nasopharyngeal Neoplasms","uri":{"id":"D009303","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carcinoma","uri":{"id":"D002277","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Therapy","uri":{"id":"D004358","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"History","uri":{"id":"D006664","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitalization","uri":{"id":"D006760","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals","uri":{"id":"D006761","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Metastasis","uri":{"id":"D009362","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiation","uri":{"id":"D011827","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Universities","uri":{"id":"D014495","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nasopharyngitis","uri":{"id":"D009304","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nasopharynx","uri":{"id":"D009305","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tunisia","uri":{"id":"D014416","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antineoplastic Agents","uri":{"id":"D000970","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Bone Neoplasms","uri":{"id":"D001859","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Retrospective Studies","uri":{"id":"D012189","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chemoradiotherapy","uri":{"id":"D059248","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carcinoma","uri":{"id":"D002277","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nasopharyngeal Neoplasms","uri":{"id":"D009303","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Fatal Outcome","uri":{"id":"D017809","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoadjuvant Therapy","uri":{"id":"D020360","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adult","Antineoplastic Agents","Bone Neoplasms","Brain Neoplasms","Carcinoma","Chemoradiotherapy","Fatal Outcome","Humans","Male","Middle Aged","Nasopharyngeal Neoplasms","Neoadjuvant Therapy","Retrospective Studies"]},"pmid":"24269014","title":"[Clinical aspects of brain metastases from nasopharyngeal carcinoma].","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: High post-operative recurrence and poor prognosis are likely to be related to the infiltrative growth of the glioblastoma multiforme (GBM). OBJECTIVES: The primary objective of this study is to investigate the possible synergistic effect of the combined treatment of gamma knife radio-surgery (GKRS) and gene therapy for GBM and secondary objective is to explore the role of GKRS for the temporal and spatial regulation of the gene expression. MATERIALS AND METHODS: The study performed on 70 nude mice and randomly divided into seven groups. Subcutaneous injection of human GBM tumor cells (T98G) was carried out to establish the animal models. Various doses of liposome-mediated pcDNA3.1-Egr. 1p-p16 recombinant plasmid were transfected through intra-tumor injection. GKRS was scheduled following the plasmid transfection. Tumor volumes were measured every 4 days after the treatment. Subcutaneous tumor nodule specimens were collected to analyze the cell apoptosis and p16 gene expression using terminal-deoxynucleoitidyl transferase mediated nick end labeling staining and reverse transcription-polymerase chain reaction. Tumor volumes, levels of cell apoptosis and p16 gene expression were compared between groups. RESULTS: Rates of tumor growth were significantly lower in the pcDNA3.1-Egr. 1p-p16 plasmid + GKRS groups than that in the remaining groups 28 days following the GKRS management. The p16mRNA expression was noted in both of the pcDNA3.1-Egr. 1p-p16 plasmid group and the pcDNA3.1-Egr. 1p-p16 plasmid + GKRS with marginal-dose of 20 Gy group. The level of messenger ribonucleic acid expression was higher in the pcDNA3.1-Egr. 1p-p16 plasmid + GKRS with the marginal-dose of 20 Gy group, with a markedly increased apoptotic and necrotic cells, than that in the pcDNA3.1-Egr. 1p-p16 plasmid group. CONCLUSIONS: In animal studies, pcDNA3.1-Egr. 1p-p16 in combination with GKRS is a preferable management option for the GBM to the sole use of GKRS or gene therapy. It may be a novel approach for the treatment of human patient with GBM.","fulltextAvailable":false,"journal":"Neurology India","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aftercare","uri":{"id":"D000359","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Expression Regulation","uri":{"id":"D005786","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gamma Rays","uri":{"id":"D005720","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Staining and Labeling","uri":{"id":"D013194","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice, Nude","uri":{"id":"D008819","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genetic Therapy","uri":{"id":"D015316","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Expression","uri":{"id":"D015870","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes, p16","uri":{"id":"D019942","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Models, Animal","uri":{"id":"D023421","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Injections, Subcutaneous","uri":{"id":"D007279","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RNA","uri":{"id":"D012313","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiosurgery","uri":{"id":"D016634","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tumor Burden","uri":{"id":"D047368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Appointments and Schedules","uri":{"id":"D001071","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes","uri":{"id":"D005796","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Plasmids","uri":{"id":"D010957","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiation","uri":{"id":"D011827","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Recurrence","uri":{"id":"D012008","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Apoptosis","uri":{"id":"D017209","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice","uri":{"id":"D051379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Transfection","uri":{"id":"D014162","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Transferases","uri":{"id":"D014166","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiosurgery","uri":{"id":"D016634","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Transplantation","uri":{"id":"D009368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Treatment Outcome","uri":{"id":"D016896","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Apoptosis","uri":{"id":"D017209","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice","uri":{"id":"D051379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Combined Modality Therapy","uri":{"id":"D003131","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice, Nude","uri":{"id":"D008819","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Proteins","uri":{"id":"D009363","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms, Experimental","uri":{"id":"D009374","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Transfection","uri":{"id":"D014162","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genetic Therapy","uri":{"id":"D015316","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiosurgery","uri":{"id":"D016634","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Early Growth Response Protein 1","uri":{"id":"D051766","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Animals","Apoptosis","Combined Modality Therapy","Early Growth Response Protein 1","Genetic Therapy","Glioblastoma","Mice","Mice, Nude","Neoplasm Proteins","Neoplasm Transplantation","Neoplasms, Experimental","Radiosurgery","Transfection","Treatment Outcome"]},"pmid":"24262451","title":"Treatment of brain glioblastoma multiforme with pcDNA3.1-Egr. 1p-p16 combined with gamma knife radiation: an experimental study on nude mice.","year":"2013 Sep-Oct"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Identifying the optimal dose of ritonavir therapy overcomes the chemical resistance may exhibit in some cases due to poor prognosis of imprecise staging. Dose modeling was performed by analyzing previously published data of ritonavir cancer growth inhibition in vitro and in vivo. In-vitro 3H-Thymidine-based cell proliferation assay was performed on samples of the GL15 cell line incubated with 0, 1, 10 and 100 μ M of ritonavir. Proliferation inhibition was quantified to identify energy of the used doses as described before in earlier studies. Models involving in-vivo growth of established breast cancer tumor (MDA-MB-231), KSIMM tumor and EL4-T cell thymomas in mice were used. The effects of 40 mg/kg/day for 52 days, 30 mg/kg/day for 15 days and 8.8 mg/mouse/day for about 1 week of ritonavir in those xenograft growths respectively were monitored and quantified to identify energy of those doses as described before in earlier studies. Ritonavir demonstrated an in-vitro reduction in proliferation rate in dose dependent manner. The energy of the in-vitro influences following ritonavir therapy were perfectly correlated (r = 1) with ritonavir dose, allowed to establish an efficient energy-model with a perfect fit (R2=1) describes the energy yield by ritonavir doses, enables to administer the appropriate dose. Ritonavir had also a significant influence in-vivo on all sizes of treated tumors compared to the control animals such that the energy yield by the administered drug as derived from the energy-model was 100% identical to the induced influence in tumor energy. The in-vitro determination of inhibition to proliferation by ritonavir doses is useful to characterize the response of cancer to ritonavir therapy targeting patient-personalized cancer medicine. The molecular method of response determination by 3H-TDR incorporation and ritonavir dose-energy model are reliable to avoid chemo-resistance by identifying the optimal dosing regimens and schedules prior therapy allowing the use of much lower dose of ritonavir and thus decreases the drug side effects and risks of relapse.","fulltextAvailable":false,"journal":"Metabolic brain disease","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Breast Neoplasms","uri":{"id":"D001943","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Breast Neoplasms","uri":{"id":"D001943","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Line","uri":{"id":"D002460","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Proliferation","uri":{"id":"D049109","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Appointments and Schedules","uri":{"id":"D001071","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Incubators","uri":{"id":"D007185","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicine","uri":{"id":"D008511","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Publishing","uri":{"id":"D011643","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Recurrence","uri":{"id":"D012008","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Transplantation, Heterologous","uri":{"id":"D014183","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ritonavir","uri":{"id":"D019438","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice","uri":{"id":"D051379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Heterografts","uri":{"id":"D064593","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thymoma","uri":{"id":"D013945","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24248635","title":"Identifying the optimal dose of ritonavir in the treatment of malignancies.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"PURPOSE: Our aim was to investigate the relationship between mutant p53 and the prognosis of malignant glioma treated with temozolomide, and the regulation of mutant TP53 induced drug resistance, by molecular experimentation and a clinical trial. METHODS: Adult patients with newly surgical diagnosed glioblastoma were randomly assigned to receive either temozolomide or semustine after radiation treatment. The statuses of TP53 and expression of TP53 and O(6)-methylguanine DNA-methyltransferase (MGMT) were determined retrospectively in tumor tissue from enrolled patients. The primary end point was overall survival. Synthetic small interfering RNA was used to knock down mutant TP53 in T98G and U138 cells, which are human glioblastoma cells with a P53 mutation, by screening of exons 4-8. Viable cell survival was measured when these cells were exposed to temozolomide or semustine. Expression of MGMT at the messenger RNA level was also determined. RESULTS: The overall survival was 34.3 % at 2 years, 22.9 % at 3 years, 11.4 % at 4 years, and 8.6 % at 5 years with temozolomide, versus 18.2, 12.1, 3.0, and 0 %, respectively, with semustine. TP53 mutation and expression of mutant TP53 and MGMT showed significant inverse correlations with overall survival. Knockdown of mutant TP53 led to a fivefold increase in chemosensitivity to temozolomide but not semustine. Mutant TP53 knockdown induced down-regulation of MGMT expression. CONCLUSIONS: Mutant TP53 is strongly associated with a poor prognosis for overall survival in patients with glioblastoma. Also, TP53 mutation may decrease the chemosensitivity of glioblastoma to temozolomide by increasing MGMT expression.","fulltextAvailable":false,"journal":"Annals of surgical oncology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aftercare","uri":{"id":"D000359","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Survival","uri":{"id":"D002470","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Resistance","uri":{"id":"D004351","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RNA, Messenger","uri":{"id":"D012333","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RNA, Small Interfering","uri":{"id":"D034741","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Exons","uri":{"id":"D005091","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mutation","uri":{"id":"D009154","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiation","uri":{"id":"D011827","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RNA","uri":{"id":"D012313","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissues","uri":{"id":"D014024","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Down-Regulation","uri":{"id":"D015536","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Semustine","uri":{"id":"D012673","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Follow-Up Studies","uri":{"id":"D005500","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mutation","uri":{"id":"D009154","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Retrospective Studies","uri":{"id":"D012189","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Expression Regulation, Neoplastic","uri":{"id":"D015972","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival Rate","uri":{"id":"D015996","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Polymerase Chain Reaction","uri":{"id":"D016133","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tumor Suppressor Protein p53","uri":{"id":"D016159","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tumor Suppressor Proteins","uri":{"id":"D025521","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dacarbazine","uri":{"id":"D003606","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"DNA Modification Methylases","uri":{"id":"D015254","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antineoplastic Agents, Alkylating","uri":{"id":"D018906","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RNA, Small Interfering","uri":{"id":"D034741","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"DNA Repair Enzymes","uri":{"id":"D045643","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adult","Aged","Antineoplastic Agents, Alkylating","Brain Neoplasms","DNA Modification Methylases","DNA Repair Enzymes","Dacarbazine","Female","Follow-Up Studies","Gene Expression Regulation, Neoplastic","Glioblastoma","Humans","Male","Middle Aged","Mutation","Polymerase Chain Reaction","Prognosis","RNA, Small Interfering","Retrospective Studies","Survival Rate","Tumor Suppressor Protein p53","Tumor Suppressor Proteins"]},"pmid":"24248532","title":"Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Glioblastoma (GB), World Health Organization Grade 4 glioma, is the most common malignant primary brain tumour with an annual incidence of 12,943 cases in the United States . It is a tumour of the elderly people with a median age of onset of 64 years, although children and young adults are also affected. GB is associated with a poor prognosis; despite best treatment, most community-based patients will not survive 1 year . Cures are rare and overall survival rates at 2 and 5 years are 26-48% and 12%, respectively, in highly selected, contemporary, clinical trial eligible patients . For protocol eligible US patients, the median survival is 16-17 months, which is partly a reflection of improved supportive care, recognition of pseudoprogression, exclusion of patients undergoing biopsy only and availability of bevacizumab at recurrence . Initial treatment for patients with high performance [Karnofsky Performance Status (KPS) > 60 and age < 71 years) consists of maximal safe surgical resection followed by adjuvant focal, external beam radiotherapy (RT) with concurrent temozolomide (TMZ) chemotherapy and post-RT TMZ for 6 months . TMZ and carmustine (BCNU) biodegradable wafer (Gliadel) are the only adjuvant chemotherapies that have improved survival in randomised GB clinical trials . The current standard treatment is based upon a European Organization for Research and Treatment of Cancer (EORTC) and National Cancer Institute of Canada (NCIC) randomised, phase 3 trial of 573 patients with newly diagnosed GB (age 19-71 years and World Health Organization Performance Status ≤ 2) that compared RT alone [total dose 60 Gray (Gy)] to TMZ chemotherapy in combination with RT (total 60 Gy), followed by 6 months of post-RT TMZ (4,6,8).","fulltextAvailable":false,"journal":"International journal of clinical practice","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Therapy, Combination","uri":{"id":"D004359","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"United States","uri":{"id":"D014481","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival Rate","uri":{"id":"D015996","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Age of Onset","uri":{"id":"D017668","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Young Adult","uri":{"id":"D055815","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"World Health","uri":{"id":"D014943","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"World Health Organization","uri":{"id":"D014944","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chemotherapy, Adjuvant","uri":{"id":"D017024","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Karnofsky Performance Status","uri":{"id":"D017567","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"National Cancer Institute (U.S.)","uri":{"id":"D054547","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Academies and Institutes","uri":{"id":"D000047","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biopsy","uri":{"id":"D001706","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Canada","uri":{"id":"D002170","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Child","uri":{"id":"D002648","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Therapy","uri":{"id":"D004358","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiotherapy","uri":{"id":"D011878","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Recurrence","uri":{"id":"D012008","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Incidence","uri":{"id":"D015994","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carmustine","uri":{"id":"D002330","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival Rate","uri":{"id":"D015996","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Randomized Controlled Trials as Topic","uri":{"id":"D016032","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chemoradiotherapy","uri":{"id":"D059248","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carmustine","uri":{"id":"D002330","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dacarbazine","uri":{"id":"D003606","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Guanosine","uri":{"id":"D006151","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Methylation","uri":{"id":"D008745","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiotherapy Dosage","uri":{"id":"D011879","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antineoplastic Agents, Alkylating","uri":{"id":"D018906","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Aged","Antineoplastic Agents, Alkylating","Brain Neoplasms","Carmustine","Chemoradiotherapy","Dacarbazine","Glioblastoma","Guanosine","Humans","Methylation","Middle Aged","Radiotherapy Dosage","Randomized Controlled Trials as Topic","Survival Rate"]},"pmid":"24246204","title":"Treatment of newly diagnosed malignant glioma in the elderly people: new trials that impact therapy.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Patients affected by malignant brain tumors present an extremely poor prognosis, notwithstanding improvements in surgery techniques and therapeutic protocols. Brain tumor treatment has been principally hampered by limited drug delivery across the blood-brain barrier (BBB). An efficacious chemotherapeutic treatment requires a pharmacological agent that can penetrate the BBB and target neoplastic cells. Nanotechnology involves the design, synthesis and characterization of materials that have a functional organization in at least one dimension on the nanometer scale. Nanoparticle systems can represent optimal devices for delivery of various drugs into the brain across the BBB. Nanoparticle drug-delivery systems can also be used to provide targeted delivery of drugs, improve bioavailability and sustain release of drugs for systemic delivery. In this patent review, the recent studies of certain nanoparticle systems in treatment of brain tumors are summarized. Common nanoparticles systems include polymeric nanoparticles, lipid nanoparticles and inorganic nanoparticles. Various patents of nanoparticle systems able to across the BBB to target brain tumors are also reported and discussed.","fulltextAvailable":false,"journal":"Pharmaceutical patent analyst","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Treatment Outcome","uri":{"id":"D016896","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blood-Brain Barrier","uri":{"id":"D001812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Equipment and Supplies","uri":{"id":"D004864","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lipids","uri":{"id":"D008055","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"General Surgery","uri":{"id":"D013502","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Penetrance","uri":{"id":"D019683","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nanoparticles","uri":{"id":"D053758","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Polymerization","uri":{"id":"D058105","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biological Availability","uri":{"id":"D001682","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nanotechnology","uri":{"id":"D036103","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nanomedicine","uri":{"id":"D050997","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antineoplastic Agents","uri":{"id":"D000970","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nanoparticles","uri":{"id":"D053758","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patents as Topic","uri":{"id":"D010330","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Delivery Systems","uri":{"id":"D016503","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nanomedicine","uri":{"id":"D050997","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Antineoplastic Agents","Brain Neoplasms","Drug Delivery Systems","Humans","Nanomedicine","Nanoparticles","Patents as Topic"]},"pmid":"24237240","title":"Patented nanomedicines for the treatment of brain tumors.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECT: Although a number of recent studies on the surgical treatment of insular low-grade glioma (LGG) have demonstrated that aggressive resection leads to increased overall patient survival and decreased malignant progression, less attention has been given to the results with respect to tumor-related epilepsy. The aim of this investigation was to evaluate the impact of volumetric, histological, and intraoperative neurophysiological factors on seizure outcome in patients with insular LGG. METHODS: The authors evaluated predictors of seizure outcome with special emphasis on both the extent of tumor resection (EOR) and the tumor's infiltrative pattern quantified by computing the difference between the preoperative T2- and T1-weighted MR images (ΔVT2T1) in 52 patients with preoperative drug-resistant epilepsy. RESULTS: The 12-month postoperative seizure outcome (Engel class) was as follows: seizure free (Class I), 67.31%; rare seizures (Class II), 7.69%; meaningful seizure improvement (Class III), 15.38%; and no improvement or worsening (Class IV), 9.62%. Poor seizure control was more common in patients with a longer preoperative seizure history (p < 0.002) and higher frequency of seizures (p = 0.008). Better seizure control was achieved in cases with EOR ≥ 90% (p < 0.001) and ΔVT2T1 < 30 cm(3) (p < 0.001). In the final model, ΔVT2T1 proved to be the strongest independent predictor of seizure outcome in insular LGG patients (p < 0.0001). CONCLUSIONS: No or little postoperative seizure improvement occurs mainly in cases with a prevalent infiltrative tumor growth pattern, expressed by high ΔVT2T1 values, which consequently reflects a smaller EOR.","fulltextAvailable":false,"journal":"Journal of neurosurgery","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Computers","uri":{"id":"D003201","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Epilepsy","uri":{"id":"D004827","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"History","uri":{"id":"D006664","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Seizures","uri":{"id":"D012640","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Specialization","uri":{"id":"D013038","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"General Surgery","uri":{"id":"D013502","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prevalence","uri":{"id":"D015995","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Personal Autonomy","uri":{"id":"D026684","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cerebral Cortex","uri":{"id":"D002540","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Treatment Outcome","uri":{"id":"D016896","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Postoperative Period","uri":{"id":"D011184","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Seizures","uri":{"id":"D012640","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neurosurgical Procedures","uri":{"id":"D019635","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adult","Brain Neoplasms","Cerebral Cortex","Female","Glioma","Humans","Male","Middle Aged","Neurosurgical Procedures","Postoperative Period","Seizures","Treatment Outcome"]},"pmid":"24236654","title":"Surgery for insular low-grade glioma: predictors of postoperative seizure outcome.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"In human glioma tumors, heme oxygenase-1 (HO-1) has been shown to be upregulated both when compared with normal brain tissues and also during oligodendroglioma progression. The cell types that express HO-1 have been shown to be mainly macrophages/microglia and T cells. However, many other reports also demonstrated that cell lines derived from glioma tumors and astrocytes express HO-1 after the occurrence of a wide variety of cell injuries and stressors. In addition, the significance of HO-1 upregulation in glioma had not, so far, been addressed. We therefore aimed at investigating the expression and significance of HO-1 in human glial tumors. For this purpose, we performed a wide screening of HO-1 expression in gliomas by using tissue microarrays containing astrocytomas, oligodendrogliomas, mixed tumors, and normal brain tissues. We subsequently correlated protein expression with patient clinicopathological data. We found differences in HO-1 positivity rates between non-malignant brain (22 %) and gliomas (54%, p = 0.01). HO-1 was expressed by tumor cells and showed cytoplasmic localization, although 19% of tumor samples also depicted nuclear staining. Importantly, a significant decrease in the overall survival time of grade II and III astrocytoma patients with HO-1 expression was observed. This result was validated at the mRNA level in a cohort of 105 samples. However, no association of HO-1 nuclear localization with patient survival was detected. In vitro experiments aimed at investigating the role of HO-1 in glioma progression showed that HO-1 modulates glioma cell proliferation, but has no effects on cellular migration. In conclusion, our results corroborate the higher frequency of HO-1 protein expression in gliomas than in normal brain, demonstrate that HO-1 is expressed by glial malignant cells, and show an association of HO-1 expression with patients’ shorter survival time.","fulltextAvailable":false,"journal":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neuroglia","uri":{"id":"D009457","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Line","uri":{"id":"D002460","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"T-Lymphocytes","uri":{"id":"D013601","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Proliferation","uri":{"id":"D049109","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Heme Oxygenase-1","uri":{"id":"D051547","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Astrocytes","uri":{"id":"D001253","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cytoplasm","uri":{"id":"D003593","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Emigration and Immigration","uri":{"id":"D004641","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Macrophages","uri":{"id":"D008264","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oligodendroglioma","uri":{"id":"D009837","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteins","uri":{"id":"D011506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RNA, Messenger","uri":{"id":"D012333","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissues","uri":{"id":"D014024","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Wounds and Injuries","uri":{"id":"D014947","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Up-Regulation","uri":{"id":"D015854","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Astrocytoma","uri":{"id":"D001254","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Heme","uri":{"id":"D006418","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microglia","uri":{"id":"D017628","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunohistochemistry","uri":{"id":"D007150","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tumor Markers, Biological","uri":{"id":"D014408","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Real-Time Polymerase Chain Reaction","uri":{"id":"D060888","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Astrocytoma","uri":{"id":"D001254","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Fluorescent Antibody Technique","uri":{"id":"D005455","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunoblotting","uri":{"id":"D015151","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissue Array Analysis","uri":{"id":"D046888","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Heme Oxygenase-1","uri":{"id":"D051547","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Kaplan-Meier Estimate","uri":{"id":"D053208","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Astrocytoma","Brain Neoplasms","Fluorescent Antibody Technique","Glioma","Heme Oxygenase-1","Humans","Immunoblotting","Immunohistochemistry","Kaplan-Meier Estimate","Prognosis","Real-Time Polymerase Chain Reaction","Tissue Array Analysis","Tumor Markers, Biological"]},"pmid":"24234335","title":"Heme oxygenase-1 expression in human gliomas  and its correlation with poor prognosis  in patients with astrocytoma.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: Undifferentiated uterine sarcoma (UUS) is a rare tumor with an aggressive growth pattern. They occur in women from 40 to 60 years and are generally characterized by poor prognosis, a high rate of local recurrence, and distant metastases. UUS accounts for 0.2% of all gynecological malignancies. Possible treatments include surgery, radiotherapy, and chemotherapy. CASE DESCRIPTION: A 65-year-old female with postmenopausal bleeding was found to have a uterine mass for which she underwent a total abdominal hysterectomy, bilateral salpingo-oophorectomy, and omentectomy. The pathologic evaluation was consistent with undifferentiated endometrial sarcoma. She began experiencing headaches with associated visual disturbances. Magnetic resonance imaging (MRI) of the brain showed a homogenous enhancing occipital dural-based mass measuring 1.6 × 1.8 × 1.7 cm. Due to the rarity of metastatic uterine sarcoma to the brain, this was believed to represent a meningioma and subsequently observed. Interval MRI scan revealed a significant increase in size of the right occipital mass to 2.3 cm with increased edema and mass effect. She underwent right occipital image guided craniotomy for resection of the mass. Histopathology confirmed UUS metastases. CONCLUSION: Randomized trials analyzing these treatment options are limited due to the rarity of this disease; therefore, a standard therapy is not established. Based on a review of the literature, this is only the fourth case reported of UUS metastatic to the brain.","fulltextAvailable":false,"journal":"Surgical neurology international","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Magnetic Resonance Imaging","uri":{"id":"D008279","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Magnetic Resonance Spectroscopy","uri":{"id":"D009682","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Therapy","uri":{"id":"D004358","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Edema","uri":{"id":"D004487","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemorrhage","uri":{"id":"D006470","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Literature","uri":{"id":"D008091","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Meningioma","uri":{"id":"D008579","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Metastasis","uri":{"id":"D009362","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiotherapy","uri":{"id":"D011878","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Recurrence","uri":{"id":"D012008","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sarcoma","uri":{"id":"D012509","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"General Surgery","uri":{"id":"D013502","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Women","uri":{"id":"D014930","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Postmenopause","uri":{"id":"D017698","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Craniotomy","uri":{"id":"D003399","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Headache","uri":{"id":"D006261","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hysterectomy","uri":{"id":"D007044","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24231690","title":"Undifferentiated uterine sarcoma metastatic to the brain.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Medulloblastoma is the most common malignant brain tumor of childhood, and represents a significant clinical challenge in pediatric oncology, since overall survival currently remains under 70%. Patients with tumors overexpressing MYC or harboring a MYC oncogene amplification have an extremely poor prognosis. Pharmacologically inhibiting MYC expression may, thus, have clinical utility given its pathogenetic role in medulloblastoma. Recent studies using the selective small molecule BET inhibitor, JQ1, have identified BET bromodomain proteins, especially BRD4, as epigenetic regulatory factors for MYC and its targets. Targeting MYC expression by BET inhibition resulted in antitumoral effects in various cancers. Our aim here was to evaluate the efficacy of JQ1 against preclinical models for high-risk MYC-driven medulloblastoma. Treatment of medulloblastoma cell lines with JQ1 significantly reduced cell proliferation and preferentially induced apoptosis in cells expressing high levels of MYC. JQ1 treatment of medulloblastoma cell lines downregulated MYC expression and resulted in a transcriptional deregulation of MYC targets, and also significantly altered expression of genes involved in cell cycle progression and p53 signalling. JQ1 treatment prolonged the survival of mice harboring medulloblastoma xenografts and reduced the tumor burden in these mice. Our preclinical data provide evidence to pursue testing BET inhibitors, such as JQ1, as molecular targeted therapeutic options for patients with high-risk medulloblastomas overexpressing MYC or harboring MYC amplifications.","fulltextAvailable":false,"journal":"Oncotarget","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Expression","uri":{"id":"D015870","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Cycle","uri":{"id":"D002453","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Line","uri":{"id":"D002460","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Proliferation","uri":{"id":"D049109","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tumor Burden","uri":{"id":"D047368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carcinogens","uri":{"id":"D002273","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes","uri":{"id":"D005796","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oncogenes","uri":{"id":"D009857","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pediatrics","uri":{"id":"D010372","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteins","uri":{"id":"D011506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Transplantation, Heterologous","uri":{"id":"D014183","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Down-Regulation","uri":{"id":"D015536","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Apoptosis","uri":{"id":"D017209","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice","uri":{"id":"D051379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Epigenomics","uri":{"id":"D057890","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Heterografts","uri":{"id":"D064593","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medulloblastoma","uri":{"id":"D008527","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nuclear Proteins","uri":{"id":"D009687","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Random Allocation","uri":{"id":"D011897","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Signal Transduction","uri":{"id":"D015398","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Down-Regulation","uri":{"id":"D015536","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Xenograft Model Antitumor Assays","uri":{"id":"D023041","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Line, Tumor","uri":{"id":"D045744","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice","uri":{"id":"D051379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Knockdown Techniques","uri":{"id":"D055785","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Azepines","uri":{"id":"D001381","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cerebellar Neoplasms","uri":{"id":"D002528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medulloblastoma","uri":{"id":"D008527","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice, Nude","uri":{"id":"D008819","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Transcription Factors","uri":{"id":"D014157","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Transfection","uri":{"id":"D014162","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Triazoles","uri":{"id":"D014230","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes, myc","uri":{"id":"D016259","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Animals","Azepines","Cell Line, Tumor","Cerebellar Neoplasms","Down-Regulation","Female","Gene Knockdown Techniques","Genes, myc","Humans","Medulloblastoma","Mice","Mice, Nude","Nuclear Proteins","Random Allocation","Signal Transduction","Transcription Factors","Transfection","Triazoles","Xenograft Model Antitumor Assays"]},"pmid":"24231268","title":"BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Diencephalic syndrome (DS) is a clinical disorder of metabolism associated with poor outcome in children with low-grade gliomas (LGGs). Since survival has been primarily reported with aggressive therapy, we report outcome data for these patients using a current, contrasting chemotherapy-driven approach. We performed a population-based review of DS patients treated with chemotherapy from 1997-2012. Metabolic rate was assessed in selected cases using open-circuit calorimetry to generate resting energy expenditure (REE) data. Tumor tissue was analyzed for BRAF alterations. Survival was compared with an age-related, radiotherapy naïve cohort of non-DS children with location-matched LGGs. Nine children (1.7% of 520 LGG diagnoses) fulfilled DS criteria. The median diagnostic age was 1.49 years (0.55-2.69 years), although neurofibromatosis Type-I patients were older (p = 0.005). All tumors analyzed exhibited either NF1 mutation or BRAF fusion. Seven tumors were histologically confirmed as low grade astrocytomas, one demonstrated neurocytic features, and one NF1 case was diagnosed using imaging and clinical criteria. All patients received chemotherapy, with seven cases also receiving initial nutritional supplementation. All nine gained weight after only 6 months of treatment. Two DS patients had serial REE measurements, revealing a hypermetabolic state (over 200% of predicted REE) at diagnosis which reduced to normal range with therapy. First-line chemotherapy treatment resulted in one minor response, stable disease in four cases, with progression in the remaining four patients. Although DS patients demonstrated inferior initial progression-free survival when compared to non-DS counterparts (5 years: 22 versus 60%, p = 0.015), all DS children remain alive at a median follow up of 5.3 years (1.2-14.9 years) with none requiring radiotherapy. Long-term sequelae included pituitary and visual dysfunction, learning difficulties and paradoxical, inappropriate weight gain. DS can be managed with non-aggressive chemotherapeutic, radiation-sparing strategies supplemented by temporary nutritional support. Multiple lines of therapy may be required to overcome disease progression but excellent survival and metabolic outcomes can be achieved. Continued surveillance is mandatory to prevent significant weight gain and support affected children with clinical sequelae.","fulltextAvailable":false,"journal":"Journal of neuro-oncology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Design","uri":{"id":"D012107","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Energy Metabolism","uri":{"id":"D004734","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Reference Values","uri":{"id":"D012016","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Weight Gain","uri":{"id":"D015430","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Disease Progression","uri":{"id":"D018450","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Disease-Free Survival","uri":{"id":"D018572","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nutritional Support","uri":{"id":"D018529","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Calorimetry","uri":{"id":"D002151","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Child","uri":{"id":"D002648","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Therapy","uri":{"id":"D004358","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Health Expenditures","uri":{"id":"D005102","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Learning","uri":{"id":"D007858","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Metabolism","uri":{"id":"D008660","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mutation","uri":{"id":"D009154","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiotherapy","uri":{"id":"D011878","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rest","uri":{"id":"D012146","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Syndrome","uri":{"id":"D013577","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissues","uri":{"id":"D014024","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neurofibromatoses","uri":{"id":"D017253","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Minors","uri":{"id":"D033242","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Astrocytoma","uri":{"id":"D001254","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adolescent","uri":{"id":"D000293","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Child","uri":{"id":"D002648","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Child, Preschool","uri":{"id":"D002675","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Infant","uri":{"id":"D007223","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Retrospective Studies","uri":{"id":"D012189","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Combined Modality Therapy","uri":{"id":"D003131","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hypothalamic Diseases","uri":{"id":"D007027","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Metabolic Diseases","uri":{"id":"D008659","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Disease-Free Survival","uri":{"id":"D018572","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adolescent","Brain Neoplasms","Child","Child, Preschool","Combined Modality Therapy","Disease-Free Survival","Female","Glioma","Humans","Hypothalamic Diseases","Infant","Male","Metabolic Diseases","Retrospective Studies"]},"pmid":"24218181","title":"Favorable survival and metabolic outcome for children with diencephalic syndrome using a radiation-sparing approach.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Integrins are transmembrane heterodimeric proteins sensing the cell microenvironment and modulating numerous signalling pathways. Changes in integrin expression between normal and tumoral cells support involvement of specific integrins in tumor progression and aggressiveness. This review highlights the current knowledge about α5β1 integrin, also called the fibronectin receptor, in solid tumors. We summarize data showing that α5β1 integrin is a pertinent therapeutic target expressed by tumoral neovessels and tumoral cells. Although mainly evaluated in preclinical models, α5β1 integrin merits interest in particular in colon, breast, ovarian, lung and brain tumors where its overexpression is associated with a poor prognosis for patients. Specific α5β1 integrin antagonists will be listed that may represent new potential therapeutic agents to fight defined subpopulations of particularly aggressive tumors.","fulltextAvailable":false,"journal":"Cancers","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Receptors, Fibronectin","uri":{"id":"D017469","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Integrin alpha5beta1","uri":{"id":"D039081","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cellular Microenvironment","uri":{"id":"D060833","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lung","uri":{"id":"D008168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteins","uri":{"id":"D011506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Knowledge","uri":{"id":"D019359","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Fibronectins","uri":{"id":"D005353","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Integrins","uri":{"id":"D016023","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24216697","title":"Integrin α5β1, the Fibronectin Receptor, as a Pertinent Therapeutic Target in Solid Tumors.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Amongst the chemokine signalling axes involved in cancer, chemokine CXCL12 acting on chemokine receptor CXCR4 is particularly significant since it orchestrates migration of cancer cells in a tissue-specific metastatic process. High CXCR4 tumour expression is associated with poor prognosis of lung, brain, CNS, blood and breast cancers. We have identified a new class of small molecule CXCR4 antagonists based on the use of computational modelling studies in concert with experimental determination of in vitro activity against CXCL12-induced intracellular calcium mobilisation, proliferation and chemotaxis. Molecular modelling proved to be a useful tool in rationalising our observed potencies, as well as informing the direction of the synthetic efforts aimed at producing more potent compounds.","fulltextAvailable":false,"journal":"PloS one","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Breast Neoplasms","uri":{"id":"D001943","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Computer Simulation","uri":{"id":"D003198","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Models, Molecular","uri":{"id":"D008958","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Receptors, Chemokine","uri":{"id":"D019707","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Receptors, CXCR4","uri":{"id":"D019718","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chemokine CXCL12","uri":{"id":"D054377","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Calcium","uri":{"id":"D002118","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Computers","uri":{"id":"D003201","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Emigration and Immigration","uri":{"id":"D004641","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lung","uri":{"id":"D008168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chemotaxis","uri":{"id":"D002633","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chemokines","uri":{"id":"D018925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Computer Simulation","uri":{"id":"D003198","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Models, Molecular","uri":{"id":"D008958","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Protein Conformation","uri":{"id":"D011487","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Structure-Activity Relationship","uri":{"id":"D013329","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Line, Tumor","uri":{"id":"D045744","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Discovery","uri":{"id":"D055808","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Receptors, CXCR4","uri":{"id":"D019718","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Small Molecule Libraries","uri":{"id":"D054852","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Cell Line, Tumor","Computer Simulation","Drug Discovery","Humans","Models, Molecular","Protein Conformation","Receptors, CXCR4","Small Molecule Libraries","Structure-Activity Relationship"]},"pmid":"24205302","title":"Discovery and computer aided potency optimization of a novel class of small molecule CXCR4 antagonists.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"A major challenge for successful immunotherapy against glioma is the identification and characterization of validated targets. We have taken a bioinformatics approach towards understanding the biological context of IL-13 receptor α2 (IL13Rα2) expression in brain tumors, and its functional significance for patient survival. Querying multiple gene expression databases, we show that IL13Rα2 expression increases with glioma malignancy grade, and expression for high-grade tumors is bimodal, with approximately 58% of WHO grade IV gliomas over-expressing this receptor. By several measures, IL13Rα2 expression in patient samples and low-passage primary glioma lines most consistently correlates with the expression of signature genes defining mesenchymal subclass tumors and negatively correlates with proneural signature genes as defined by two studies. Positive associations were also noted with proliferative signature genes, whereas no consistent associations were found with either classical or neural signature genes. Probing the potential functional consequences of this mesenchymal association through IPA analysis suggests that IL13Rα2 expression is associated with activation of proinflammatory and immune pathways characteristic of mesenchymal subclass tumors. In addition, survival analyses indicate that IL13Rα2 over-expression is associated with poor patient prognosis, a single gene correlation ranking IL13Rα2 in the top ~1% of total gene expression probes with regard to survival association with WHO IV gliomas. This study better defines the functional consequences of IL13Rα2 expression by demonstrating association with mesenchymal signature gene expression and poor patient prognosis. It thus highlights the utility of IL13Rα2 as a therapeutic target, and helps define patient populations most likely to respond to immunotherapy in present and future clinical trials.","fulltextAvailable":false,"journal":"PloS one","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Transcriptome","uri":{"id":"D059467","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Expression","uri":{"id":"D015870","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival Analysis","uri":{"id":"D016019","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Transcriptome","uri":{"id":"D059467","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Receptors, Interleukin-13","uri":{"id":"D053660","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Data Collection","uri":{"id":"D003625","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Forecasting","uri":{"id":"D005544","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes","uri":{"id":"D005796","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunity","uri":{"id":"D007109","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunization","uri":{"id":"D007114","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mesoderm","uri":{"id":"D008648","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"World Health Organization","uri":{"id":"D014944","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Interleukin-13","uri":{"id":"D018793","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Computational Biology","uri":{"id":"D019295","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunotherapy","uri":{"id":"D007167","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Flow Cytometry","uri":{"id":"D005434","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Follow-Up Studies","uri":{"id":"D005500","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Recurrence, Local","uri":{"id":"D009364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Staging","uri":{"id":"D009367","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prospective Studies","uri":{"id":"D011446","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tumor Markers, Biological","uri":{"id":"D014408","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Expression Regulation, Neoplastic","uri":{"id":"D015972","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival Rate","uri":{"id":"D015996","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Young Adult","uri":{"id":"D055815","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Transcriptome","uri":{"id":"D059467","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mesoderm","uri":{"id":"D008648","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tumor Cells, Cultured","uri":{"id":"D014407","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Regulatory Networks","uri":{"id":"D053263","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Interleukin-13 Receptor alpha2 Subunit","uri":{"id":"D053663","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Grading","uri":{"id":"D060787","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adult","Brain Neoplasms","Female","Flow Cytometry","Follow-Up Studies","Gene Expression Regulation, Neoplastic","Gene Regulatory Networks","Glioma","Humans","Interleukin-13 Receptor alpha2 Subunit","Male","Mesoderm","Middle Aged","Neoplasm Grading","Neoplasm Recurrence, Local","Neoplasm Staging","Prognosis","Prospective Studies","Survival Rate","Transcriptome","Tumor Cells, Cultured","Tumor Markers, Biological","Young Adult"]},"pmid":"24204956","title":"Glioma IL13Rα2 is associated with mesenchymal signature gene expression and poor patient prognosis.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: Long noncoding RNA Hox transcript antisense intergenic RNA (HOTAIR) has been characterized as a negative prognostic factor in breast and colon cancer patients. The clinical significance and function of HOTAIR in glioma remains unclear. METHODS: We analyzed the clinical significance of HOTAIR in 3 different glioma cohorts with gene expression data, including correlation with tumor grade, prognosis, and molecular subtype. The function of HOTAIR in glioma was explored by performing gene set enrichment analysis and in vitro and in vivo experiments. RESULTS: HOTAIR expression was closely associated with glioma grade and poor prognosis. Multivariate Cox regression analysis revealed that HOTAIR was an independent prognostic factor in glioblastoma multiforme patients. HOTAIR expression correlated with glioma molecular subtype, including those of The Cancer Genome Atlas. HOTAIR was preferentially expressed in the classical and mesenchymal subtypes compared with the neural and proneural subtypes. A gene set enrichment analysis designed to show gene set differences between patients with high and low HOTAIR expression indicated that HOTAIR expression was associated with gene sets involved in cell cycle progression. HOTAIR reduction induced colony formation suppression, cell cycle G0/G1 arrest, and orthotopic tumor growth inhibition. CONCLUSION: Our data establish that HOTAIR is an important long noncoding RNA that primarily serves as a prognostic factor for glioma patient survival, as well as a biomarker for identifying glioma molecular subtypes, a critical regulator of cell cycle progression.","fulltextAvailable":false,"journal":"Neuro-oncology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Statistics as Topic","uri":{"id":"D013223","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RNA, Antisense","uri":{"id":"D016372","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Cycle","uri":{"id":"D002453","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Colonic Neoplasms","uri":{"id":"D003110","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Regression Analysis","uri":{"id":"D012044","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Expression","uri":{"id":"D015870","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes, vif","uri":{"id":"D016341","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RNA, Untranslated","uri":{"id":"D022661","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Grading","uri":{"id":"D060787","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RNA, Long Noncoding","uri":{"id":"D062085","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes","uri":{"id":"D005796","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mesoderm","uri":{"id":"D008648","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RNA","uri":{"id":"D012313","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biological Markers","uri":{"id":"D015415","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genome","uri":{"id":"D016678","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Colonialism","uri":{"id":"D018595","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genomics","uri":{"id":"D023281","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes, vif","uri":{"id":"D016341","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Follow-Up Studies","uri":{"id":"D005500","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice, Inbred BALB C","uri":{"id":"D008807","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RNA, Messenger","uri":{"id":"D012333","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tumor Markers, Biological","uri":{"id":"D014408","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blotting, Western","uri":{"id":"D015153","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival Rate","uri":{"id":"D015996","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Case-Control Studies","uri":{"id":"D016022","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Reverse Transcriptase Polymerase Chain Reaction","uri":{"id":"D020133","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Expression Profiling","uri":{"id":"D020869","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Xenograft Model Antitumor Assays","uri":{"id":"D023041","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Proliferation","uri":{"id":"D049109","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice","uri":{"id":"D051379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Real-Time Polymerase Chain Reaction","uri":{"id":"D060888","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Cycle","uri":{"id":"D002453","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mesoderm","uri":{"id":"D008648","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice, Nude","uri":{"id":"D008819","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tumor Cells, Cultured","uri":{"id":"D014407","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oligonucleotide Array Sequence Analysis","uri":{"id":"D020411","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Grading","uri":{"id":"D060787","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RNA, Long Noncoding","uri":{"id":"D062085","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adult","Animals","Blotting, Western","Brain Neoplasms","Case-Control Studies","Cell Cycle","Cell Proliferation","Female","Follow-Up Studies","Gene Expression Profiling","Glioma","Humans","Male","Mesoderm","Mice","Mice, Inbred BALB C","Mice, Nude","Middle Aged","Neoplasm Grading","Oligonucleotide Array Sequence Analysis","Prognosis","RNA, Long Noncoding","RNA, Messenger","Real-Time Polymerase Chain Reaction","Reverse Transcriptase Polymerase Chain Reaction","Survival Rate","Tumor Cells, Cultured","Tumor Markers, Biological","Xenograft Model Antitumor Assays"]},"pmid":"24203894","title":"HOTAIR, a cell cycle-associated long noncoding RNA and a strong predictor of survival, is preferentially expressed in classical and mesenchymal glioma.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Aberrant CpG island methylation is a common phenomenon in malignancy. The methylation status of multiple tumor suppressor genes may serve as a biomarker for early diagnostics and the prediction of prognosis. In this study, we quantitatively determined the promoter methylation status of five tumor-related genes in tumor tissue and paired serum from 240 patients with gliomas. The relationship between hyper-methylation and clinic-pathological parameters was evaluated, and the prognostic value of the methylation status was determined. Hypermethylation in serum was shown to be accompanied by hypermethylation in paired tumor tissues. In both tumors and serum, methylation of polymerase-1 (PARP-1), SHP-1, DAPK-1 and TIMP-3 genes was at significantly higher levels in high-grade compared with low-grade gliomas, indicating that the promoter methylation status positively correlates with tumor grade. In malignant gliomas, the serum methylation levels of PARP-1, and SHP-1 together with IDH-1 mutations were found to be independent prognostic factors for overall survival. Moreover, hypermethylation of PARP-1 in serum correlated with a shorter progression-free survival time. These results suggest that hypermethylation in gliomas correlates with increased malignancy and poor prognosis. Analysis of the serum promoter methylation status of multiple genes could therefore be used as a biomarker for the detection and evaluation of the prognosis of glioma patients.","fulltextAvailable":false,"journal":"Journal of neuro-oncology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes, Tumor Suppressor","uri":{"id":"D016147","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes, Suppressor","uri":{"id":"D016153","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Disease-Free Survival","uri":{"id":"D018572","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"CpG Islands","uri":{"id":"D018899","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Grading","uri":{"id":"D060787","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes","uri":{"id":"D005796","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Methylation","uri":{"id":"D008745","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mutation","uri":{"id":"D009154","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissues","uri":{"id":"D014024","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biological Markers","uri":{"id":"D015415","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Incidence","uri":{"id":"D015994","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Serum","uri":{"id":"D044967","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissue Inhibitor of Metalloproteinase-3","uri":{"id":"D019717","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"DNA Mutational Analysis","uri":{"id":"D004252","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Incidence","uri":{"id":"D015994","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"DNA Methylation","uri":{"id":"D019175","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Young Adult","uri":{"id":"D055815","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Isocitrate Dehydrogenase","uri":{"id":"D007521","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Poly(ADP-ribose) Polymerases","uri":{"id":"D011065","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Promoter Regions, Genetic","uri":{"id":"D011401","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Disease-Free Survival","uri":{"id":"D018572","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissue Inhibitor of Metalloproteinase-3","uri":{"id":"D019717","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Protein Tyrosine Phosphatase, Non-Receptor Type 6","uri":{"id":"D053824","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Death-Associated Protein Kinases","uri":{"id":"D064550","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adult","Aged","Brain Neoplasms","DNA Methylation","DNA Mutational Analysis","Death-Associated Protein Kinases","Disease-Free Survival","Female","Glioma","Humans","Incidence","Isocitrate Dehydrogenase","Male","Middle Aged","Poly(ADP-ribose) Polymerases","Prognosis","Promoter Regions, Genetic","Protein Tyrosine Phosphatase, Non-Receptor Type 6","Tissue Inhibitor of Metalloproteinase-3","Young Adult"]},"pmid":"24197988","title":"Incidence and prognostic value of multiple gene promoter methylations in gliomas.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Glioma is the most common and fatal primary brain tumour with poor prognosis; however, the functional roles of miRNAs in glioma malignant progression are insufficiently understood. Here, we used an integrated approach to identify miRNA functional targets during glioma malignant progression by combining the paired expression profiles of miRNAs and mRNAs across 160 Chinese glioma patients, and further constructed the functional miRNA-mRNA regulatory network. As a result, most tumour-suppressive miRNAs in glioma progression were newly discovered, whose functions were widely involved in gliomagenesis. Moreover, three miRNA signatures, with different combinations of hub miRNAs (regulations≥30) were constructed, which could independently predict the survival of patients with all gliomas, high-grade glioma and glioblastoma. Our network-based method increased the ability to identify the prognostic biomarkers, when compared with the traditional method and random conditions. Hsa-miR-524-5p and hsa-miR-628-5p, shared by these three signatures, acted as protective factors and their expression decreased gradually during glioma progression. Functional analysis of these miRNA signatures highlighted their critical roles in cell cycle and cell proliferation in glioblastoma malignant progression, especially hsa-miR-524-5p and hsa-miR-628-5p exhibited dominant regulatory activities. Therefore, network-based biomarkers are expected to be more effective and provide deep insights into the molecular mechanism of glioma malignant progression.","fulltextAvailable":false,"journal":"Nucleic acids research","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Cycle","uri":{"id":"D002453","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Cycle","uri":{"id":"D002453","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Proliferation","uri":{"id":"D049109","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RNA, Messenger","uri":{"id":"D012333","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biological Markers","uri":{"id":"D015415","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"MicroRNAs","uri":{"id":"D035683","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Asian Continental Ancestry Group","uri":{"id":"D044466","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adolescent","uri":{"id":"D000293","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Child","uri":{"id":"D002648","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RNA, Messenger","uri":{"id":"D012333","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tumor Markers, Biological","uri":{"id":"D014408","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival Analysis","uri":{"id":"D016019","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Disease Progression","uri":{"id":"D018450","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Expression Profiling","uri":{"id":"D020869","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genomics","uri":{"id":"D023281","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"MicroRNAs","uri":{"id":"D035683","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Young Adult","uri":{"id":"D055815","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Regulatory Networks","uri":{"id":"D053263","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adolescent","Adult","Aged","Brain Neoplasms","Child","Disease Progression","Female","Gene Expression Profiling","Gene Regulatory Networks","Genomics","Glioblastoma","Glioma","Humans","Male","MicroRNAs","Middle Aged","Prognosis","RNA, Messenger","Survival Analysis","Tumor Markers, Biological","Young Adult"]},"pmid":"24194606","title":"Comprehensive analysis of the functional microRNA-mRNA regulatory network identifies miRNA signatures associated with glioma malignant progression.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: Brain glioma is a malignant tumor with a high incidence rate and poor prognosis that has become a focus of studies of central nervous system diseases. Previous studies have suggested that δ-opioid receptors may affect the proliferation and apoptosis of numerous types of tumor cells. However, to date, their precise mechanism(s) of action have not been elucidated. The present study aimed to investigate the effects of inhibiting δ-opioid receptors in brain glioma cell proliferation and apoptosis and their relevant molecular mechanisms. Various doses of naltrindole were supplied to treat brain glioma cells using the MTT method to assess the proliferation index. Flow cytometry was used to investigate the changes in cell apoptosis and mitochondrial membrane potential. The expression levels of Bax, Bcl-2, Bcl-xL, cytochrome c, caspase-9, caspase-3 and protein kinase C (PKC) were measured using western blotting. Naltrindole was observed to inhibit brain glioma cell proliferation and promote apoptosis in a dose- and time-dependent manner. Furthermore, the addition of naltrindole lead to changes in the brain glioma cell membrane potential and regulated Bax translocation to the mitochondrial membrane, consequently promoting the release of cytochrome c into the cytoplasm, followed by the activation of caspase-9 and -3, which caused cell apoptosis. In addition, naltrindole was able to regulate the expression levels of the cellular internal phosphorylated PKC proteins, which are closely associated with the inhibition of cell proliferation. In conclusion, the inhibition of δ-opioid receptors may inhibit brain glioma cell proliferation and lead to apoptosis, which is closely associated with the mitochondrial and PKC pathways.","fulltextAvailable":false,"journal":"Oncology letters","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Protein C","uri":{"id":"D011486","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mitochondrial Proteins","uri":{"id":"D024101","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Membrane","uri":{"id":"D002462","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Central Nervous System","uri":{"id":"D002490","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Flow Cytometry","uri":{"id":"D005434","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Membrane Potentials","uri":{"id":"D008564","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nervous System","uri":{"id":"D009420","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nervous System Diseases","uri":{"id":"D009422","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Protein Kinase C","uri":{"id":"D011493","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Protein Kinases","uri":{"id":"D011494","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cytochromes c","uri":{"id":"D045304","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Proliferation","uri":{"id":"D049109","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blotting, Western","uri":{"id":"D015153","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mitochondrial Membranes","uri":{"id":"D051336","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Membrane Potential, Mitochondrial","uri":{"id":"D053078","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Abstracting and Indexing as Topic","uri":{"id":"D000043","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cytochromes","uri":{"id":"D003580","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cytoplasm","uri":{"id":"D003593","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Equipment and Supplies","uri":{"id":"D004864","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Membranes","uri":{"id":"D008566","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phosphorylation","uri":{"id":"D010766","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phosphotransferases","uri":{"id":"D010770","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Protein Kinases","uri":{"id":"D011494","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteins","uri":{"id":"D011506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Incidence","uri":{"id":"D015994","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Apoptosis","uri":{"id":"D017209","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Caspase 3","uri":{"id":"D053148","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Caspase 9","uri":{"id":"D053453","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24179523","title":"Inhibition of δ-opioid receptors induces brain glioma cell apoptosis through the mitochondrial and protein kinase C pathways.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Special AT-rich sequence-binding protein 1 (SATB1) is a global chromatin organizer and gene regulator, and high expression of SATB1 is associated with progression and poor prognosis in several malignancies. Here, we examine the expression pattern of SATB1 in glioma. Microarray analysis of 127 clinical samples showed that SATB1 mRNA was expressed at lower levels in highly malignant glioblastoma multiforme (GBM) than in low-grade glioma and normal brain tissue. This result was further confirmed by real-time RT-PCR in the clinical samples, three GBM cell lines, primary SU3 glioma cells and tumor cells harvested by laser-capture microdissection. Consistent with the mRNA levels, SATB1 protein expression was downregulated in high-grade glioma, as shown by western blotting. However, phospho-SATB1 levels showed an opposite pattern, with a significant increase in these tumors. Immunohistochemical analysis of phospho-SATB1 expression in tissue microarrays with tumors from 122 glioma cases showed that phospho-SATB1 expression was significantly associated with high histological grade and poor survival by Kaplan-Meier analysis. In vitro transfection analysis showed that phospho-SATB1 DNA binding has a key role in regulating the proliferation and invasion of glioma cells. The effect of SATB1 in glioma cell is mainly histone deacetylase (HDAC1)-dependent. We conclude that phospho-SATB1, but not SATB1 mRNA expression, is associated with the progression and prognosis of glioma. By interaction with HDAC1, phospho-SATB1 contributes to the invasive and proliferative phenotype of GBM cells.","fulltextAvailable":false,"journal":"Cell death & disease","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Line","uri":{"id":"D002460","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes, Regulator","uri":{"id":"D005809","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Histone Deacetylases","uri":{"id":"D006655","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blotting, Western","uri":{"id":"D015153","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microarray Analysis","uri":{"id":"D046228","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Kaplan-Meier Estimate","uri":{"id":"D053208","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Histone Deacetylase 1","uri":{"id":"D056284","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chromatin","uri":{"id":"D002843","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"DNA","uri":{"id":"D004247","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes","uri":{"id":"D005796","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Histones","uri":{"id":"D006657","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phenotype","uri":{"id":"D010641","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phosphorylation","uri":{"id":"D010766","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteins","uri":{"id":"D011506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RNA, Messenger","uri":{"id":"D012333","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Specialization","uri":{"id":"D013038","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissues","uri":{"id":"D014024","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Down-Regulation","uri":{"id":"D015536","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Internationality","uri":{"id":"D038622","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Transfection","uri":{"id":"D014162","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microdissection","uri":{"id":"D042282","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phosphorylation","uri":{"id":"D010766","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blotting, Western","uri":{"id":"D015153","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Expression Regulation, Neoplastic","uri":{"id":"D015972","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Disease Progression","uri":{"id":"D018450","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Reverse Transcriptase Polymerase Chain Reaction","uri":{"id":"D020133","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Line, Tumor","uri":{"id":"D045744","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Astrocytoma","uri":{"id":"D001254","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Matrix Attachment Region Binding Proteins","uri":{"id":"D036961","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunoprecipitation","uri":{"id":"D047468","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Astrocytoma","Blotting, Western","Cell Line, Tumor","Disease Progression","Gene Expression Regulation, Neoplastic","Glioma","Humans","Immunoprecipitation","Matrix Attachment Region Binding Proteins","Phosphorylation","Prognosis","Reverse Transcriptase Polymerase Chain Reaction"]},"pmid":"24176859","title":"Phosphorylated SATB1 is associated with the progression and prognosis of glioma.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Telomerase reverse transcriptase (TERT) promoter mutations were recently shown to drive telomerase activity in various cancer types, including medulloblastoma. However, the clinical and biological implications of TERT mutations in medulloblastoma have not been described. Hence, we sought to describe these mutations and their impact in a subgroup-specific manner. We analyzed the TERT promoter by direct sequencing and genotyping in 466 medulloblastomas. The mutational distributions were determined according to subgroup affiliation, demographics, and clinical, prognostic, and molecular features. Integrated genomics approaches were used to identify specific somatic copy number alterations in TERT promoter-mutated and wild-type tumors. Overall, TERT promoter mutations were identified in 21 % of medulloblastomas. Strikingly, the highest frequencies of TERT mutations were observed in SHH (83 %; 55/66) and WNT (31 %; 4/13) medulloblastomas derived from adult patients. Group 3 and Group 4 harbored this alteration in <5 % of cases and showed no association with increased patient age. The prognostic implications of these mutations were highly subgroup-specific. TERT mutations identified a subset with good and poor prognosis in SHH and Group 4 tumors, respectively. Monosomy 6 was mostly restricted to WNT tumors without TERT mutations. Hallmark SHH focal copy number aberrations and chromosome 10q deletion were mutually exclusive with TERT mutations within SHH tumors. TERT promoter mutations are the most common recurrent somatic point mutation in medulloblastoma, and are very highly enriched in adult SHH and WNT tumors. TERT mutations define a subset of SHH medulloblastoma with distinct demographics, cytogenetics, and outcomes.","fulltextAvailable":false,"journal":"Acta neuropathologica","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chromosome Aberrations","uri":{"id":"D002869","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chromosome Deletion","uri":{"id":"D002872","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RNA-Directed DNA Polymerase","uri":{"id":"D012194","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Point Mutation","uri":{"id":"D017354","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Telomerase","uri":{"id":"D019098","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chromosomes","uri":{"id":"D002875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Demography","uri":{"id":"D003710","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drive","uri":{"id":"D004328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genotype","uri":{"id":"D005838","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mutation","uri":{"id":"D009154","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Recurrence","uri":{"id":"D012008","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"DNA-Directed RNA Polymerases","uri":{"id":"D012321","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Symbiosis","uri":{"id":"D013559","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genome","uri":{"id":"D016678","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genomics","uri":{"id":"D023281","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cytogenetics","uri":{"id":"D003582","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medulloblastoma","uri":{"id":"D008527","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Monosomy","uri":{"id":"D009006","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Telomerase","uri":{"id":"D019098","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adolescent","uri":{"id":"D000293","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Child","uri":{"id":"D002648","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Child, Preschool","uri":{"id":"D002675","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"DNA Mutational Analysis","uri":{"id":"D004252","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genotype","uri":{"id":"D005838","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Infant","uri":{"id":"D007223","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mutation","uri":{"id":"D009154","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Telomerase","uri":{"id":"D019098","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Expression Profiling","uri":{"id":"D020869","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medulloblastoma","uri":{"id":"D008527","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Promoter Regions, Genetic","uri":{"id":"D011401","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adolescent","Adult","Brain Neoplasms","Child","Child, Preschool","DNA Mutational Analysis","Female","Gene Expression Profiling","Genotype","Humans","Infant","Male","Medulloblastoma","Middle Aged","Mutation","Prognosis","Promoter Regions, Genetic","Telomerase"]},"pmid":"24174164","title":"TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Brain metastases are common in cancer patients, may significantly diminish neurocognitive function and quality of life and carry a poor prognosis. Brain metastases differ from metastases in other organs such as liver, lung, lymph nodes and bone, both from a pathobiological and from a clinical perspective. Despite the high incidence of brain metastases, only relatively few studies aiming at better understanding of their pathobiology have been performed in the past. However, recently druggable targets have been identified in brain metastases of several tumor types and novel treatment approaches are becoming a feasible option for selected patients. In addition, scientific advances are elucidating some fundamental aspects of brain metastasis formation and may lead to effective strategies of drug-mediated prevention of metastatic brain invasion or inhibition of intracerebral outgrowth.","fulltextAvailable":false,"journal":"Expert review of anticancer therapy","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lymph Nodes","uri":{"id":"D008198","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Quality of Life","uri":{"id":"D011788","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biology","uri":{"id":"D001695","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lung","uri":{"id":"D008168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lymph","uri":{"id":"D008196","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Metastasis","uri":{"id":"D009362","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Incidence","uri":{"id":"D015994","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Life","uri":{"id":"D019369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Combined Modality Therapy","uri":{"id":"D003131","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Animals","Brain Neoplasms","Combined Modality Therapy","Humans"]},"pmid":"24168051","title":"Biology in prevention and treatment of brain metastases.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Glioblastoma multiforme (GBM) is the most common primary brain malignancy. The current standard of therapy consists of surgical resection followed by concurrent chemoradiotherapy with temozolomide. Despite steady advances in all therapeutic modalities, clinical improvements have been slow and the prognosis remains poor. Utilizing powerful large-scale molecular techniques, several key pathways implicated in gliomagenesis have recently been identified and confirmed. These represent potential therapeutic targets, and by developing novel methods to specifically manipulate these pathways, we may achieve a meaningful and substantial improvement in the way we treat GBM. Here, we present and discuss the current status of research into the molecular pathways and potential therapeutic targets in GBM.","fulltextAvailable":false,"journal":"Expert review of anticancer therapy","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chemoradiotherapy","uri":{"id":"D059248","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chemoradiotherapy","uri":{"id":"D059248","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antineoplastic Agents","uri":{"id":"D000970","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Signal Transduction","uri":{"id":"D015398","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Proteins","uri":{"id":"D009363","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Molecular Targeted Therapy","uri":{"id":"D058990","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Antineoplastic Agents","Brain Neoplasms","Glioblastoma","Humans","Molecular Targeted Therapy","Neoplasm Proteins","Signal Transduction"]},"pmid":"24168050","title":"Molecular pathways and potential therapeutic targets in glioblastoma multiforme.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Choroid plexus carcinoma (CPC) is a rare, malignant, primary brain tumor with a poor prognosis. While previous reports have shown benefits of aggressive surgery, very few large-scale studies have focused exclusively on the pediatric population, for whom the risks of aggressive surgery must be weighed carefully against the benefits. We performed a comprehensive systematic review of pediatric CPCs to test the effects of gross total resection (GTR) on overall survival (OS) and progression-free survival (PFS). A Pubmed search was performed to identify children with CPC who underwent surgical resection. Only disaggregated clinical cases in which extent of resection was confirmed by CT or MRI were included for analysis. Kaplan-Meier and multivariate Cox regression survival analyses were performed to determine the effects of extent of resection on OS and PFS. Disaggregated clinical data from a total of 102 pediatric CPC patients (age ≤18 years) with known extent of resection and overall survival were analyzed. GTR was significantly associated with better OS by Kaplan-Meier analysis (logrank p < 0.001). Multivariate Cox regression analysis adjusting for age, gender, tumor location (supratentorial vs. infratentorial), and type of adjuvant therapy (chemotherapy, radiation, and combined therapy), showed that GTR independently increased OS (p = 0.006). While GTR also improved PFS on Kaplan-Meier analysis (p = 0.027), the effect did not meet our criteria for significance in our multivariate Cox model (p = 0.120). GTR improved OS of pediatric CPC and is recommended if it can be safely performed.","fulltextAvailable":false,"journal":"Journal of neuro-oncology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Regression Analysis","uri":{"id":"D012044","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Supratentorial Neoplasms","uri":{"id":"D015173","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chemotherapy, Adjuvant","uri":{"id":"D017024","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Regression Analysis","uri":{"id":"D012044","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proportional Hazards Models","uri":{"id":"D016016","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival Analysis","uri":{"id":"D016019","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Disease-Free Survival","uri":{"id":"D018572","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Choroid Plexus","uri":{"id":"D002831","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Kaplan-Meier Estimate","uri":{"id":"D053208","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carcinoma","uri":{"id":"D002277","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Child","uri":{"id":"D002648","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Choroid","uri":{"id":"D002829","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Choroiditis","uri":{"id":"D002833","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Classification","uri":{"id":"D002965","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Therapy","uri":{"id":"D004358","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pediatrics","uri":{"id":"D010372","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiation","uri":{"id":"D011827","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"General Surgery","uri":{"id":"D013502","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"PubMed","uri":{"id":"D039781","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Child","uri":{"id":"D002648","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Child, Preschool","uri":{"id":"D002675","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Magnetic Resonance Imaging","uri":{"id":"D008279","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tomography, X-Ray Computed","uri":{"id":"D014057","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proportional Hazards Models","uri":{"id":"D016016","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Treatment Outcome","uri":{"id":"D016896","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carcinoma","uri":{"id":"D002277","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Choroid Plexus Neoplasms","uri":{"id":"D016545","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neurosurgical Procedures","uri":{"id":"D019635","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Kaplan-Meier Estimate","uri":{"id":"D053208","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Brain Neoplasms","Carcinoma","Child","Child, Preschool","Choroid Plexus Neoplasms","Female","Humans","Kaplan-Meier Estimate","Magnetic Resonance Imaging","Male","Neurosurgical Procedures","Proportional Hazards Models","Tomography, X-Ray Computed","Treatment Outcome"]},"pmid":"24166581","title":"Gross total resection improves overall survival in children with choroid plexus carcinoma.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: The aim of our study is to evaluate the outcome of patients affected by brain metastases from colorectal cancer and to correlate the outcome with prognostic factors. METHODS: Patients were retrospectively evaluated. Survival distributions were estimated by using the Kaplan-Meier method. The log-rank test was used to assess the impact on survival of individual factors. RESULTS: Among 41 patients (25M and 16F; median age 58), 58.5 % had rectal cancer and 39 % synchronous metastatic disease; 95 % had extracranial metastases, most common site was lung (87.8 %). Seven patients had synchronous brain metastases. Median overall survival after diagnosis of brain metastases was 5 months [95 % confidence interval 3-12 months]. Median survival from brain metastases diagnosis was 4.2 months in patients treated with radiotherapy (29.3 %), 11.9 months in those with radio- and chemotherapy (21.9 %) and 21.4 months in those with surgery with/without radiotherapy or chemotherapy (29.3 %) (P < 0.0001). On multivariate analysis, no independent prognostic factors were found for disease-free interval from diagnosis to brain metastases and overall survival; amount of chemotherapy before brain metastases have no statistically significant relation to brain-metastases-free-interval even if patients who received more than one line of chemotherapy have a longer median brain-metastases-free-interval than those who received less than one. KRAS was found mutated in 17/28 patients without statistically significant correlation to outcome due to the small sample size. CONCLUSIONS: Prognosis of brain-metastases-patients is poor. An interesting tool is to evaluate the correlation of KRAS status and brain metastases with aim to tailor treatment and follow-up.","fulltextAvailable":false,"journal":"International journal of colorectal disease","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rectal Neoplasms","uri":{"id":"D012004","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Colorectal Neoplasms","uri":{"id":"D015179","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Multivariate Analysis","uri":{"id":"D015999","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Confidence Intervals","uri":{"id":"D016001","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sample Size","uri":{"id":"D018401","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Therapy","uri":{"id":"D004358","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lung","uri":{"id":"D008168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mutation","uri":{"id":"D009154","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Metastasis","uri":{"id":"D009362","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiotherapy","uri":{"id":"D011878","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"General Surgery","uri":{"id":"D013502","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Conditioning (Psychology)","uri":{"id":"D003213","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Risk Factors","uri":{"id":"D012307","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival Analysis","uri":{"id":"D016019","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Treatment Outcome","uri":{"id":"D016896","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Young Adult","uri":{"id":"D055815","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Colorectal Neoplasms","uri":{"id":"D015179","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adult","Aged","Brain Neoplasms","Colorectal Neoplasms","Female","Humans","Male","Middle Aged","Risk Factors","Survival Analysis","Treatment Outcome","Young Adult"]},"pmid":"24158623","title":"Brain metastases from colorectal cancer: main clinical factors conditioning outcome.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: Glioblastoma multiforme (GBM) is a high-grade glioma with poor prognosis. Identification of new biomarkers specific to GBM could help in disease diagnosis. We have developed and validated a bioinformatics method to predict proteins likely to be suitable as glioma biomarkers via a global microarray meta-analysis to identify uncharacterized genes consistently coexpressed with known glioma-associated genes. METHODS: A novel bioinformatics method was implemented called global microarray meta-analysis, using approximately 16,000 microarray experiments to identify uncharacterized genes consistently coexpressed with known glioma-associated genes. These novel biomarkers were validated as proteins highly expressed in human gliomas varying in tumor grades using immunohistochemistry. Glioma gene databases were used to assess delineation of expression of these markers in varying glioma grades and subtypes of GBM. RESULTS: We have identified 5 potential biomarkers-spondin1, Plexin-B2, SLIT3, fibulin-1, and LINGO1-that were validated as proteins highly expressed on the surface of human gliomas using immunohistochemistry. Expression of spondin1, Plexin-B2, and SLIT3 was significantly higher (P < .01) in high-grade gliomas than in low-grade gliomas. These biomarkers were significant discriminators in grade IV gliomas compared with either grade III or II tumors and also distinguished between GBM subclasses. CONCLUSIONS: This study strongly suggests that this type of bioinformatics approach has high translational potential to rapidly discern which poorly characterized proteins may be of clinical relevance.","fulltextAvailable":false,"journal":"Neuro-oncology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Grading","uri":{"id":"D060787","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Discrimination (Psychology)","uri":{"id":"D004192","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes","uri":{"id":"D005796","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunohistochemistry","uri":{"id":"D007150","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteins","uri":{"id":"D011506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biological Markers","uri":{"id":"D015415","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Computational Biology","uri":{"id":"D019295","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Internationality","uri":{"id":"D038622","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Algorithms","uri":{"id":"D000465","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain","uri":{"id":"D001921","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Calcium-Binding Proteins","uri":{"id":"D002135","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Membrane Proteins","uri":{"id":"D008565","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nerve Tissue Proteins","uri":{"id":"D009419","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tumor Markers, Biological","uri":{"id":"D014408","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Expression Regulation, Neoplastic","uri":{"id":"D015972","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Case-Control Studies","uri":{"id":"D016022","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Expression Profiling","uri":{"id":"D020869","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Extracellular Matrix Proteins","uri":{"id":"D016326","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oligonucleotide Array Sequence Analysis","uri":{"id":"D020411","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Grading","uri":{"id":"D060787","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Algorithms","Brain","Brain Neoplasms","Calcium-Binding Proteins","Case-Control Studies","Extracellular Matrix Proteins","Gene Expression Profiling","Gene Expression Regulation, Neoplastic","Glioma","Humans","Membrane Proteins","Neoplasm Grading","Nerve Tissue Proteins","Oligonucleotide Array Sequence Analysis","Prognosis","Tumor Markers, Biological"]},"pmid":"24158112","title":"Experimental validation of 5 in-silico predicted glioma biomarkers.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Primary gliosarcoma (PGS) is a rare neoplasm with a poor prognosis. It is considered as a variant of glioblastoma multiforme (GBM) and as a grade IV neoplasm. There is little evidence on the optimal therapy for this disease: treatment of PGS includes surgery, radiotherapy and chemotherapy, and often the same treatment used for GBM is employed for PGS. Several studies have demonstrated that somatostatin receptors are overexpressed in gliomas; somatostatin analogues could therefore also be employed in this mixed form but to date the experience reported in the literature is unclear and there are no studies about the use of these agents in PGS. We present the case of a patient affected by both PGS and neuroendocrine pancreatic cancer. The case is interesting for the prolonged survival and for the stabilization of disease obtained during therapy with somatostatin analogues.","fulltextAvailable":false,"journal":"Tumori","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Grading","uri":{"id":"D060787","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pancreatic Neoplasms","uri":{"id":"D010190","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Receptors, Somatostatin","uri":{"id":"D017481","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Therapy","uri":{"id":"D004358","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Literature","uri":{"id":"D008091","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pancreatitis","uri":{"id":"D010195","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiotherapy","uri":{"id":"D011878","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"General Surgery","uri":{"id":"D013502","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Somatostatin","uri":{"id":"D013004","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gliosarcoma","uri":{"id":"D018316","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Administration Schedule","uri":{"id":"D004334","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Magnetic Resonance Imaging","uri":{"id":"D008279","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Staging","uri":{"id":"D009367","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tomography, X-Ray Computed","uri":{"id":"D014057","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Positron-Emission Tomography","uri":{"id":"D049268","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pancreatic Neoplasms","uri":{"id":"D010190","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Octreotide","uri":{"id":"D015282","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survivors","uri":{"id":"D017741","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gliosarcoma","uri":{"id":"D018316","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neuroendocrine Tumors","uri":{"id":"D018358","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm, Residual","uri":{"id":"D018365","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antineoplastic Agents, Hormonal","uri":{"id":"D018931","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chemoradiotherapy, Adjuvant","uri":{"id":"D059186","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Aged","Antineoplastic Agents, Hormonal","Brain Neoplasms","Chemoradiotherapy, Adjuvant","Drug Administration Schedule","Gliosarcoma","Humans","Magnetic Resonance Imaging","Male","Neoplasm Staging","Neoplasm, Residual","Neuroendocrine Tumors","Octreotide","Pancreatic Neoplasms","Positron-Emission Tomography","Survivors","Tomography, X-Ray Computed"]},"pmid":"24158079","title":"The case of a patient affected by primary gliosarcoma and neuroendocrine pancreatic cancer with prolonged survival.","year":"2013 May-Jun"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Glioblastoma multiforme (GBM) is the most common primary malignant adult brain tumor and is associated with poor survival. Recently, stem-like cell populations have been identified in numerous malignancies including GBM. To identify genes whose expression is changed with differentiation, we compared transcript profiles from a GBM oncosphere line before and after differentiation. Bioinformatic analysis of the gene expression profiles identified podocalyxin-like protein (PODXL), a protein highly expressed in human embryonic stem cells, as a potential marker of undifferentiated GBM stem-like cells. The loss of PODXL expression upon differentiation of GBM stem-like cell lines was confirmed by quantitative real-time PCR and flow cytometry. Analytical flow cytometry of numerous GBM oncosphere lines demonstrated PODXL expression in all lines examined. Knockdown studies and flow cytometric cell sorting experiments demonstrated that PODXL is involved in GBM stem-like cell proliferation and oncosphere formation. Compared to PODXL-negative cells, PODXL-positive cells had increased expression of the progenitor/stem cell markers Musashi1, SOX2, and BMI1. Finally, PODXL expression directly correlated with increasing glioma grade and was a marker for poor outcome in patients with GBM. In summary, we have demonstrated that PODXL is expressed in GBM stem-like cells and is involved in cell proliferation and oncosphere formation. Moreover, high PODXL expression correlates with increasing glioma grade and decreased overall survival in patients with GBM.","fulltextAvailable":false,"journal":"PloS one","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Expression","uri":{"id":"D015870","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Stem Cells","uri":{"id":"D013234","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Line","uri":{"id":"D002460","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Flow Cytometry","uri":{"id":"D005434","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Stem Cells","uri":{"id":"D013234","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Expression","uri":{"id":"D015870","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Expression Profiling","uri":{"id":"D020869","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Proliferation","uri":{"id":"D049109","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Embryonic Stem Cells","uri":{"id":"D053595","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Transcriptome","uri":{"id":"D059467","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Real-Time Polymerase Chain Reaction","uri":{"id":"D060888","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes","uri":{"id":"D005796","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteins","uri":{"id":"D011506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Polymerase Chain Reaction","uri":{"id":"D016133","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Computational Biology","uri":{"id":"D019295","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Differentiation","uri":{"id":"D002454","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Flow Cytometry","uri":{"id":"D005434","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nerve Tissue Proteins","uri":{"id":"D009419","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tumor Markers, Biological","uri":{"id":"D014408","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplastic Stem Cells","uri":{"id":"D014411","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Expression Regulation, Neoplastic","uri":{"id":"D015972","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival Analysis","uri":{"id":"D016019","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Line, Tumor","uri":{"id":"D045744","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Proliferation","uri":{"id":"D049109","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Knockdown Techniques","uri":{"id":"D055785","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sialoglycoproteins","uri":{"id":"D012795","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RNA-Binding Proteins","uri":{"id":"D016601","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Spheroids, Cellular","uri":{"id":"D018874","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"SOXB1 Transcription Factors","uri":{"id":"D055748","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Grading","uri":{"id":"D060787","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Polycomb Repressive Complex 1","uri":{"id":"D063150","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adult","Brain Neoplasms","Cell Differentiation","Cell Line, Tumor","Cell Proliferation","Flow Cytometry","Gene Expression Regulation, Neoplastic","Gene Knockdown Techniques","Glioblastoma","Humans","Neoplasm Grading","Neoplastic Stem Cells","Nerve Tissue Proteins","Polycomb Repressive Complex 1","Prognosis","RNA-Binding Proteins","SOXB1 Transcription Factors","Sialoglycoproteins","Spheroids, Cellular","Survival Analysis","Tumor Markers, Biological"]},"pmid":"24146797","title":"Podocalyxin-like protein is expressed in glioblastoma multiforme stem-like cells and is associated with poor outcome.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Patients with cerebral metastasis of carcinomas have a poor prognosis. However, the process at the metastatic site has barely been investigated, in particular the role of the resident (stromal) cells. Studies in primary carcinomas demonstrate the influence of the microenvironment on metastasis, even on prognosis(1,2). Especially the tumor associated macrophages (TAM) support migration, invasion and proliferation(3). Interestingly, the major target sites of metastasis possess tissue-specific macrophages, such as Kupffer cells in the liver or microglia in the CNS. Moreover, the metastatic sites also possess other tissue-specific cells, like astrocytes. Recently, astrocytes were demonstrated to foster proliferation and persistence of cancer cells(4,5). Therefore, functions of these tissue-specific cell types seem to be very important in the process of brain metastasis(6,7). Despite these observations, however, up to now there is no suitable in vivo/in vitro model available to directly visualize glial reactions during cerebral metastasis formation, in particular by bright field microscopy. Recent in vivo live imaging of carcinoma cells demonstrated their cerebral colonization behavior(8). However, this method is very laborious, costly and technically complex. In addition, these kinds of animal experiments are restricted to small series and come with a substantial stress for the animals (by implantation of the glass plate, injection of tumor cells, repetitive anaesthesia and long-term fixation). Furthermore, in vivo imaging is thus far limited to the visualization of the carcinoma cells, whereas interactions with resident cells have not yet been illustrated. Finally, investigations of human carcinoma cells within immunocompetent animals are impossible(8). For these reasons, we established a coculture system consisting of an organotypic mouse brain slice and epithelial cells embedded in matrigel (3D cell sphere). The 3D carcinoma cell spheres were placed directly next to the brain slice edge in order to investigate the invasion of the neighboring brain tissue. This enables us to visualize morphological changes and interactions between the glial cells and carcinoma cells by fluorescence and even by bright field microscopy. After the coculture experiment, the brain tissue or the 3D cell spheroids can be collected and used for further molecular analyses (e.g. qRT-PCR, IHC, or immunoblot) as well as for investigations by confocal microscopy. This method can be applied to monitor the events within a living brain tissue for days without deleterious effects to the brain slices. The model also allows selective suppression and replacement of resident cells by cells from a donor tissue to determine the distinct impact of a given genotype. Finally, the coculture model is a practicable alternative to in vivo approaches when testing targeted pharmacological manipulations.","fulltextAvailable":false,"journal":"Journal of visualized experiments : JoVE","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Communication","uri":{"id":"D002450","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Epithelial Cells","uri":{"id":"D004847","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Kupffer Cells","uri":{"id":"D007728","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neuroglia","uri":{"id":"D009457","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissue Donors","uri":{"id":"D014019","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Stromal Cells","uri":{"id":"D017154","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microscopy, Confocal","uri":{"id":"D018613","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animal Experimentation","uri":{"id":"D032761","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Astrocytes","uri":{"id":"D001253","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carcinoma","uri":{"id":"D002277","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Emigration and Immigration","uri":{"id":"D004641","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Fluorescence","uri":{"id":"D005453","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Foster Home Care","uri":{"id":"D005581","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genotype","uri":{"id":"D005838","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Internship and Residency","uri":{"id":"D007396","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Macrophages","uri":{"id":"D008264","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microscopy","uri":{"id":"D008853","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Metastasis","uri":{"id":"D009362","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissue Donors","uri":{"id":"D014019","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissues","uri":{"id":"D014024","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunoblotting","uri":{"id":"D015151","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Living Wills","uri":{"id":"D016224","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Coculture Techniques","uri":{"id":"D018920","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice","uri":{"id":"D051379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunocompetence","uri":{"id":"D007121","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microglia","uri":{"id":"D017628","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Astrocytes","uri":{"id":"D001253","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Invasiveness","uri":{"id":"D009361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice","uri":{"id":"D051379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Breast Neoplasms","uri":{"id":"D001943","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carcinoma","uri":{"id":"D002277","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Collagen","uri":{"id":"D003094","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Combinations","uri":{"id":"D004338","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Laminin","uri":{"id":"D007797","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neuroglia","uri":{"id":"D009457","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Organ Culture Techniques","uri":{"id":"D009924","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteoglycans","uri":{"id":"D011509","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microscopy, Video","uri":{"id":"D018715","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Spheroids, Cellular","uri":{"id":"D018874","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Coculture Techniques","uri":{"id":"D018920","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"MCF-7 Cells","uri":{"id":"D061986","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Animals","Astrocytes","Brain Neoplasms","Breast Neoplasms","Carcinoma","Coculture Techniques","Collagen","Drug Combinations","Female","Humans","Laminin","MCF-7 Cells","Mice","Microscopy, Video","Neoplasm Invasiveness","Neuroglia","Organ Culture Techniques","Proteoglycans","Spheroids, Cellular"]},"pmid":"24145580","title":"Coculture system with an organotypic brain slice and 3D spheroid of carcinoma cells.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVE: This study sought to report patient characteristics, risk factors, and trends in management for astroblastoma patients. METHODS: A retrospective analysis was conducted utilizing the Surveillance, Epidemiology and End Results Program of the National Cancer Institute. RESULTS: Two hundred and thirty-nine patients were identified, with 206 patients receiving treatment. The median age at diagnosis was 35 years (range 0 to 84 years). Tumor location was available for 177 patients, and the majority were supratentorial (n = 144, 81.3%). The median overall survival and cause-specific survival for the cohort receiving treatment was 55 and 65 months, respectively. On univariate analysis, patients receiving surgery alone compared to only radiotherapy displayed improved overall survival (OS) and cause-specific survival (CSS) with a 5-year OS of 62.2% vs. 27.3%, P < .001, and CSS of 67.3% vs. 31.9%, P = .003. Supratentorial tumor location was associated with worse survival, with an estimated 5-year OS of 44.9% for supratentorial tumors compared to 75% for infratentorial tumors (hazard ratio 3.41 [95% CI, 1.76 to 6.62]; P < .001) and CSS of 47.5% (supratentorial) to 82% (infratentorial) (hazard ratio 3.95 [95% CI, 1.81 to 8.62]; P = .001). Age >60 years at diagnosis and treatment before 1990 were correlated with decreased survival on both the univariate and the multivariate analyses. CONCLUSIONS: To our knowledge, this is the largest report of astroblastoma patients described in the literature. Supratentorial tumor location, older age, and treatment prior to 1990 were poor prognostic factors.","fulltextAvailable":false,"journal":"World neurosurgery","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Risk Factors","uri":{"id":"D012307","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Multivariate Analysis","uri":{"id":"D015999","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Supratentorial Neoplasms","uri":{"id":"D015173","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Infratentorial Neoplasms","uri":{"id":"D015192","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"SEER Program","uri":{"id":"D018426","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"National Cancer Institute (U.S.)","uri":{"id":"D054547","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Academies and Institutes","uri":{"id":"D000047","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Literature","uri":{"id":"D008091","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiotherapy","uri":{"id":"D011878","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"General Surgery","uri":{"id":"D013502","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Knowledge","uri":{"id":"D019359","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Epidemiology","uri":{"id":"D004813","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms, Neuroepithelial","uri":{"id":"D018302","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adolescent","uri":{"id":"D000293","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged, 80 and over","uri":{"id":"D000369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aging","uri":{"id":"D000375","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cause of Death","uri":{"id":"D002423","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Child","uri":{"id":"D002648","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Child, Preschool","uri":{"id":"D002675","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Infant","uri":{"id":"D007223","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Infant, Newborn","uri":{"id":"D007231","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Multivariate Analysis","uri":{"id":"D015999","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival Analysis","uri":{"id":"D016019","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Databases, Factual","uri":{"id":"D016208","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Treatment Outcome","uri":{"id":"D016896","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Age of Onset","uri":{"id":"D017668","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Age Distribution","uri":{"id":"D017677","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Young Adult","uri":{"id":"D055815","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Supratentorial Neoplasms","uri":{"id":"D015173","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Infratentorial Neoplasms","uri":{"id":"D015192","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms, Neuroepithelial","uri":{"id":"D018302","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"SEER Program","uri":{"id":"D018426","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adolescent","Adult","Age Distribution","Age of Onset","Aged","Aged, 80 and over","Aging","Brain Neoplasms","Cause of Death","Child","Child, Preschool","Databases, Factual","Female","Humans","Infant","Infant, Newborn","Infratentorial Neoplasms","Male","Middle Aged","Multivariate Analysis","Neoplasms, Neuroepithelial","Prognosis","SEER Program","Supratentorial Neoplasms","Survival Analysis","Treatment Outcome","Young Adult"]},"pmid":"24141003","title":"Astroblastomas: a Surveillance, Epidemiology, and End Results (SEER)-based patterns of care analysis.","year":"2014 Jul-Aug"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND AND OBJECTIVES: Bmi1 and EZH2 are involved in tumorigenesis of gliomas. However, clinicopathologic significance of their expression in gliomas is unknown; especially, the prognostic value of combined expression of Bmi1 and EZH2 has not been explored. METHODS: Bmi1 and EZH2 expression in human gliomas and nonneoplastic brain tissues was measured by immunohistochemistry. RESULTS: Both Bmi1 and EZH2 expressions in glioma tissues were significantly higher than those in corresponding nonneoplastic brain tissues (both P<0.001). Additionally, the upregulations of Bmi1 and EZH2 proteins were both significantly associated with advanced WHO grades (both P<0.001) and low KPS (P=0.008 and 0.01, respectively). Moreover, the overall survival of patients with high Bmi1 protein expression (P=0.006) or high EZH2 protein expression (P=0.01) was obviously lower than those with low expressions. More interestingly, glioma patients with combined overexpression of Bmi1 and EZH2 proteins had the shortest overall survival (P<0.001). Furthermore, multivariate analysis showed that Bmi1n expression (P=0.02), EZH2 expression (P=0.03), and combined expression of Bmi1 and EZH2 (P=0.008), were all independent prognostic factors for overall survival in glioma patients. CONCLUSIONS: Our data suggest for the first time that the combination of Bmi1 and EZH2 overexpression may be a highly sensitive marker for the prognosis in glioma patients.","fulltextAvailable":false,"journal":"Journal of the neurological sciences","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Multivariate Analysis","uri":{"id":"D015999","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunohistochemistry","uri":{"id":"D007150","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteins","uri":{"id":"D011506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissues","uri":{"id":"D014024","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"World Health Organization","uri":{"id":"D014944","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Up-Regulation","uri":{"id":"D015854","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carcinogenesis","uri":{"id":"D063646","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adolescent","uri":{"id":"D000293","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain","uri":{"id":"D001921","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Child","uri":{"id":"D002648","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Expression Regulation, Neoplastic","uri":{"id":"D015972","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Young Adult","uri":{"id":"D055815","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Polycomb Repressive Complex 1","uri":{"id":"D063150","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Polycomb Repressive Complex 2","uri":{"id":"D063151","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adolescent","Adult","Aged","Brain","Brain Neoplasms","Child","Female","Gene Expression Regulation, Neoplastic","Glioma","Humans","Male","Middle Aged","Polycomb Repressive Complex 1","Polycomb Repressive Complex 2","Prognosis","Young Adult"]},"pmid":"24139839","title":"Combined aberrant expression of Bmi1 and EZH2 is predictive of poor prognosis in glioma patients.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: We hypothesized that KRAS mutations function as a marker of poor sensitivity to first-line platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type (WT) non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Consecutive advanced nonsquamous EGFR WT NSCLCs treated at the Medical Oncology of Perugia with simultaneous assessment of KRAS mutation status were eligible. Anaplastic lymphoma kinase (ALK) gene status was known in roughly half of the patients who had KRAS WT. RESULTS: Two hundred four patients were included. Among them, the 77 individuals carrying a KRAS-mutant phenotype experienced a significantly inferior outcome in terms of response rate (P = .04), disease control rate (P = .05), and progression-free survival (PFS) (P = .05) compared with the EGFR WT/KRAS WT population. The association between KRAS mutation and shorter PFS remained statistically significant at multivariate analysis (hazard ratio [HR], 1.45). In addition, patients with KRAS mutations reported a significantly shorter overall survival (OS) compared with patients with EGFR WT/KRAS WT/ALK negativity (n = 64) (P = .02). Among patients with KRAS mutations, those harboring a mutation at codon 13 (n = 12) performed worse than those with a mutation at codon 12 (n = 62) in terms of both PFS and OS (P = .09 for both). CONCLUSION: KRAS mutation appears to negatively affect sensitivity to first-line platinum-based chemotherapy in patients with advanced nonsquamous EGFR WT NSCLC. Studies on larger case series are needed to address differences in clinical outcome according to the type of mutation.","fulltextAvailable":false,"journal":"Clinical lung cancer","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lung Neoplasms","uri":{"id":"D008175","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Multivariate Analysis","uri":{"id":"D015999","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Disease-Free Survival","uri":{"id":"D018572","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medical Oncology","uri":{"id":"D008495","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Therapy","uri":{"id":"D004358","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes","uri":{"id":"D005796","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lung","uri":{"id":"D008168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lymphoma","uri":{"id":"D008223","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mutation","uri":{"id":"D009154","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phenotype","uri":{"id":"D010641","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phosphotransferases","uri":{"id":"D010770","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lifting","uri":{"id":"D017770","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Codon","uri":{"id":"D003062","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged, 80 and over","uri":{"id":"D000369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antineoplastic Combined Chemotherapy Protocols","uri":{"id":"D000971","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Follow-Up Studies","uri":{"id":"D005500","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mutation","uri":{"id":"D009154","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Staging","uri":{"id":"D009367","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tumor Markers, Biological","uri":{"id":"D014408","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cohort Studies","uri":{"id":"D015331","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival Rate","uri":{"id":"D015996","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adenocarcinoma","uri":{"id":"D000230","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carcinoma, Non-Small-Cell Lung","uri":{"id":"D002289","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lung Neoplasms","uri":{"id":"D008175","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Platinum","uri":{"id":"D010984","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proto-Oncogene Proteins","uri":{"id":"D011518","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Receptor, Epidermal Growth Factor","uri":{"id":"D011958","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Rearrangement","uri":{"id":"D015321","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"ras Proteins","uri":{"id":"D018631","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Receptor Protein-Tyrosine Kinases","uri":{"id":"D020794","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adenocarcinoma","Adult","Aged","Aged, 80 and over","Antineoplastic Combined Chemotherapy Protocols","Brain Neoplasms","Carcinoma, Non-Small-Cell Lung","Cohort Studies","Female","Follow-Up Studies","Gene Rearrangement","Humans","Lung Neoplasms","Male","Middle Aged","Mutation","Neoplasm Staging","Platinum","Prognosis","Proto-Oncogene Proteins","Receptor Protein-Tyrosine Kinases","Receptor, Epidermal Growth Factor","Survival Rate","Tumor Markers, Biological","ras Proteins"]},"pmid":"24139827","title":"Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECT: This study reviews the first operative series of pediatric brain tumors from Uganda, the largest series from Sub-Saharan Africa, and explores the challenges to progress in pediatric neuro-oncology in the region. METHODS: This is a retrospective operative series of brain tumors in 172 children at Cure Children's Hospital of Uganda over 10 years. Demographics, clinical presentation, lesion location, histopathology, operative management, and outcome were investigated. Survival was assessed using Kaplan-Meier method. Log-rank test and p value with Bonferroni correction were used to determine significance of survival differences. RESULTS: There were 103 males (59.9 %) and 69 females (40.1 %; mean age at diagnosis 6.5 years with 29 % < 2 years). The most common histologic types were pilocytic astrocytoma (23.2 %), ependymoma (16.3 %), craniopharyngioma (9.9 %), choroid plexus papilloma (9.3 %), and medulloblastoma (8.1 %). Supratentorial tumors (62.2 %) were more common. Symptomatic hydrocephalus predominated at presentation (66.9 %). In 71 (41.3 %), the presentation was macrocephaly or a visible mass. Estimated 5-year survival was 60 %. CONCLUSIONS: The majority of pediatric brain tumors in the region likely go unrecognized. Most that do come to attention have a \"visible diagnosis.\" Unlike operative series from developed countries, information about the incidence, prevalence, and overall burden of disease for different tumor types cannot be deduced from the various operative series reported from limited resource countries because of the selection bias that is unique to this context. Delayed presentation and poor access to adjuvant therapies were important contributors to the high mortality. The epidemiology of pediatric brain tumors in sub-Saharan Africa is obscure.","fulltextAvailable":false,"journal":"Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Developing Countries","uri":{"id":"D003906","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Treatment Outcome","uri":{"id":"D016896","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Developed Countries","uri":{"id":"D019049","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Astrocytoma","uri":{"id":"D001254","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Child, Hospitalized","uri":{"id":"D002673","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Choroid Plexus","uri":{"id":"D002831","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Supratentorial Neoplasms","uri":{"id":"D015173","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Selection Bias","uri":{"id":"D015983","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Africa South of the Sahara","uri":{"id":"D017954","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Papilloma, Choroid Plexus","uri":{"id":"D020288","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Africa","uri":{"id":"D000349","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Child","uri":{"id":"D002648","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Choroid","uri":{"id":"D002829","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Choroiditis","uri":{"id":"D002833","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Demography","uri":{"id":"D003710","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitalization","uri":{"id":"D006760","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals","uri":{"id":"D006761","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mortality","uri":{"id":"D009026","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pathology","uri":{"id":"D010336","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pediatrics","uri":{"id":"D010372","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Bias (Epidemiology)","uri":{"id":"D015982","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Incidence","uri":{"id":"D015994","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prevalence","uri":{"id":"D015995","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Uncertainty","uri":{"id":"D035501","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Astrocytoma","uri":{"id":"D001254","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Craniopharyngioma","uri":{"id":"D003397","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ependymoma","uri":{"id":"D004806","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Epidemiology","uri":{"id":"D004813","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hydrocephalus","uri":{"id":"D006849","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medulloblastoma","uri":{"id":"D008527","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Papilloma","uri":{"id":"D010212","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Uganda","uri":{"id":"D014454","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Macrocephaly","uri":{"id":"D058627","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Child","uri":{"id":"D002648","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Child, Preschool","uri":{"id":"D002675","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Follow-Up Studies","uri":{"id":"D005500","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Infant","uri":{"id":"D007223","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Retrospective Studies","uri":{"id":"D012189","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Uganda","uri":{"id":"D014454","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Treatment Outcome","uri":{"id":"D016896","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals, Pediatric","uri":{"id":"D006776","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Africa South of the Sahara","uri":{"id":"D017954","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Africa South of the Sahara","Brain Neoplasms","Child","Child, Preschool","Female","Follow-Up Studies","Hospitals, Pediatric","Humans","Infant","Male","Retrospective Studies","Treatment Outcome","Uganda"]},"pmid":"24132516","title":"Presentation, pathology, and treatment outcome of brain tumors in 172 consecutive children at CURE Children's Hospital of Uganda. The predominance of the visible diagnosis and the uncertainties of epidemiology in sub-Saharan Africa.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Cancer stem cells are thought to be responsible for tumor recurrence and resistance in glioblastomas. An isocitrate dehydrogenase1 (IDH1) mutation, affecting codon132 of the isocitrate dehydrogenase1 gene, has prognostic significance in glioblastomas. We investigated whether stem cell marker expression [CD133, CD34, and vascular endothelial growth factor (VEGF)] and IDH1 mutation correlate with clinical factors and prognosis in glioblastoma. CD133, CD34, and VEGF expression was evaluated by immunohistochemistry in 67 cases of glioblastoma identified between 2005 and 2012. IDH1 mutation was assessed by immunohistochemistry, peptide-nucleic-acid mediated PCR clamping, and direct gene sequencing. Diffuse CD133 expression was detected in 12 (17.9 %) cases and was associated with poor overall survival (OS) (P = 0.010) and progression-free survival (P = 0.017). CD34 and VEGF expression were not associated with prognosis in these samples. IDH1 mutation was detected in ten (14.9 %) cases. Eight were clinically secondary tumors and two were primary tumors (P < 0.001); the mean age of the secondary tumor patients was significantly younger (P = 0.001, 41.20 vs. 59.14). IDH1-positive patients had longer OS than IDH1-negative patients (25.78 vs. 22.95 months), but this difference was not significant. In addition, IDH1 and CD34 expression showed a negative correlation (P = 0.024). Multivariate analysis showed that age, extent of surgery, and diffuse CD133 expression correlated with OS. CD133 may be a survival marker for glioblastoma. Further characterization of CD133, IDH1, and vascular markers in glioblastoma may help identify new therapeutic targets.","fulltextAvailable":false,"journal":"Journal of neuro-oncology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Stem Cells","uri":{"id":"D013234","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Multivariate Analysis","uri":{"id":"D015999","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Endothelial Growth Factors","uri":{"id":"D016228","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Disease-Free Survival","uri":{"id":"D018572","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Intercellular Signaling Peptides and Proteins","uri":{"id":"D036341","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplastic Stem Cells","uri":{"id":"D014411","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Constriction","uri":{"id":"D003250","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes","uri":{"id":"D005796","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunohistochemistry","uri":{"id":"D007150","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Isocitrates","uri":{"id":"D007523","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mutation","uri":{"id":"D009154","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Recurrence","uri":{"id":"D012008","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"General Surgery","uri":{"id":"D013502","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Polymerase Chain Reaction","uri":{"id":"D016133","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vascular Endothelial Growth Factor A","uri":{"id":"D042461","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Follow-Up Studies","uri":{"id":"D005500","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunoenzyme Techniques","uri":{"id":"D007124","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mutation","uri":{"id":"D009154","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Staging","uri":{"id":"D009367","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Peptides","uri":{"id":"D010455","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Retrospective Studies","uri":{"id":"D012189","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tumor Markers, Biological","uri":{"id":"D014408","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplastic Stem Cells","uri":{"id":"D014411","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival Rate","uri":{"id":"D015996","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Polymerase Chain Reaction","uri":{"id":"D016133","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glycoproteins","uri":{"id":"D006023","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Isocitrate Dehydrogenase","uri":{"id":"D007521","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antigens, CD","uri":{"id":"D015703","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Antigens, CD","Brain Neoplasms","Female","Follow-Up Studies","Glioblastoma","Glycoproteins","Humans","Immunoenzyme Techniques","Isocitrate Dehydrogenase","Male","Middle Aged","Mutation","Neoplasm Staging","Neoplastic Stem Cells","Peptides","Polymerase Chain Reaction","Prognosis","Retrospective Studies","Survival Rate","Tumor Markers, Biological"]},"pmid":"24129546","title":"Correlation between the prognostic value and the expression of the stem cell marker CD133 and isocitrate dehydrogenase1 in glioblastomas.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"The prognosis of glioblastoma remains poor despite significant improvement in cytoreductive surgery, external irradiation and new approach of systemic treatment as antiangiogenic therapy. One of the issues is the low concentration in the infiltrated parenchyma of therapeutic agent administered intravenously mainly due to the blood-brain barrier. An intracerebral injection is advocated to overpass this barrier, this kind of administration need a low flow and continuous injection. The development of sophisticated implanted devices for convection-enhanced delivery is a mandatory step to have a controlled released of a therapeutic agent in glioblastoma treatment. Before testing such a device in a clinical trial a serious preclinical studies are required, in order to test it in realistic conditions we have develop the first induced high grade glioma model in a non-rodent animal: the pig. 21 pigs have been implanted in the parietal lobe with human glioblastoma cell lineage under a chemical immunosuppression by ciclosporine. A MRI follow up was then realized. 15 pigs have been implanted with U87MG, 14 have presented a macroscopic significant tumor, with radiological and anatomapathological characteristics of high grade glioma. 6 pigs were implanted with G6, stem-like cells tumors of glioblastoma, 1 pig develops a macroscopic tumor. This is the first reproducible glioma model in a large animal described, it open the way to preclinical studies to test implanted devices in anatomic realistic conditions, without the ethical issues of a primate use.","fulltextAvailable":false,"journal":"Journal of neuroscience methods","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Lineage","uri":{"id":"D019070","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blood-Brain Barrier","uri":{"id":"D001812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ethics","uri":{"id":"D004989","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Parietal Lobe","uri":{"id":"D010296","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Equipment and Supplies","uri":{"id":"D004864","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Primates","uri":{"id":"D011323","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"General Surgery","uri":{"id":"D013502","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Transplantation, Heterologous","uri":{"id":"D014183","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Heterografts","uri":{"id":"D064593","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunosuppression","uri":{"id":"D007165","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cyclosporine","uri":{"id":"D016572","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rabeprazole","uri":{"id":"D064750","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Disease Models, Animal","uri":{"id":"D004195","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Magnetic Resonance Imaging","uri":{"id":"D008279","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Line, Tumor","uri":{"id":"D045744","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sus scrofa","uri":{"id":"D034421","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Heterografts","uri":{"id":"D064593","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Animals","Brain Neoplasms","Cell Line, Tumor","Disease Models, Animal","Glioma","Heterografts","Humans","Magnetic Resonance Imaging","Sus scrofa"]},"pmid":"24126047","title":"Imaging and histological characterization of a human brain xenograft in pig: the first induced glioma model in a large animal.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"The management of melanoma brain metastases (MBM) includes different therapeutic modalities, such as surgery, radiotherapy and chemotherapy. Despite the choice of treatments, survival remains poor, exceeding 1 year only in patients with solitary metastases and absence of extracranial disease. A total of 115 consecutive MBM patients observed between 1994 and 2010 were included in an historical cohort study. Demographic, clinical data and tumour characteristics were collected and survival status was ascertained across the follow-up window. The statistical associations between individual and tumour data and overall survival were investigated using Kaplan-Meier survival function and Cox's multiple regression analysis. The median survival was 4.3 months (95% confidence interval 2.6-6.1). Patients who underwent surgery or stereotactic radiosurgery showed a significantly (P<0.001) better prognosis than those who received chemotherapy and/or radiotherapy or supportive therapies. Patients without clinical symptoms experienced a statistically significant better survival (P=0.02) than patients with clinical symptoms; analogue difference was observed to be in favour of patients whose symptoms improved after the first treatment of MBM (P<0.001). The presence of symptoms, clinical outcome and first treatment received were the only independent variables to predict survival. Patients who cannot receive surgery or stereotactic radiosurgery have the worst overall survival.","fulltextAvailable":false,"journal":"Melanoma research","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Regression Analysis","uri":{"id":"D012044","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cohort Studies","uri":{"id":"D015331","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Confidence Intervals","uri":{"id":"D016001","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiosurgery","uri":{"id":"D016634","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Demography","uri":{"id":"D003710","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Therapy","uri":{"id":"D004358","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Melanoma","uri":{"id":"D008545","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Metastasis","uri":{"id":"D009362","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiotherapy","uri":{"id":"D011878","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"General Surgery","uri":{"id":"D013502","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiosurgery","uri":{"id":"D016634","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Melanoma","uri":{"id":"D008545","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proportional Hazards Models","uri":{"id":"D016016","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival Analysis","uri":{"id":"D016019","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Treatment Outcome","uri":{"id":"D016896","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiosurgery","uri":{"id":"D016634","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Kaplan-Meier Estimate","uri":{"id":"D053208","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Brain Neoplasms","Female","Humans","Kaplan-Meier Estimate","Male","Melanoma","Middle Aged","Prognosis","Proportional Hazards Models","Radiosurgery","Survival Analysis","Treatment Outcome"]},"pmid":"24121190","title":"The treatment of melanoma brain metastases before the advent of targeted therapies: associations between therapeutic choice, clinical symptoms and outcome with survival.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Aberrant expression of the simple mucin-type carbohydrate antigens such as T, Tn, sialyl-T and sialyl-Tn is associated with poor prognosis in several cancers. β1,3-N-acetylglucosaminyltransferase-3 (B3GNT3), a member of the β3GlcNAcT family, is responsible for forming extended core 1 (T antigen) oligosaccharides. The role of B3GNT3, which is expressed in various tissues including human fetal brain, in regulating neuroblastoma (NB) formation and cell behaviors remains unclear. Here, we showed that increased B3GNT3 expression evaluated using immunohistochemistry in NB tumor tissues correlated well with the histological grade of differentiation as well as a favorable Shimada's subset of pathology. Univariate and multivariate analyses revealed that positive B3GNT3 expression in tumor tissues predicted a favorable prognosis in NB patients independent of other prognostic markers. B3GNT3 overexpression suppresses T antigen formation and malignant phenotypes including migration and invasion of SK-N-SH cells, whereas B3GNT3 knockdown enhances these phenotypes of SK-N-SH cells. Moreover, B3GNT3 expression decreased phosphorylation of focal adhesion kinase (FAK), Src, paxillin, Akt and ERK1/2. We conclude that B3GNT3 predicts a favorable cancer behavior of NB and suppresses malignant phenotypes by modulating mucin-type O-glycosylation and signaling in NB cells.","fulltextAvailable":false,"journal":"Cancer science","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"src-Family Kinases","uri":{"id":"D019061","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Multivariate Analysis","uri":{"id":"D015999","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antigens, Viral, Tumor","uri":{"id":"D000957","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Movement","uri":{"id":"D002465","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Focal Adhesions","uri":{"id":"D022001","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Focal Adhesion Protein-Tyrosine Kinases","uri":{"id":"D051416","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antigens","uri":{"id":"D000941","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Emigration and Immigration","uri":{"id":"D004641","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunohistochemistry","uri":{"id":"D007150","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oligosaccharides","uri":{"id":"D009844","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pathology","uri":{"id":"D010336","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phenotype","uri":{"id":"D010641","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phosphorylation","uri":{"id":"D010766","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phosphotransferases","uri":{"id":"D010770","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissues","uri":{"id":"D014024","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carbohydrates","uri":{"id":"D002241","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neuroblastoma","uri":{"id":"D009447","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Paxillin","uri":{"id":"D051419","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Movement","uri":{"id":"D002465","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Invasiveness","uri":{"id":"D009361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tumor Markers, Biological","uri":{"id":"D014408","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Signal Transduction","uri":{"id":"D015398","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival Rate","uri":{"id":"D015996","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Line, Tumor","uri":{"id":"D045744","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Proliferation","uri":{"id":"D049109","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proto-Oncogene Proteins c-akt","uri":{"id":"D051057","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glycosylation","uri":{"id":"D006031","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neuroblastoma","uri":{"id":"D009447","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Transfection","uri":{"id":"D014162","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"N-Acetylglucosaminyltransferases","uri":{"id":"D017351","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"src-Family Kinases","uri":{"id":"D019061","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RNA Interference","uri":{"id":"D034622","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RNA, Small Interfering","uri":{"id":"D034741","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Extracellular Signal-Regulated MAP Kinases","uri":{"id":"D048049","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Focal Adhesion Protein-Tyrosine Kinases","uri":{"id":"D051416","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Paxillin","uri":{"id":"D051419","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Cell Line, Tumor","Cell Movement","Cell Proliferation","Extracellular Signal-Regulated MAP Kinases","Female","Focal Adhesion Protein-Tyrosine Kinases","Glycosylation","Humans","Male","N-Acetylglucosaminyltransferases","Neoplasm Invasiveness","Neuroblastoma","Paxillin","Prognosis","Proto-Oncogene Proteins c-akt","RNA Interference","RNA, Small Interfering","Signal Transduction","Survival Rate","Transfection","Tumor Markers, Biological","src-Family Kinases"]},"pmid":"24118321","title":"B3GNT3 expression suppresses cell migration and invasion and predicts favorable outcomes in neuroblastoma.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Ependymomas are among the most challenging childhood brain tumors. Although 50-70% of ependymomas are cured with surgery and irradiation, a significant percentage of tumors recur. Ependymomas that are not amenable to complete resection at diagnosis have a particularly poor prognosis, and the vast majority of affected children experience tumor recurrence. Although transient responses have been observed in recurrent tumors treated with re-irradiation and several chemotherapy regimens, long-term disease control is rarely achieved. Children with recurrent disease commonly experience cumulative neurological morbidity from repeated surgical and adjuvant therapy interventions and almost universally succumb to refractory tumor progression. Accordingly, conceptually new treatment approaches are needed, both to decrease the risk of tumor recurrence and to enhance disease control in those children who experience recurrent disease. This article reviews the current application of risk-based treatment stratification at diagnosis, the rationale for exploring the role of novel therapeutic strategies such as immunotherapy at recurrence and the concept behind a vaccine-based trial for these tumors.","fulltextAvailable":false,"journal":"Expert review of neurotherapeutics","meshAnnotations":{"@type":"java.util.ArrayList"},"meshHeading":{"@type":"java.util.ArrayList","@items":["Brain Neoplasms","Cancer Vaccines","Ependymoma","Humans","Immunotherapy"]},"pmid":"24117271","title":"Ependymomas: development of immunotherapeutic strategies.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Giloblastoma multiforme (GBM) is the most aggressive brain neoplasm, and patients have a poor prognosis after radiation and chemotherapy. The chemotherapy protocols still marginally improve the anti-tumor effect of patients with glioblastoma because the therapeutic dosage of many drugs is impeded by the blood-brain barrier (BBB). The use of liposomal drugs to GBM treatment might benefit from a more crossing of the BBB due to the lipid nature achieving higher doses of drug at the tumor sites. Human GBM-bearing mice were injected intravenously with cisplatin encapsulated in atherosclerotic plaque-specific peptide-1 (AP-1)-conjugated liposomes or unconjugated liposome. Moreover, the administration of AP-1 liposomal cisplatin (lipoplatin) followed by focused ultrasound (FUS)-induced BBB disruption. Tumor progression was monitored by biophotonic imaging. The preliminary data demonstrated that the GBM chemotherapy with AP-1 lipoplatin followed by pulsed FUS showed a modest improvement of tumor growth in the brain compared to the group treated with lipoplatin alone. Further investigations are needed to use this new targeted lipoplatin in treatment of malignancies.","fulltextAvailable":false,"journal":"Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blood-Brain Barrier","uri":{"id":"D001812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Platinum Compounds","uri":{"id":"D017671","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cisplatin","uri":{"id":"D002945","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Therapy","uri":{"id":"D004358","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lipids","uri":{"id":"D008055","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Platinum","uri":{"id":"D010984","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pulse","uri":{"id":"D011674","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiation","uri":{"id":"D011827","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Electric Impedance","uri":{"id":"D017097","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nature","uri":{"id":"D019368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice","uri":{"id":"D051379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Injections","uri":{"id":"D007267","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Liposomes","uri":{"id":"D008081","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Transcription Factor AP-1","uri":{"id":"D018808","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24111178","title":"Chemotherapy of glioblastoma by targeted liposomal platinum compounds with focused ultrasound.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"The prognosis of malignant gliomas is poor. The 5-year survival rate of patients with glioblastomas is still less than 10%. It is difficult to cure this disease by a single treatment modality, and thus, the use of multi-disciplinary therapy mainly comprising surgery, radiotherapy, and chemotherapy is necessary. Malignant gliomas invade the adjacent brain tissue; however, it is well known that greater the extent of tumor resection better is the prognosis. Maximal resection is very important, and various procedures such as intraoperative navigation, evoked potential, photodynamic diagnosis, intraoperative magnetic resonance imaging (MRI), and awake surgery are performed to preserve speech and motor function in patients. According to a phase III trial by the European Organization for Research and Treatment for Cancer (EORTC), the standard therapy for glioblastomas is radiotherapy with concomitant administration of temozolomide; however, the median survival time is only 14.6 months. Multi-institutional, cooperative trials are necessary for the development of more effective and safe standard therapy.","fulltextAvailable":false,"journal":"Gan to kagaku ryoho. Cancer & chemotherapy","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Magnetic Resonance Imaging","uri":{"id":"D008279","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Magnetic Resonance Spectroscopy","uri":{"id":"D009682","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival Rate","uri":{"id":"D015996","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evoked Potentials","uri":{"id":"D005071","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Therapy","uri":{"id":"D004358","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Forecasting","uri":{"id":"D005544","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Methods","uri":{"id":"D008722","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiotherapy","uri":{"id":"D011878","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"General Surgery","uri":{"id":"D013502","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissues","uri":{"id":"D014024","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival Rate","uri":{"id":"D015996","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Clinical Trials as Topic","uri":{"id":"D002986","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Combined Modality Therapy","uri":{"id":"D003131","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Brain Neoplasms","Clinical Trials as Topic","Combined Modality Therapy","Glioma","Humans","Prognosis","Survival Rate"]},"pmid":"24105050","title":"[Present status and future prospects of multi-disciplinary therapy for malignant gliomas].","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Glioblastoma is the most aggressive cerebral gliomas. Despite advances in therapies, the prognosis is still very poor. Therefore, novel therapeutic strategies are required. As a proteasome inhibitor, bortezomib has shown its efficacy as an active antitumor agent against a variety of tumors. However, inhibition of proteasome activity leads to cell death and also induces cell autophagy, and due to the dual roles of autophagy in the survival and death of tumor cells, the effect of inhibition of autophagy on glioblastoma cells remains to be explored. We therefore assessed whether bortezomib is capable of inducing autophagy, and investigated the antitumor effect of bortezomib combined with autophagy inhibitors on human glioblastoma U251 and U87 cells. Cell viability was measured by MTT assay. The expressions of autophagy and apoptosis-related proteins were determined by Western blot analysis. U251 and U87 cells proliferation was inhibited in a dose-dependent manner. Both apoptosis and autophagy induced by bortezomib were observed in human glioblastoma U87 and U251 cells. However, when U251 and U87 cells were co-treated with bortezomib and autophagy inhibitors 3-MA or Atg7 siRNA, the autophagy inhibitors blocked the autophagy in the cells and resulted in a further inhibition of cell proliferation and a further increase in cell apoptosis as compared with that treated with bortezomib alone. These findings indicated that combination of bortezomib and autophagy inhibitors may shed new light on glioblastoma treatment.","fulltextAvailable":false,"journal":"Molecular and cellular biochemistry","meshAnnotations":{"@type":"java.util.ArrayList"},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adenine","Apoptosis","Apoptosis Regulatory Proteins","Autophagy","Boronic Acids","Brain Neoplasms","Cell Line, Tumor","Cell Proliferation","Glioblastoma","Humans","Mitochondria","Proteasome Inhibitors","Pyrazines","RNA, Small Interfering","Signal Transduction","Ubiquitin-Activating Enzymes"]},"pmid":"24104452","title":"Inhibition of autophagy enhances apoptosis induced by proteasome inhibitor bortezomib in human glioblastoma U87 and U251 cells.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Impaired heart rate variability (HRV) has been demonstrated as a negative survival prognosticator in various diseases. We conducted this prospective study to evaluate how HRV affects brain metastasis (BM) patients. Fifty-one BM patients who had not undergone previous brain operation or radiotherapy (RT) were recruited from January 2010 to July 2012, and 40 patients were included in the final analysis. A 5-minute electrocardiogram was obtained before whole brain radiotherapy. Time domain indices of HRV were compared with other clinical factors on overall survival (OS). In the univariate analysis, Karnofsky performance status (KPS) <70 (P = 0.002) and standard deviation of the normal-to-normal interval (SDNN) <10 ms (P = 0.004) significantly predict poor survival. The multivariate analysis revealed that KPS <70 and SDNN <10 ms were independent negative prognosticators for survival in BM patients with hazard ratios of 2.657 and 2.204, respectively. In conclusion, HRV is associated with survival and may be a novel prognostic factor for BM patients.","fulltextAvailable":false,"journal":"BioMed research international","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Heart Rate","uri":{"id":"D006339","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prospective Studies","uri":{"id":"D011446","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Multivariate Analysis","uri":{"id":"D015999","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Karnofsky Performance Status","uri":{"id":"D017567","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Electrocardiography","uri":{"id":"D004562","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Metastasis","uri":{"id":"D009362","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiotherapy","uri":{"id":"D011878","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Heart Rate","uri":{"id":"D006339","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proportional Hazards Models","uri":{"id":"D016016","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival Analysis","uri":{"id":"D016019","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Electrocardiography","uri":{"id":"D004562","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adult","Aged","Brain Neoplasms","Electrocardiography","Female","Heart Rate","Humans","Male","Middle Aged","Neoplasms","Prognosis","Proportional Hazards Models","Survival Analysis"]},"pmid":"24102056","title":"Heart rate variability is associated with survival in patients with brain metastasis: a preliminary report.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Glioblastoma multiforme (GBM) is the most common and malignant glioma. Although there has been considerable progress in treatment strategies, the prognosis of many patients with GBM remains poor. In this work, polyethylenimine (PEI) and the VTWTPQAWFQWV (VTW) peptide were modified and synthesized into GBM-targeting nanoparticles. The transfection efficiency of U-87 (human glioblastoma) cells was evaluated using fluorescence microscopy and flow cytometry. Cell internalization was investigated to verify the nanoparticle delivery into the cytoplasm. Results showed that the methods of polymer conjugation and the amount of VTW peptide were important factors to polymer synthesis and transfection. The PEI-VTW20 nanoparticles increased the transfection efficiency significantly. This report describes the use of VTW peptide-based PEI nanoparticles for intracellular gene delivery in a GBM cell-specific manner.","fulltextAvailable":false,"journal":"International journal of nanomedicine","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Flow Cytometry","uri":{"id":"D005434","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microscopy, Fluorescence","uri":{"id":"D008856","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Targeting","uri":{"id":"D018390","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Transfer Techniques","uri":{"id":"D018014","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cytoplasm","uri":{"id":"D003593","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Fluorescence","uri":{"id":"D005453","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes","uri":{"id":"D005796","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microscopy","uri":{"id":"D008853","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Peptides","uri":{"id":"D010455","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Polymers","uri":{"id":"D011108","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Work","uri":{"id":"D014937","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nanoparticles","uri":{"id":"D053758","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Polyethyleneimine","uri":{"id":"D011094","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Transfection","uri":{"id":"D014162","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"DNA","uri":{"id":"D004247","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Peptides","uri":{"id":"D010455","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Line, Tumor","uri":{"id":"D045744","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rats","uri":{"id":"D051381","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Transfection","uri":{"id":"D014162","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genetic Therapy","uri":{"id":"D015316","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Targeting","uri":{"id":"D018390","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nanocapsules","uri":{"id":"D053769","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Animals","Cell Line, Tumor","DNA","Gene Targeting","Genetic Therapy","Glioblastoma","Humans","Nanocapsules","Peptides","Rats","Transfection"]},"pmid":"24101872","title":"A peptide-mediated targeting gene delivery system for malignant glioma cells.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"A 64-year-old male presented with an incidental tumor in the sella turcica during a brain medical checkup. Because he lacked any neurological symptoms or signs of pituitary dysfunction, the patient did not undergo surgery. Three years later, visual disturbances developed, including poor eyesight and visual field defects. The response to the growth hormone(GH)releasing peptide-2 demonstrated severe GH deficiency. MRI revealed an enlarged tumor appearing as a mosaic pattern of high and very low intensity on T2-weighted imaging. The region of very low intensity on T2-weighted imaging exhibited enhancement after T1 gadolinium-DTPA administration. The tumor was totally removed via the microscopic trans-sphenoidal approach in combination with endoscopic observation. The hard tumor adhered to the dura of the sella turcica and the medial wall of the left cavernous sinus. Histological verification confirmed a solitary fibrous tumor(SFT). Fourteen months after the operation, MRI revealed no recurrent tumors. SFT infrequently occurs in the sella turcica; however it should be included in the differential diagnosis in cases of enhanced tumors with marked low intensity on T2-weighted imaging.","fulltextAvailable":false,"journal":"No shinkei geka. Neurological surgery","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Image Enhancement","uri":{"id":"D007089","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis, Differential","uri":{"id":"D003937","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cavernous Sinus","uri":{"id":"D002426","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neurologic Manifestations","uri":{"id":"D009461","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sella Turcica","uri":{"id":"D012658","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Signs and Symptoms","uri":{"id":"D012816","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Growth Hormone","uri":{"id":"D013006","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Visual Fields","uri":{"id":"D014794","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Solitary Fibrous Tumors","uri":{"id":"D054364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hardness","uri":{"id":"D006244","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hormones","uri":{"id":"D006728","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Recurrence","uri":{"id":"D012008","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"General Surgery","uri":{"id":"D013502","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Endoscopes","uri":{"id":"D019723","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Caves","uri":{"id":"D059552","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Magnetic Resonance Imaging","uri":{"id":"D008279","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Treatment Outcome","uri":{"id":"D016896","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gadolinium DTPA","uri":{"id":"D019786","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pituitary Neoplasms","uri":{"id":"D010911","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Remission Induction","uri":{"id":"D012074","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sella Turcica","uri":{"id":"D012658","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Solitary Fibrous Tumors","uri":{"id":"D054364","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Gadolinium DTPA","Humans","Magnetic Resonance Imaging","Male","Middle Aged","Pituitary Neoplasms","Remission Induction","Sella Turcica","Solitary Fibrous Tumors","Treatment Outcome"]},"pmid":"24091460","title":"[A case of solitary fibrous tumor in the sella turcica].","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVE: Lung cancer is an uncommon diagnosis during pregnancy. The combination of smoking in young women, increased maternal age during pregnancy, and increasing incidence of lung cancer worldwide may cause an increase of pregnancy associated lung cancer. The aim of this study was to describe all cases of lung cancer during pregnancy, registered in the international Cancer in Pregnancy registration study (CIP study; www.cancerinpregnancy.org). MATERIALS AND METHODS: We present nine cases, all advanced lung cancer during the course of pregnancy. Collected data included demographic features of the study patients, cancer treatment, pregnancy outcome as well as maternal and fetal outcomes. RESULTS AND CONCLUSION: Nine pregnant patients from 4 European centres with a median age of 33 years old (range, 26-42) were included. The median gestational age at diagnosis was 17 weeks (range, 6-28). All patients presented with metastatic disease including bone, lung, brain, spinal cord, pleura, lymph nodes, adrenal and liver. Histopathology was compatible with adenocarcinoma in 4 patients, non-small cell lung cancer with unidentified subtype in 2 patients and squamous-cell, large-cell and a poorly differentiated carcinoma in 3 patients, respectively. Eight patients were treated with systemic therapy, five of them during gestation. No responses were seen. The maternal postpartum outcome was poor with less than one year survival following delivery. One patient experienced a spontaneous abortion and three pregnancies were terminated. Five infants were all born premature due to poor maternal status by cesarean section, with a median gestational age of 30 weeks (range 26-33). To summarize, lung cancer in pregnancy has a dismal maternal outcome in our series. We add nine new cases and discuss both therapeutic and prognostic results.","fulltextAvailable":false,"journal":"Lung cancer (Amsterdam, Netherlands)","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Treatment Outcome","uri":{"id":"D016896","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Bone Diseases","uri":{"id":"D001847","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lung Neoplasms","uri":{"id":"D008175","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lymph Nodes","uri":{"id":"D008198","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pregnancy Outcome","uri":{"id":"D011256","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Spinal Cord","uri":{"id":"D013116","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Abortion, Spontaneous","uri":{"id":"D000022","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carcinoma, Non-Small-Cell Lung","uri":{"id":"D002289","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cesarean Section","uri":{"id":"D002585","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gestational Age","uri":{"id":"D005865","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Maternal Age","uri":{"id":"D008423","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adenocarcinoma","uri":{"id":"D000230","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carcinoma","uri":{"id":"D002277","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cooperative Behavior","uri":{"id":"D003299","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Demography","uri":{"id":"D003710","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Infant","uri":{"id":"D007223","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lung","uri":{"id":"D008168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lymph","uri":{"id":"D008196","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pregnancy","uri":{"id":"D011247","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Women","uri":{"id":"D014930","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Incidence","uri":{"id":"D015994","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Postpartum Period","uri":{"id":"D049590","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pleura","uri":{"id":"D010994","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Europe","uri":{"id":"D005060","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pregnancy","uri":{"id":"D011247","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival Analysis","uri":{"id":"D016019","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Premature Birth","uri":{"id":"D047928","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Abortion, Spontaneous","uri":{"id":"D000022","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adenocarcinoma","uri":{"id":"D000230","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cooperative Behavior","uri":{"id":"D003299","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"International Cooperation","uri":{"id":"D007391","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lung Neoplasms","uri":{"id":"D008175","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Metastasis","uri":{"id":"D009362","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pregnancy Complications, Neoplastic","uri":{"id":"D011252","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Abortion, Spontaneous","Adenocarcinoma","Adult","Cooperative Behavior","Europe","Female","Humans","International Cooperation","Lung Neoplasms","Neoplasm Metastasis","Pregnancy","Pregnancy Complications, Neoplastic","Premature Birth","Prognosis","Survival Analysis"]},"pmid":"24091171","title":"Lung cancer in pregnancy: report of nine cases from an international collaborative study.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: Neck lymph node metastasis (NLNM) in epithelial ovarian cancer (EOC) is rare and treated as advanced stage cancer. However, ovarian cancer with lymphatic metastasis may manifest a different clinical course from peritoneal carcinomatosis. METHODS: The authors retrospectively assessed 20 patients with EOC and pathologically diagnosed as NLNM between January 2001 and December 2010. The patients were divided into two groups according to the time of NLNM identification. Statistical methods included Kaplan-Meier, log-rank, and Cox regression analysis. RESULTS: Eleven patients were diagnosed with NLNM at the same time of surgical exploration of EOC (Group A) and nine patients at cancer recurrence 43.3 months after initial surgery (Group B). In Group A, patients with tumors confined to the pelvic cavity had no recurrence or had isolated lymph node recurrence (ILNR), and survived longer than patients with abdominal tumor spreading (P = 0.0007). In Group B, 2 patients showed ILNR. The median survival time after NLNM was 42 months in Group A and 6 months in Group B (P = 0.01). Cox model demonstrated that non-serous histology, brain metastasis, and NLNM identified at cancer recurrence were major predictors for poor overall survival (Hazard ratio [HR] = 18.67, 6.93, and 4.52; P = 0.01, 0.02, and 0.04, respectively). CONCLUSIONS: A subgroup of EOC patients with NLNM who presented limited pelvic cancer had much better overall survival than patients who had cancer spreading beyond the pelvic cavity or were diagnosed with NLNM at cancer recurrence.","fulltextAvailable":false,"journal":"World journal of surgical oncology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Operative Time","uri":{"id":"D061646","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lymph Nodes","uri":{"id":"D008198","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Staging","uri":{"id":"D009367","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ovarian Neoplasms","uri":{"id":"D010051","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Regression Analysis","uri":{"id":"D012044","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proportional Hazards Models","uri":{"id":"D016016","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lymphatic Metastasis","uri":{"id":"D008207","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pelvic Neoplasms","uri":{"id":"D010386","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carcinoma","uri":{"id":"D002277","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Histology","uri":{"id":"D006653","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lymph","uri":{"id":"D008196","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lymphatic Diseases","uri":{"id":"D008206","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Metastasis","uri":{"id":"D009362","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Peritonitis","uri":{"id":"D010538","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Recurrence","uri":{"id":"D012008","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"General Surgery","uri":{"id":"D013502","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged, 80 and over","uri":{"id":"D000369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Follow-Up Studies","uri":{"id":"D005500","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neck","uri":{"id":"D009333","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Staging","uri":{"id":"D009367","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Retrospective Studies","uri":{"id":"D012189","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival Rate","uri":{"id":"D015996","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lymphatic Metastasis","uri":{"id":"D008207","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms, Glandular and Epithelial","uri":{"id":"D009375","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ovarian Neoplasms","uri":{"id":"D010051","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adult","Aged","Aged, 80 and over","Female","Follow-Up Studies","Humans","Lymphatic Metastasis","Middle Aged","Neck","Neoplasm Staging","Neoplasms, Glandular and Epithelial","Ovarian Neoplasms","Prognosis","Retrospective Studies","Survival Rate"]},"pmid":"24088247","title":"Clinical features and outcomes of neck lymphatic metastasis in ovarian epithelial carcinoma.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Observation following gross-total resection (GTR) for non-anaplastic supratentorial ependymomas is often advocated based on small, retrospective series. The purpose of this study is to perform a population-based analysis to examine outcomes for this rare cohort of low-risk patients. A retrospective analysis was conducted utilizing the Surveillance, Epidemiology and End Results Program of the United States National Cancer Institute. We identified patients with supratentorial non-anaplastic ependymoma who underwent GTR alone or GTR followed by radiation. We identified 92 patients who met these criteria. The median age was 17.5 years (range 1-83) with the majority female (58 %) and white (75 %). Radiotherapy (RT) was delivered in half of patients. The 5-/10-year Kaplan-Meier estimated overall survival (OS) and cause-specific survival (CSS) for the overall cohort was 83.2/71.4 and 84.1/78.0 %, respectively. There was no evidence of decreased CSS (HR 0.52 [0.18-1.51]; p = 0.23) or OS (HR 0.63 [0.25-1.59]; p = 0.33) with the omission of RT on univariate analysis. Age ≥18 years correlated with worse OS (HR 4.01 [1.45-11.11]; p = 0.008) and CSS (HR 2.86 [0.99-8.31]; p = 0.05). RT did not impact outcome for this low-risk cohort of patients. Older age correlates with poor prognosis.","fulltextAvailable":false,"journal":"Journal of neuro-oncology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"United States","uri":{"id":"D014481","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"SEER Program","uri":{"id":"D018426","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Kaplan-Meier Estimate","uri":{"id":"D053208","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"National Cancer Institute (U.S.)","uri":{"id":"D054547","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Academies and Institutes","uri":{"id":"D000047","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiation","uri":{"id":"D011827","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiotherapy","uri":{"id":"D011878","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"European Continental Ancestry Group","uri":{"id":"D044465","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ependymoma","uri":{"id":"D004806","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Epidemiology","uri":{"id":"D004813","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adolescent","uri":{"id":"D000293","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged, 80 and over","uri":{"id":"D000369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Child","uri":{"id":"D002648","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Child, Preschool","uri":{"id":"D002675","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Follow-Up Studies","uri":{"id":"D005500","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Infant","uri":{"id":"D007223","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Physician's Practice Patterns","uri":{"id":"D010818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Retrospective Studies","uri":{"id":"D012189","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival Rate","uri":{"id":"D015996","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Young Adult","uri":{"id":"D055815","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ependymoma","uri":{"id":"D004806","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Texas","uri":{"id":"D013781","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Supratentorial Neoplasms","uri":{"id":"D015173","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adolescent","Adult","Aged","Aged, 80 and over","Brain Neoplasms","Child","Child, Preschool","Ependymoma","Female","Follow-Up Studies","Humans","Infant","Male","Middle Aged","Physician's Practice Patterns","Prognosis","Retrospective Studies","Supratentorial Neoplasms","Survival Rate","Texas","Young Adult"]},"pmid":"24085643","title":"Supratentorial gross-totally resected non-anaplastic ependymoma: population based patterns of care and outcomes analysis.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Glioblastoma (GBM) is the most common, malignant adult primary tumor with dismal patient survival, yet the molecular determinants of patient survival are poorly characterized. Global methylation profile of GBM samples (our cohort; n = 44) using high-resolution methylation microarrays was carried out. Cox regression analysis identified a 9-gene methylation signature that predicted survival in GBM patients. A risk-score derived from methylation signature predicted survival in univariate analysis in our and The Cancer Genome Atlas (TCGA) cohort. Multivariate analysis identified methylation risk score as an independent survival predictor in TCGA cohort. Methylation risk score stratified the patients into low-risk and high-risk groups with significant survival difference. Network analysis revealed an activated NF-κB pathway association with high-risk group. NF-κB inhibition reversed glioma chemoresistance, and RNA interference studies identified interleukin-6 and intercellular adhesion molecule-1 as key NF-κB targets in imparting chemoresistance. Promoter hypermethylation of neuronal pentraxin II (NPTX2), a risky methylated gene, was confirmed by bisulfite sequencing in GBMs. GBMs and glioma cell lines had low levels of NPTX2 transcripts, which could be reversed upon methylation inhibitor treatment. NPTX2 overexpression induced apoptosis, inhibited proliferation and anchorage-independent growth, and rendered glioma cells chemosensitive. Furthermore, NPTX2 repressed NF-κB activity by inhibiting AKT through a p53-PTEN-dependent pathway, thus explaining the hypermethylation and downregulation of NPTX2 in NF-κB-activated high-risk GBMs. Taken together, a 9-gene methylation signature was identified as an independent GBM prognosticator and could be used for GBM risk stratification. Prosurvival NF-κB pathway activation characterized high-risk patients with poor prognosis, indicating it to be a therapeutic target.","fulltextAvailable":false,"journal":"Cancer research","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Line","uri":{"id":"D002460","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Regression Analysis","uri":{"id":"D012044","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Multivariate Analysis","uri":{"id":"D015999","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"DNA Methylation","uri":{"id":"D019175","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RNA Interference","uri":{"id":"D034622","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Intercellular Adhesion Molecule-1","uri":{"id":"D018799","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"DNA","uri":{"id":"D004247","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes","uri":{"id":"D005796","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Methylation","uri":{"id":"D008745","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neurons","uri":{"id":"D009474","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RNA","uri":{"id":"D012313","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Down-Regulation","uri":{"id":"D015536","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genome","uri":{"id":"D016678","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Apoptosis","uri":{"id":"D017209","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genomics","uri":{"id":"D023281","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Internationality","uri":{"id":"D038622","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Interleukin-6","uri":{"id":"D015850","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nerve Tissue Proteins","uri":{"id":"D009419","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Signal Transduction","uri":{"id":"D015398","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Expression Regulation, Neoplastic","uri":{"id":"D015972","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"DNA Methylation","uri":{"id":"D019175","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Line, Tumor","uri":{"id":"D045744","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microarray Analysis","uri":{"id":"D046228","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rats","uri":{"id":"D051381","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Transcriptome","uri":{"id":"D059467","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"C-Reactive Protein","uri":{"id":"D002097","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"NF-kappa B","uri":{"id":"D016328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"PTEN Phosphohydrolase","uri":{"id":"D051059","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Animals","Brain Neoplasms","C-Reactive Protein","Cell Line, Tumor","DNA Methylation","Gene Expression Regulation, Neoplastic","Glioblastoma","Humans","Microarray Analysis","NF-kappa B","Nerve Tissue Proteins","PTEN Phosphohydrolase","Prognosis","Rats","Signal Transduction","Transcriptome"]},"pmid":"24078801","title":"A DNA methylation prognostic signature of glioblastoma: identification of NPTX2-PTEN-NF-κB nexus.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"High-grade malignant glioma patients face a poor prognosis, preceded by rapid functional and neurobehavioural changes, making multidisciplinary care incorporating supportive and palliative care important. This study aimed to quantify the association between symptoms,receipt of supportive and palliative care and site of death. We undertook a retrospective cohort study between 2003 and 2009 of incident malignant glioma cases who survived for at least 120 days between their first hospitalisation and their death (n = 678) in Victoria, Australia, using linked hospital, emergency department and death data. The median age of patients was 62 years, 40% were female, and the median survival was 11 months. Twenty-six percent of patients died outside of hospital, 49% in a palliative care bed/hospice setting and 25% in an acute hospital bed. Patients having 1 or more symptoms were more than five times as likely to receive palliative care. Patients who receive palliative care are 1.7 times more likely to die outside of hospital. In conclusion malignant glioma patients with a high burden of symptoms are more likely to receive palliative care and, in turn, patients who receive palliative care are more likely to die at home.","fulltextAvailable":false,"journal":"Journal of neuro-oncology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Retrospective Studies","uri":{"id":"D012189","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospital Departments","uri":{"id":"D006748","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospice Care","uri":{"id":"D017051","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Emergency Service, Hospital","uri":{"id":"D004636","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cohort Studies","uri":{"id":"D015331","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Palliative Care","uri":{"id":"D010166","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Australia","uri":{"id":"D001315","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Emergencies","uri":{"id":"D004630","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitalization","uri":{"id":"D006760","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals","uri":{"id":"D006761","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Incidence","uri":{"id":"D015994","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospices","uri":{"id":"D006738","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Victoria","uri":{"id":"D014739","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Age Factors","uri":{"id":"D000367","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Time Factors","uri":{"id":"D013997","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cohort Studies","uri":{"id":"D015331","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Logistic Models","uri":{"id":"D016015","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Death","uri":{"id":"D003643","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Palliative Care","uri":{"id":"D010166","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sex Factors","uri":{"id":"D012737","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Terminal Care","uri":{"id":"D013727","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospice Care","uri":{"id":"D017051","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Age Factors","Aged","Brain Neoplasms","Cohort Studies","Death","Female","Glioma","Hospice Care","Humans","Logistic Models","Male","Middle Aged","Palliative Care","Sex Factors","Terminal Care","Time Factors"]},"pmid":"24078175","title":"Mapping the patterns of care, the receipt of palliative care  and the site of death for patients with malignant glioma.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Outcomes for children with relapsed ependymoma are poor. Re-irradiation is a potentially viable salvage option in these patients. Data were reviewed for 12 patients (median age 5.6 years) with relapsed ependymoma who received fractionated stereotactic radiosurgery (fSRS) following maximal surgical resection from 1995 to 2012. Four patients experienced a second recurrence, including 2 in-field and 2 distant failures. Median time to second recurrence (32 months) was significantly longer than time to first recurrence (24 months) (p = 0.008). Three-year local control was 89 %, and median event free survival from fSRS was 3.4 years. Radiation necrosis was observed in 6 patients, 3 who were symptomatic. In conclusion, fSRS offers durable response with a tolerable toxicity profile in children with recurrent EPN.","fulltextAvailable":false,"journal":"Journal of neuro-oncology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Disease-Free Survival","uri":{"id":"D018572","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiosurgery","uri":{"id":"D016634","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Child","uri":{"id":"D002648","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Necrosis","uri":{"id":"D009336","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiation","uri":{"id":"D011827","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Recurrence","uri":{"id":"D012008","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Personal Autonomy","uri":{"id":"D026684","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ependymoma","uri":{"id":"D004806","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiosurgery","uri":{"id":"D016634","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adolescent","uri":{"id":"D000293","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Child","uri":{"id":"D002648","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Child, Preschool","uri":{"id":"D002675","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Infant","uri":{"id":"D007223","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Recurrence, Local","uri":{"id":"D009364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Treatment Outcome","uri":{"id":"D016896","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ependymoma","uri":{"id":"D004806","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiosurgery","uri":{"id":"D016634","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Kaplan-Meier Estimate","uri":{"id":"D053208","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adolescent","Brain Neoplasms","Child","Child, Preschool","Ependymoma","Humans","Infant","Kaplan-Meier Estimate","Neoplasm Recurrence, Local","Radiosurgery","Treatment Outcome"]},"pmid":"24078173","title":"Fractionated stereotactic radiosurgery for recurrent ependymoma  in children.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: The development of brain metastases is common in patients with melanoma and is associated with a poor prognosis. Treating patients with melanoma brain metastases (MBMs) is a major therapeutic challenge. Standard approaches with conventional chemotherapy are disappointing, while surgery and radiotherapy have improved outcomes. METHODS: In this article, we discuss the biology of MBMs, briefly outline current treatment approaches, and emphasize novel and emerging therapies for MBMs. RESULTS: The mechanisms that underlie the metastases of melanoma to the brain are unknown; therefore, it is necessary to identify pathways to target MBMs. Most patients with MBMs have short survival times. Recent use of immune-based and targeted therapies has changed the natural history of metastatic melanoma and may be effective for the treatment of patients with MBMs. CONCLUSIONS: Developing a better understanding of the factors responsible for MBMs will lead to improved management of this disease. In addition, determining the optimal treatments for MBMs and how they can be optimized or combined with other therapies, along with appropriate patient selection, are challenges for the management of this disease.","fulltextAvailable":false,"journal":"Cancer control : journal of the Moffitt Cancer Center","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patient Selection","uri":{"id":"D018579","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Natural History","uri":{"id":"D019021","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biology","uri":{"id":"D001695","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Therapy","uri":{"id":"D004358","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"History","uri":{"id":"D006664","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Melanoma","uri":{"id":"D008545","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Metastasis","uri":{"id":"D009362","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiotherapy","uri":{"id":"D011878","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"General Surgery","uri":{"id":"D013502","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nature","uri":{"id":"D019368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Melanoma","uri":{"id":"D008545","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Skin Neoplasms","uri":{"id":"D012878","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Animals","Brain Neoplasms","Humans","Melanoma","Skin Neoplasms"]},"pmid":"24077406","title":"Novel treatments for melanoma brain metastases.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"PURPOSE: Currently, there are few effective adjuvant therapies for pediatric ependymoma outside confocal radiation, and prognosis remains poor. The phosphoinositide 3-kinase (PI3K) pathway is one of the most commonly activated pathways in cancer. PI3Ks transduce signals from growth factors and cytokines, resulting in the phosphorylation and activation of AKT, which in turn induces changes in cell growth, proliferation, and apoptosis. EXPERIMENTAL DESIGN: PI3K pathway status was analyzed in ependymoma using gene expression data and immunohistochemical analysis of phosphorylated AKT (P-AKT). The effect of the PI3K pathway on cell proliferation was investigated by immunohistochemical analysis of cyclin D1 and Ki67, plus in vitro functional analysis. To identify a potential mechanism of PI3K pathway activation, PTEN protein expression and the mutation status of PI3K catalytic subunit α-isoform gene (PIK3CA) was investigated. RESULTS: Genes in the pathway displayed significantly higher expression in supratentorial than in posterior fossa and spinal ependymomas. P-AKT protein expression, indicating pathway activation, was seen in 72% of tumors (n = 169) and P-AKT expression was found to be an independent marker of a poorer progression-free survival. A significant association between PI3K pathway activation and cell proliferation was identified, suggesting that pathway activation was influencing this process. PTEN protein loss was not associated with P-AKT staining and no mutations were identified in PIK3CA. CONCLUSIONS: Our results suggest that the PI3K pathway could act as a biomarker, not only identifying patients with a worse prognosis but also those that could be treated with therapies targeted against the pathway, a strategy potentially effective in a high percentage of ependymoma patients.","fulltextAvailable":false,"journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Proliferation","uri":{"id":"D049109","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Signal Transduction","uri":{"id":"D015398","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Expression","uri":{"id":"D015870","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Disease-Free Survival","uri":{"id":"D018572","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Catalytic Domain","uri":{"id":"D020134","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Intercellular Signaling Peptides and Proteins","uri":{"id":"D036341","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Proliferation","uri":{"id":"D049109","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"PTEN Phosphohydrolase","uri":{"id":"D051059","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cyclin D1","uri":{"id":"D019938","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes","uri":{"id":"D005796","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mutation","uri":{"id":"D009154","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pediatrics","uri":{"id":"D010372","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phosphatidylinositols","uri":{"id":"D010716","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phosphorylation","uri":{"id":"D010766","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteins","uri":{"id":"D011506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiation","uri":{"id":"D011827","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Transducers","uri":{"id":"D014159","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biological Markers","uri":{"id":"D015415","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cytokines","uri":{"id":"D016207","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cyclins","uri":{"id":"D016213","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Apoptosis","uri":{"id":"D017209","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ependymoma","uri":{"id":"D004806","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Child","uri":{"id":"D002648","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Child, Preschool","uri":{"id":"D002675","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tumor Markers, Biological","uri":{"id":"D014408","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Signal Transduction","uri":{"id":"D015398","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phosphatidylinositol 3-Kinases","uri":{"id":"D019869","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Line, Tumor","uri":{"id":"D045744","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Proliferation","uri":{"id":"D049109","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proto-Oncogene Proteins c-akt","uri":{"id":"D051057","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Transcriptome","uri":{"id":"D059467","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ependymoma","uri":{"id":"D004806","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Disease-Free Survival","uri":{"id":"D018572","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cyclin D1","uri":{"id":"D019938","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"PTEN Phosphohydrolase","uri":{"id":"D051059","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Kaplan-Meier Estimate","uri":{"id":"D053208","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Molecular Targeted Therapy","uri":{"id":"D058990","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Brain Neoplasms","Cell Line, Tumor","Cell Proliferation","Child","Child, Preschool","Cyclin D1","Disease-Free Survival","Ependymoma","Female","Humans","Kaplan-Meier Estimate","Male","Molecular Targeted Therapy","PTEN Phosphohydrolase","Phosphatidylinositol 3-Kinases","Prognosis","Proto-Oncogene Proteins c-akt","Signal Transduction","Transcriptome","Tumor Markers, Biological"]},"pmid":"24077346","title":"PI3K pathway activation provides a novel therapeutic target for pediatric ependymoma and is an independent marker of progression-free survival.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Tumors of the central nervous system are the second most common malignancy in children. In particular, diffuse intrinsic pontine gliomas (DIPGs) are aggressive tumors with poor prognosis and account for 10% to 25% of pediatric brain tumors. The majority of DIPGs are astrocytic, infiltrative, and localized to the pons. Studies have shown median survival times of less than a year, with 90% of children dying within 2 years. We built multitissue arrays with 24 postmortem DIPG samples and analyzed the morphology and expression of several proteins (p53, EGFR, GFAP, MIB1, BMI1, β-catenin, p16, Nanog, Nestin, OCT4, OLIG2, SOX2) with the goal of identifying potential treatment targets and improving our understanding of the biology of these tumors. The majority of DIPGs were high-grade gliomas (22), with 18 cases having features of glioblastoma (World Health Organization [WHO] grade IV) and 4 cases with high-grade features consistent with anaplastic astrocytoma (WHO grade III). One case was low grade (WHO grade II), and 1 case showed intermediate features between a grade II and grade III glioma (low mitotic rate but increased cellularity and cell atypia), being difficult to grade precisely. The majority of the tumors were positive for GFAP (24/24), MIB1 (23/24), OLIG2 (22/24), p16 (20/24), p53 (20/24), SOX2 (19/24), EGFR (16/24), and BMI1 (9/24). Our results suggest that dysregulation of EGFR and p53 may play an important role in the development of DIPGs. The majority of DIPGs express stem cell markers such as SOX2 and OLIG2, consistent with a role for tumor stem cells in the origin and maintenance of these tumors. Targeted therapies against these proteins could be beneficial in treatment.","fulltextAvailable":false,"journal":"The American journal of surgical pathology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Astrocytoma","uri":{"id":"D001254","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Central Nervous System","uri":{"id":"D002490","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nervous System","uri":{"id":"D009420","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Stem Cells","uri":{"id":"D013234","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Astrocytoma","uri":{"id":"D001254","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplastic Stem Cells","uri":{"id":"D014411","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"World Health","uri":{"id":"D014943","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"World Health Organization","uri":{"id":"D014944","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Astrocytes","uri":{"id":"D001253","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biology","uri":{"id":"D001695","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Child","uri":{"id":"D002648","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Maintenance","uri":{"id":"D008283","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pediatrics","uri":{"id":"D010372","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteins","uri":{"id":"D011506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"World Health Organization","uri":{"id":"D014944","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Astrocytoma","uri":{"id":"D001254","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pons","uri":{"id":"D011149","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nestin","uri":{"id":"D064231","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adolescent","uri":{"id":"D000293","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Child","uri":{"id":"D002648","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Child, Preschool","uri":{"id":"D002675","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunohistochemistry","uri":{"id":"D007150","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Predictive Value of Tests","uri":{"id":"D011237","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tumor Markers, Biological","uri":{"id":"D014408","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biopsy","uri":{"id":"D001706","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mitotic Index","uri":{"id":"D008940","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Stem Neoplasms","uri":{"id":"D020295","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissue Array Analysis","uri":{"id":"D046888","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Grading","uri":{"id":"D060787","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adolescent","Biopsy","Brain Stem Neoplasms","Child","Child, Preschool","Female","Glioma","Humans","Immunohistochemistry","Male","Mitotic Index","Neoplasm Grading","Predictive Value of Tests","Prognosis","Tissue Array Analysis","Tumor Markers, Biological"]},"pmid":"24076776","title":"Morphologic characteristics and immunohistochemical profile of diffuse intrinsic pontine gliomas.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"PURPOSE OF REVIEW: The advent of integrated genomics revealed profound insights into medulloblastoma pathogenesis. However, these biological findings have yet to be translated into the clinic, as current treatment comprises surgical resection, conventional irradiation, and chemotherapy resulting in significant long-term sequelae. We sought to highlight the potential areas for targeted therapy based on our new understanding of the subgroup-specific tumor biology. RECENT FINDINGS: Recently, four distinct molecular subgroups of medulloblastoma have been identified [WNT (wingless), SHH (sonic hedgehog), Group 3, and Group 4]. Profiling of these subgroups revealed distinct genomic events, several of which represent actionable targets for therapy. Specifically, stratification of patients into their respective subgroups has profound prognostic impact, wherein therapy can be de-escalated in patients with favorable prognosis, and intensified therapy or novel agents can be considered in patients with poor prognosis. Novel subgroup-specific therapies are being explored in clinical trials, particularly for the SHH subgroup. Epigenetic modifiers are also recurrently affected in medulloblastoma suggesting that epigenetic therapy can be considered in a subset of patients. SUMMARY: The identification of subgroup-specific, actionable therapeutic targets has the potential to revolutionize therapy for medulloblastoma patients, and result in significantly improved quality of life in survivors and improved overall survival.","fulltextAvailable":false,"journal":"Current opinion in oncology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Quality of Life","uri":{"id":"D011788","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Quality Improvement","uri":{"id":"D058996","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biology","uri":{"id":"D001695","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dissection","uri":{"id":"D004210","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Therapy","uri":{"id":"D004358","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Recurrence","uri":{"id":"D012008","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sonication","uri":{"id":"D013010","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genome","uri":{"id":"D016678","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survivors","uri":{"id":"D017741","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Life","uri":{"id":"D019369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genomics","uri":{"id":"D023281","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Epigenomics","uri":{"id":"D057890","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medulloblastoma","uri":{"id":"D008527","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adolescent","uri":{"id":"D000293","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Child","uri":{"id":"D002648","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Child, Preschool","uri":{"id":"D002675","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mutation","uri":{"id":"D009154","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Quality of Life","uri":{"id":"D011788","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RNA, Messenger","uri":{"id":"D012333","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tumor Markers, Biological","uri":{"id":"D014408","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Signal Transduction","uri":{"id":"D015398","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival Analysis","uri":{"id":"D016019","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Expression Profiling","uri":{"id":"D020869","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Wnt Proteins","uri":{"id":"D051153","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cerebellar Neoplasms","uri":{"id":"D002528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medulloblastoma","uri":{"id":"D008527","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Disease-Free Survival","uri":{"id":"D018572","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hedgehog Proteins","uri":{"id":"D053823","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Epigenomics","uri":{"id":"D057890","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Molecular Targeted Therapy","uri":{"id":"D058990","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adolescent","Adult","Cerebellar Neoplasms","Child","Child, Preschool","Disease-Free Survival","Epigenomics","Female","Gene Expression Profiling","Hedgehog Proteins","Humans","Male","Medulloblastoma","Molecular Targeted Therapy","Mutation","Prognosis","Quality of Life","RNA, Messenger","Signal Transduction","Survival Analysis","Tumor Markers, Biological","Wnt Proteins"]},"pmid":"24076581","title":"Medulloblastoma molecular dissection: the way toward targeted therapy.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVE: To investigate the prognosis and prognostic factors of patients with metastatic renal cell carcinoma who underwent metastasectomy. METHODS: We sent questionnaires to Japanese hospitals. The questionnaires included data of patients with metastatic renal cell carcinoma who had their metastatic lesions removed between January 1988 and December 2009. We collected them and retrospectively analyzed these data and calculated the overall survival from the first metastasectomy until death or last follow-up. We also analyzed the relationship between survival and clinico-pathologic features and determined adverse prognostic factors. Furthermore, we identified a poor prognostic group by counting the number of prognostic factors. RESULTS: A sample size of 556 patients from 48 institutions was studied. The median overall survival was 80 months. Four adverse prognostic factors were detected: incomplete resection by metastasectomy (hazard ratio [HR], 2.15), brain metastasis (HR, 3.73), >1.0 mg/dL C-reactive protein (HR, 2.45), and the highest histologic grade in Japanese classification (nuclei of tumor cells are larger than nuclei of normal tubular cells; HR, 1.88). The median overall survivals of patients with 3 or 4 prognostic factors, 2 factors, and 0 and 1 factors were 10 months, 42 months, and 105 months, respectively. CONCLUSION: Four adverse prognostic factors for predicting the survival of patients with removed metastases were identified. Patients with 3 or 4 of these adverse prognostic factors had a worse prognosis.","fulltextAvailable":false,"journal":"Urology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sample Size","uri":{"id":"D018401","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"C-Reactive Protein","uri":{"id":"D002097","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carcinoma, Renal Cell","uri":{"id":"D002292","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carcinoma","uri":{"id":"D002277","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Classification","uri":{"id":"D002965","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitalization","uri":{"id":"D006760","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals","uri":{"id":"D006761","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Metastasis","uri":{"id":"D009362","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteins","uri":{"id":"D011506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Questionnaires","uri":{"id":"D011795","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Asian Continental Ancestry Group","uri":{"id":"D044466","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Metastasectomy","uri":{"id":"D059146","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged, 80 and over","uri":{"id":"D000369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carcinoma, Renal Cell","uri":{"id":"D002292","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Retrospective Studies","uri":{"id":"D012189","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival Rate","uri":{"id":"D015996","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Asian Continental Ancestry Group","uri":{"id":"D044466","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Kidney Neoplasms","uri":{"id":"D007680","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Metastasectomy","uri":{"id":"D059146","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adult","Aged","Aged, 80 and over","Asian Continental Ancestry Group","Carcinoma, Renal Cell","Female","Humans","Kidney Neoplasms","Male","Metastasectomy","Middle Aged","Prognosis","Retrospective Studies","Survival Rate"]},"pmid":"24074981","title":"Prognostic factors of patients with metastatic renal cell carcinoma with removed metastases: a multicenter study of 556 patients.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Malignant astrocytomas are the most aggressive primary brain tumors with a poor prognosis despite optimal treatment. Dysfunction of mismatch repair (MMR) system accelerates the accumulation of mutations throughout the genome causing uncontrolled cell growth. The aim of this study was to characterize the MMR system defects that could be involved in malignant astrocytoma pathogenesis. We analyzed protein expression and promoter methylation of MLH1, MSH2 and MSH6 as well as microsatellite instability (MSI) and MMR gene mutations in a set of 96 low- and high-grade astrocytomas. Forty-one astrocytomas failed to express at least one MMR protein. Loss of MSH2 expression was more frequent in low-grade astrocytomas. Loss of MLH1 expression was associated with MLH1 promoter hypermethylation and MLH1-93G>A promoter polymorphism. However, MSI was not related with MMR protein expression and only 5% of tumors were MSI-High. Furthermore, the incidence of tumors carrying germline mutations in MMR genes was low and only one glioblastoma was associated with Lynch syndrome. Interestingly, survival analysis identified that tumors lacking MSH6 expression presented longer overall survival in high-grade astrocytoma patients treated only with radiotherapy while MSH6 expression did not modify the prognosis of those patients treated with both radiotherapy and chemotherapy. Our findings suggest that MMR system alterations are a frequent event in malignant astrocytomas and might help to define a subgroup of patients with different outcome.","fulltextAvailable":false,"journal":"PloS one","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival Analysis","uri":{"id":"D016019","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Germ-Line Mutation","uri":{"id":"D018095","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Colorectal Neoplasms, Hereditary Nonpolyposis","uri":{"id":"D003123","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microsatellite Instability","uri":{"id":"D053842","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"DNA Mismatch Repair","uri":{"id":"D053843","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Acceleration","uri":{"id":"D000054","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Therapy","uri":{"id":"D004358","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes","uri":{"id":"D005796","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Methylation","uri":{"id":"D008745","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mutation","uri":{"id":"D009154","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteins","uri":{"id":"D011506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiotherapy","uri":{"id":"D011878","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Syndrome","uri":{"id":"D013577","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Incidence","uri":{"id":"D015994","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genome","uri":{"id":"D016678","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lifting","uri":{"id":"D017770","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microsatellite Repeats","uri":{"id":"D018895","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genomics","uri":{"id":"D023281","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Astrocytoma","uri":{"id":"D001254","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunoenzyme Techniques","uri":{"id":"D007124","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mutation","uri":{"id":"D009154","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tumor Markers, Biological","uri":{"id":"D014408","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cohort Studies","uri":{"id":"D015331","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival Rate","uri":{"id":"D015996","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"DNA Methylation","uri":{"id":"D019175","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Astrocytoma","uri":{"id":"D001254","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Promoter Regions, Genetic","uri":{"id":"D011401","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"DNA Repair Enzymes","uri":{"id":"D045643","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissue Array Analysis","uri":{"id":"D046888","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microsatellite Instability","uri":{"id":"D053842","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"DNA Mismatch Repair","uri":{"id":"D053843","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Grading","uri":{"id":"D060787","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adult","Aged","Astrocytoma","Cohort Studies","DNA Methylation","DNA Mismatch Repair","DNA Repair Enzymes","Female","Humans","Immunoenzyme Techniques","Male","Microsatellite Instability","Middle Aged","Mutation","Neoplasm Grading","Prognosis","Promoter Regions, Genetic","Survival Rate","Tissue Array Analysis","Tumor Markers, Biological"]},"pmid":"24073290","title":"Integrated analysis of mismatch repair system in malignant astrocytomas.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"PURPOSE: Referral to supportive and palliative care services for people with high-grade primary malignant glioma (PMG) often occurs late in the illness course, despite significant care needs and overall poor prognosis. This study aimed to understand patient experience at the end of life and document supportive and palliative care needs. METHODS: A qualitative study was conducted involving ten PMG patients who were at different stages in the illness course including the end of life and had varying levels of physical and cognitive function. Consecutive, eligible patients attending neurosurgery, oncology, and palliative care services of two metropolitan hospitals were recruited. In-depth interviews explored supportive and palliative care needs across the disease trajectory. Interviews were analysed independently by three investigators consistent with a grounded theory approach, and emerging ideas were compared and refined to define key patient experiences. RESULTS: Despite the medical treatment and supportive care available, there remains a gap in services addressing complex existential and psychosocial needs that were markedly valued by patients. Patient experience was characterised by a pervasive loss of all that encompassed their former sense of self and a focus on immediate needs. CONCLUSIONS: Patients in this study had substantial needs, which were often not shared and not addressed by the current medical system of care. An improved multidisciplinary care model is indicated, which proactively (1) engages care coordination and advocacy; (2) minimises patients' sense of waiting and uncertainty through mapping out a plan, including involvement of palliative care in a timely fashion; and (3) actively invites discussion around goals and preferences for care to promote patients' sense of self.","fulltextAvailable":false,"journal":"Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patient Education as Topic","uri":{"id":"D010353","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blood Glucose Self-Monitoring","uri":{"id":"D015190","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diabetes Mellitus","uri":{"id":"D003920","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diabetes Mellitus, Type 2","uri":{"id":"D003924","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Motor Activity","uri":{"id":"D009043","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blood Glucose","uri":{"id":"D001786","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Food Preferences","uri":{"id":"D005518","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemoglobin A, Glycosylated","uri":{"id":"D006442","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patient Education as Topic","uri":{"id":"D010353","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Resistance Training","uri":{"id":"D055070","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Education","uri":{"id":"D004493","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glucose","uri":{"id":"D005947","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glycosylation","uri":{"id":"D006031","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemoglobins","uri":{"id":"D006454","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Insulin","uri":{"id":"D007328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Physics","uri":{"id":"D010825","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"PubMed","uri":{"id":"D039781","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Insulins","uri":{"id":"D061385","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blood Glucose","uri":{"id":"D001786","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diabetes Mellitus, Type 2","uri":{"id":"D003924","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Food Habits","uri":{"id":"D005510","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemoglobin A, Glycosylated","uri":{"id":"D006442","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Life Style","uri":{"id":"D008019","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adult","Aged","Attitude to Death","Brain Neoplasms","Female","Glioma","Humans","Interviews as Topic","Male","Middle Aged","Palliative Care","Qualitative Research","Terminal Care"]},"pmid":"24072476","title":"\"I'm just waiting…\": an exploration of the experience of living and dying with primary malignant glioma.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Basal ganglia germinomas (BGG) are often associated with delayed diagnosis because of their nonspecific clinical presentation and subtle abnormalities on initial neuroimaging. Despite excellent survival, the prognostic indicators still remained unclear. From our case series, we demonstrated that the MRI classification scheme devised by Phi and colleagues is useful in predicting neurological and cognitive outcomes for patients with unilateral BGG. Subtle lesions with faint or no contrast enhancement are associated with early cerebral atrophy with progressive neurological deficits and poor cognitive outcomes. BGG along with bilateral involvement, regardless of the types of lesion, are also associated with poor neurological and cognitive outcomes.","fulltextAvailable":false,"journal":"Journal of pediatric hematology/oncology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Basal Ganglia","uri":{"id":"D001479","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neurologic Manifestations","uri":{"id":"D009461","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Delayed Diagnosis","uri":{"id":"D057210","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Atrophy","uri":{"id":"D001284","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Classification","uri":{"id":"D002965","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Indicators and Reagents","uri":{"id":"D007202","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neuroimaging","uri":{"id":"D059906","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ganglia","uri":{"id":"D005724","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Syncope","uri":{"id":"D013575","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Germinoma","uri":{"id":"D018237","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adolescent","uri":{"id":"D000293","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Child","uri":{"id":"D002648","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cognition","uri":{"id":"D003071","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Magnetic Resonance Imaging","uri":{"id":"D008279","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Retrospective Studies","uri":{"id":"D012189","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Treatment Outcome","uri":{"id":"D016896","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chemoradiotherapy","uri":{"id":"D059248","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Basal Ganglia","uri":{"id":"D001479","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Germinoma","uri":{"id":"D018237","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adolescent","Basal Ganglia","Brain Neoplasms","Chemoradiotherapy","Child","Cognition","Germinoma","Humans","Magnetic Resonance Imaging","Male","Retrospective Studies","Treatment Outcome"]},"pmid":"24072250","title":"Basal ganglia germinoma: MRI classification correlates well with neurological and cognitive outcome.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Glioblastoma is one of the most malignant brain tumors with a poor prognosis. In this study, we examined the effects of transferrin (Tf)-modified poly ethyleneglycol-poly lactic acid (PEG-PLA) nanoparticles conjugated with resveratrol (Tf-PEG-PLA-RSV) to glioma therapy in vitro and in vivo. The cell viability of Tf-PEG-PLA-RSV on C6 and U87 glioma cells was determined by the MTT assay. In vivo biodistribution and antitumor activity were investigated in Brain glioma bearing rat model of C6 glioma by i.p. administration of RSV-polymer conjugates. We found that the average diameter of each Tf-PEG-PLA-RSV is around 150 nm with 32 molecules of Tf on surface. In vitro cytotoxicity of PEG-PLA-RSV against C6 and U87 cells was higher than that of free RSV, and further the modification of Tf enhanced the cytotoxicity of the RSV-polymer conjugates as a result of the increased cellular uptake of the RSV-modified conjugates by glioma cells. In comparison with free RSV, RSV conjugates could significantly decrease tumor volume and accumulate in brain tumor, which resulted in prolonging the survival of C6 glioma-bearing rats. These results suggest that Tf-NP-RSV had a potential of therapeutic effect to glioma both in vitro and in vivo and might be a potential candidate for targeted therapy of glioma and worthy of further investigation.","fulltextAvailable":false,"journal":"European journal of pharmacology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Survival","uri":{"id":"D002470","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lactic Acid","uri":{"id":"D019344","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tumor Burden","uri":{"id":"D047368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Personal Autonomy","uri":{"id":"D026684","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nanoparticles","uri":{"id":"D053758","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Transferrin","uri":{"id":"D014168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Transferrins","uri":{"id":"D061250","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antineoplastic Agents","uri":{"id":"D000970","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain","uri":{"id":"D001921","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Polyethylene Glycols","uri":{"id":"D011092","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Polymers","uri":{"id":"D011108","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival Analysis","uri":{"id":"D016019","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Apoptosis","uri":{"id":"D017209","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Xenograft Model Antitumor Assays","uri":{"id":"D023041","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Line, Tumor","uri":{"id":"D045744","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Proliferation","uri":{"id":"D049109","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rats","uri":{"id":"D051381","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nanoparticles","uri":{"id":"D053758","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biological Transport","uri":{"id":"D001692","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Carriers","uri":{"id":"D004337","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Stilbenes","uri":{"id":"D013267","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Transferrin","uri":{"id":"D014168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lactic Acid","uri":{"id":"D019344","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Molecular Targeted Therapy","uri":{"id":"D058990","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Animals","Antineoplastic Agents","Apoptosis","Biological Transport","Brain","Cell Line, Tumor","Cell Proliferation","Drug Carriers","Glioma","Lactic Acid","Male","Molecular Targeted Therapy","Nanoparticles","Polyethylene Glycols","Polymers","Rats","Stilbenes","Survival Analysis","Transferrin","Xenograft Model Antitumor Assays"]},"pmid":"24070814","title":"Transferrin modified PEG-PLA-resveratrol conjugates: in vitro and in vivo studies for glioma.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Malignant gliomas remain associated with poor prognosis and high morbidity because of their ability to invade the brain; furthermore, human gliomas exhibit a phenotype of accelerated brain invasion in response to anti-angiogenic drugs. Here, we study 8 human glioblastoma cell lines; U251, U87, D54 and LN229 show accelerated motility in low ambient oxygen. Src inhibition by Dasatinib abrogates this phenotype. Molecular discovery and validation studies evaluate 46 molecules related to motility or the src pathway in U251 cells. Demanding that the molecular changes induced by low ambient oxygen are reversed by Dasatinib in U251 cells, identifies neural Wiskott-Aldrich syndrome protein (NWASP), Focal adhesion Kinase (FAK), [Formula: see text]-Catenin, and Cofilin. However, only Src-mediated NWASP phosphorylation distinguishes the four cell lines that exhibit enhanced motility in low ambient oxygen. Downregulating c-Src or NWASP by RNA interference abrogates the low-oxygen-induced enhancement in motility by in vitro assays and in organotypic brain slice cultures. The findings support the idea that c-Src and NWASP play key roles in mediating the molecular pathogenesis of low oxygen-induced accelerated brain invasion by gliomas.","fulltextAvailable":false,"journal":"PloS one","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Line","uri":{"id":"D002460","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RNA Interference","uri":{"id":"D034622","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Wiskott-Aldrich Syndrome","uri":{"id":"D014923","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Angiogenesis Inhibitors","uri":{"id":"D020533","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Focal Adhesions","uri":{"id":"D022001","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Wiskott-Aldrich Syndrome Protein","uri":{"id":"D051316","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Focal Adhesion Protein-Tyrosine Kinases","uri":{"id":"D051416","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Acceleration","uri":{"id":"D000054","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Culture","uri":{"id":"D003469","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Morbidity","uri":{"id":"D009017","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oxygen","uri":{"id":"D010100","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oxygenators","uri":{"id":"D010106","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phenotype","uri":{"id":"D010641","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phosphorylation","uri":{"id":"D010766","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phosphotransferases","uri":{"id":"D010770","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteins","uri":{"id":"D011506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RNA","uri":{"id":"D012313","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Syndrome","uri":{"id":"D013577","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Down-Regulation","uri":{"id":"D015536","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Text Messaging","uri":{"id":"D060145","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Catenins","uri":{"id":"D051177","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Actin Depolymerizing Factors","uri":{"id":"D051339","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Movement","uri":{"id":"D002465","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Disease Models, Animal","uri":{"id":"D004195","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Invasiveness","uri":{"id":"D009361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Expression Profiling","uri":{"id":"D020869","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Line, Tumor","uri":{"id":"D045744","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice","uri":{"id":"D051379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anoxia","uri":{"id":"D000860","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"src-Family Kinases","uri":{"id":"D019061","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RNA Interference","uri":{"id":"D034622","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Protein Kinase Inhibitors","uri":{"id":"D047428","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Wiskott-Aldrich Syndrome Protein, Neuronal","uri":{"id":"D051317","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Heterografts","uri":{"id":"D064593","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Animals","Anoxia","Cell Line, Tumor","Cell Movement","Disease Models, Animal","Gene Expression Profiling","Glioma","Heterografts","Humans","Mice","Neoplasm Invasiveness","Protein Kinase Inhibitors","RNA Interference","Wiskott-Aldrich Syndrome Protein, Neuronal","src-Family Kinases"]},"pmid":"24069415","title":"c-Src and neural Wiskott-Aldrich syndrome protein (N-WASP) promote low oxygen-induced accelerated brain invasion by gliomas.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Glioblastoma (GBM) remains the most pervasive and lethal of all brain malignancies. One factor that contributes to this poor prognosis is the highly invasive character of the tumor. GBM is characterized by microscopic infiltration of tumor cells throughout the brain, whereas non-neural metastases, as well as select lower grade gliomas, develop as self-contained and clearly delineated lesions. Illustrated by rodent xenograft tumor models as well as pathological human patient specimens, we present evidence that one fundamental switch between these two distinct pathologies--invasion and noninvasion--is mediated through the tumor extracellular matrix. Specifically, noninvasive lesions are associated with a rich matrix containing substantial amounts of glycosylated chondroitin sulfate proteoglycans (CSPGs), whereas glycosylated CSPGs are essentially absent from diffusely infiltrating tumors. CSPGs, acting as central organizers of the tumor microenvironment, dramatically influence resident reactive astrocytes, inducing their exodus from the tumor mass and the resultant encapsulation of noninvasive lesions. Additionally, CSPGs induce activation of tumor-associated microglia. We demonstrate that the astrogliotic capsule can directly inhibit tumor invasion, and its absence from GBM presents an environment favorable to diffuse infiltration. We also identify the leukocyte common antigen-related phosphatase receptor (PTPRF) as a putative intermediary between extracellular glycosylated CSPGs and noninvasive tumor cells. In all, we present CSPGs as critical regulators of brain tumor histopathology and help to clarify the role of the tumor microenvironment in brain tumor invasion.","fulltextAvailable":false,"journal":"The Journal of neuroscience : the official journal of the Society for Neuroscience","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Receptor-Like Protein Tyrosine Phosphatases, Class 2","uri":{"id":"D054623","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Extracellular Matrix","uri":{"id":"D005109","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chondroitin Sulfates","uri":{"id":"D002809","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chondroitin Sulfate Proteoglycans","uri":{"id":"D011508","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tumor Microenvironment","uri":{"id":"D059016","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Astrocytes","uri":{"id":"D001253","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Character","uri":{"id":"D002605","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Environment","uri":{"id":"D004777","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glycosylation","uri":{"id":"D006031","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Internship and Residency","uri":{"id":"D007396","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Leukocytes","uri":{"id":"D007962","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Metastasis","uri":{"id":"D009362","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pathology","uri":{"id":"D010336","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phosphoric Monoester Hydrolases","uri":{"id":"D010744","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rodentia","uri":{"id":"D012377","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Transplantation, Heterologous","uri":{"id":"D014183","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Heterografts","uri":{"id":"D064593","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chondroitin","uri":{"id":"D002807","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteoglycans","uri":{"id":"D011509","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sulfates","uri":{"id":"D013431","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microglia","uri":{"id":"D017628","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Astrocytes","uri":{"id":"D001253","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Movement","uri":{"id":"D002465","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cells, Cultured","uri":{"id":"D002478","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Child","uri":{"id":"D002648","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Invasiveness","uri":{"id":"D009361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Xenograft Model Antitumor Assays","uri":{"id":"D023041","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Line, Tumor","uri":{"id":"D045744","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice","uri":{"id":"D051379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glycosylation","uri":{"id":"D006031","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chondroitin Sulfate Proteoglycans","uri":{"id":"D011508","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microglia","uri":{"id":"D017628","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Receptor-Like Protein Tyrosine Phosphatases, Class 2","uri":{"id":"D054623","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tumor Microenvironment","uri":{"id":"D059016","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adult","Animals","Astrocytes","Brain Neoplasms","Cell Line, Tumor","Cell Movement","Cells, Cultured","Child","Chondroitin Sulfate Proteoglycans","Female","Glioma","Glycosylation","Humans","Male","Mice","Microglia","Middle Aged","Neoplasm Invasiveness","Receptor-Like Protein Tyrosine Phosphatases, Class 2","Tumor Microenvironment","Xenograft Model Antitumor Assays"]},"pmid":"24068827","title":"Chondroitin sulfate proteoglycans potently inhibit invasion and serve as a central organizer of the brain tumor microenvironment.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Choroid plexus carcinoma (CPC) is a World Health Organization (WHO) grade III brain tumor with a poor prognosis that occurs mainly in children. Gross total resection of CPC is highly recommended and is associated with improved overall survival, although it is often associated with increased morbidity. The use of adjuvant therapies has yet to be standardized, although evidence suggests that for patients with incompletely resected CPCs, a combination of chemotherapy and radiation therapy may be beneficial. The use of radiation therapy for younger children (<3 years old) with CPC, however, is not recommended, due to the potential negative neurological sequelae associated with radiation to the developing brain. Given that the majority of CPC patients are young children, questions regarding optimal radiation dose, chemotherapy agents, and how to combine these two adjuvant treatment modalities to achieve the best outcomes remain unanswered. In this paper we summarize the current management of CPC in the literature. Further studies are needed to standardize the treatment paradigm for this malignant brain tumor.","fulltextAvailable":false,"journal":"Neurosurgical review","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Therapy, Combination","uri":{"id":"D004359","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Choroid Plexus","uri":{"id":"D002831","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"World Health","uri":{"id":"D014943","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"World Health Organization","uri":{"id":"D014944","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carcinoma","uri":{"id":"D002277","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Child","uri":{"id":"D002648","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Choroid","uri":{"id":"D002829","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Choroiditis","uri":{"id":"D002833","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Therapy","uri":{"id":"D004358","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Literature","uri":{"id":"D008091","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Morbidity","uri":{"id":"D009017","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiation","uri":{"id":"D011827","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"World Health Organization","uri":{"id":"D014944","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24068529","title":"Current management of choroid plexus carcinomas.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: Glioblastoma (GBM) is the most common malignant primary brain tumor in adults. Tumor control and survival have improved with the use of radiotherapy (RT) plus concomitant and adjuvant chemotherapy, but the prognosis remain poor. In most cases the recurrence occurs within 7-9 months after primary treatment. Currently, many approaches are available for the salvage treatment of patients with recurrent GBM, including resection, re-irradiation or systemic agents, but no standard of care exists. METHODS: We analysed a cohort of patients with recurrent GBM treated with frame-less hypofractionated stereotactic radiation therapy with a total dose of 25 Gy in 5 fractions. RESULTS: Of 91 consecutive patients with newly diagnosed GBM treated between 2007 and 2012 with conventional adjuvant chemo-radiation therapy, 15 underwent salvage RT at recurrence. The median time interval between primary RT and salvage RT was 10.8 months (range, 6-54 months). Overall, patients undergoing salvage RT showed a longer survival, with a median survival of 33 vs. 9.9 months (p= 0.00149). Median overall survival (OS) from salvage RT was 9.5 months. No patients demonstrated clinically significant acute morbidity, and all patients were able to complete the prescribed radiation therapy without interruption. CONCLUSION: Our results suggest that hypofractionated stereotactic radiation therapy is effective and safe in recurrent GBM. However, until prospective randomized trials will confirm these results, the decision for salvage treatment should remain individual and based on a multidisciplinary evaluation of each patient.","fulltextAvailable":false,"journal":"Radiation oncology (London, England)","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aftercare","uri":{"id":"D000359","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cohort Studies","uri":{"id":"D015331","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Standard of Care","uri":{"id":"D059039","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chemotherapy, Adjuvant","uri":{"id":"D017024","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Therapy","uri":{"id":"D004358","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Morbidity","uri":{"id":"D009017","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiation","uri":{"id":"D011827","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiotherapy","uri":{"id":"D011878","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Recurrence","uri":{"id":"D012008","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24066926","title":"Hypofractionated stereotactic radiation therapy for recurrent glioblastoma: single institutional experience.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND AND PURPOSE: The safety of thrombolysis for acute stroke in patients with cancer is not well established. Our aim is to study the outcomes after thrombolysis in patients with stroke with cancer. METHODS: Patients with acute ischemic stroke who received thrombolysis were identified from the 2009 and 2010 Nationwide Inpatient Sample. Patients with cancer-associated strokes and noncancer strokes were compared based on demographics, comorbidities, and outcomes. RESULTS: Of the 32 576 strokes treated with thrombolysis, cancer-associated strokes had significantly higher comorbidity indices overall, but fewer vascular risk factors than noncancer strokes. There was no difference in the rates of home discharge and in-hospital mortality, after adjusting for confounders. Subgroup analysis showed that compared with liquid cancers, patients with solid tumors had worse home discharge (odds ratio, 0.178; 95% confidence interval, 0.109-0.290; P<0.001) and higher in-hospital mortality (odds ratio, 3.018; 95% confidence interval, 1.37-6.646; P=0.006) after thrombolysis. Metastatic cancers had poorest outcomes, but intracerebral hemorrhage rates were similar. CONCLUSIONS: Thrombolytic therapy for acute stroke in patients with cancer is not associated with increased risk of intracerebral hemorrhage or in-hospital mortality. However, careful consideration of the cancer subtype may help delineate the subset of patients with poor response to thrombolysis. Prospective confirmation is warranted.","fulltextAvailable":false,"journal":"Stroke; a journal of cerebral circulation","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Outcome Assessment (Health Care)","uri":{"id":"D017063","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Stroke","uri":{"id":"D020521","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Risk Factors","uri":{"id":"D012307","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Confidence Intervals","uri":{"id":"D016001","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Odds Ratio","uri":{"id":"D016017","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospital Mortality","uri":{"id":"D017052","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Stroke","uri":{"id":"D020521","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cerebral Hemorrhage","uri":{"id":"D002543","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thrombolytic Therapy","uri":{"id":"D015912","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Demography","uri":{"id":"D003710","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemorrhage","uri":{"id":"D006470","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Inpatients","uri":{"id":"D007297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mortality","uri":{"id":"D009026","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Safety","uri":{"id":"D012449","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Comorbidity","uri":{"id":"D015897","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged, 80 and over","uri":{"id":"D000369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissue Plasminogen Activator","uri":{"id":"D010959","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Risk Factors","uri":{"id":"D012307","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Time Factors","uri":{"id":"D013997","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Treatment Outcome","uri":{"id":"D016896","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Ischemia","uri":{"id":"D002545","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Fibrinolytic Agents","uri":{"id":"D005343","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thrombolytic Therapy","uri":{"id":"D015912","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Stroke","uri":{"id":"D020521","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adult","Aged","Aged, 80 and over","Brain Ischemia","Female","Fibrinolytic Agents","Humans","Male","Middle Aged","Neoplasms","Risk Factors","Stroke","Thrombolytic Therapy","Time Factors","Tissue Plasminogen Activator","Treatment Outcome"]},"pmid":"24065712","title":"Thrombolysis for acute ischemic stroke in patients with cancer: a population study.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"High-grade glioma is incurable and is associated with a short survival time and a poor prognosis. There are two forms of brain-derived neurotrophic factor (BDNF), proBDNF and mature BDNF, which exert opposite effects. Their diverse actions are mediated through two different transmembrane receptor signalling systems: p75NTR and TrkB. The important roles of the BDNF/TrkB signalling system in tumour cell proliferation and survival have been demonstrated. However, few studies have been able to distinguish mature BDNF from proBDNF due to the limitation of specific antibodies. Using specific proBDNF antibodies, we demonstrated that the proBDNF/p75NTR pathway appears to inhibit malignant glioma cell growth and migration. In the present study using specific mature BDNF antibodies, we found that mature BDNF inhibited C6 glioma cell apoptosis and increased cell growth and migration in vitro. Our data suggest that the counterbalance between mature BDNF and proBDNF may regulate tumour growth.","fulltextAvailable":false,"journal":"Oncology reports","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antibody Specificity","uri":{"id":"D000918","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nerve Growth Factors","uri":{"id":"D009414","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain-Derived Neurotrophic Factor","uri":{"id":"D019208","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Proliferation","uri":{"id":"D049109","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antibody Specificity","uri":{"id":"D000918","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antibodies","uri":{"id":"D000906","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Emigration and Immigration","uri":{"id":"D004641","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Apoptosis","uri":{"id":"D017209","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain-Derived Neurotrophic Factor","uri":{"id":"D019208","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Movement","uri":{"id":"D002465","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nerve Tissue Proteins","uri":{"id":"D009419","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neurons","uri":{"id":"D009474","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Signal Transduction","uri":{"id":"D015398","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Apoptosis","uri":{"id":"D017209","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Line, Tumor","uri":{"id":"D045744","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Proliferation","uri":{"id":"D049109","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antibodies","uri":{"id":"D000906","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Receptors, Nerve Growth Factor","uri":{"id":"D017475","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain-Derived Neurotrophic Factor","uri":{"id":"D019208","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Receptor, trkB","uri":{"id":"D020813","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Grading","uri":{"id":"D060787","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Antibodies","Apoptosis","Brain-Derived Neurotrophic Factor","Cell Line, Tumor","Cell Movement","Cell Proliferation","Glioma","Humans","Neoplasm Grading","Nerve Tissue Proteins","Neurons","Prognosis","Receptor, trkB","Receptors, Nerve Growth Factor","Signal Transduction"]},"pmid":"24064679","title":"Mature BDNF promotes the growth of glioma cells in vitro.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Brain tumors are a diverse group of neoplasms that often carry a poor prognosis for patients. Despite tremendous efforts to develop diagnostic tools and therapeutic avenues, the treatment of brain tumors remains a formidable challenge in the field of neuro-oncology. Physiological barriers including the blood-brain barrier result in insufficient accumulation of therapeutic agents at the site of a tumor, preventing adequate destruction of malignant cells. Furthermore, there is a need for improvements in brain tumor imaging to allow for better characterization and delineation of tumors, visualization of malignant tissue during surgery, and tracking of response to chemotherapy and radiotherapy. Multifunctional nanoparticles offer the potential to improve upon many of these issues and may lead to breakthroughs in brain tumor management. In this review, we discuss the diagnostic and therapeutic applications of nanoparticles for brain tumors with an emphasis on innovative approaches in tumor targeting, tumor imaging, and therapeutic agent delivery. Clinically feasible nanoparticle administration strategies for brain tumor patients are also examined. Furthermore, we address the barriers towards clinical implementation of multifunctional nanoparticles in the context of brain tumor management.","fulltextAvailable":false,"journal":"Advanced drug delivery reviews","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neuroimaging","uri":{"id":"D059906","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blood-Brain Barrier","uri":{"id":"D001812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Therapy","uri":{"id":"D004358","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiotherapy","uri":{"id":"D011878","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"General Surgery","uri":{"id":"D013502","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissues","uri":{"id":"D014024","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Track and Field","uri":{"id":"D014142","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nanoparticles","uri":{"id":"D053758","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antineoplastic Agents","uri":{"id":"D000970","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Contrast Media","uri":{"id":"D003287","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nanoparticles","uri":{"id":"D053758","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnostic Imaging","uri":{"id":"D003952","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Animals","Antineoplastic Agents","Brain Neoplasms","Contrast Media","Diagnostic Imaging","Humans","Nanoparticles"]},"pmid":"24060923","title":"Multifunctional nanoparticles for brain tumor imaging and therapy.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"The aim of this study was to investigate the prognostic value of the RNA-binding protein Musashi-1 in adult patients with primary gliomas. Musashi-1 has been suggested to be a cancer stem cell-related marker in gliomas, and high levels of Musashi-1 have been associated with high tumor grades and hence poor prognosis. Samples of 241 gliomas diagnosed between 2005 and 2009 were stained with an anti-Musashi-1 antibody using a fluorescent staining protocol followed by automated image acquisition and processing. Musashi-1 area fraction and intensity in cytoplasm and in nuclei were quantified by systematic random sampling in 2 % of the vital tumor area. In WHO grade III tumors high levels of Musashi-1 were associated with poor survival in multivariate analysis (HR 3.39, p = 0.02). We identified a sub-population of glioblastoma (GBM) patients with high levels of Musashi-1 and a superior prognosis (HR 0.65, p = 0.038). In addition patients with high levels of Musashi-1 benefitted most from post-surgical treatment, indicating that Musashi-1 may be a predictive marker in GBMs. In conclusion, our results suggest that high levels of Musashi-1 are associated with poor survival in patients with WHO grade III tumors and that Musashi-1 may be a predictive marker in GBMs, although further validation is needed. We find the combination of immunofluorescence and automated quantitation to be a feasible, robust, and reproducible approach for quantitative biomarker studies.","fulltextAvailable":false,"journal":"Journal of neuro-oncology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Grading","uri":{"id":"D060787","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Multivariate Analysis","uri":{"id":"D015999","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RNA-Binding Proteins","uri":{"id":"D016601","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Grading","uri":{"id":"D060787","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antibodies","uri":{"id":"D000906","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Classification","uri":{"id":"D002965","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cytoplasm","uri":{"id":"D003593","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Fluorescence","uri":{"id":"D005453","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Fluorescent Antibody Technique","uri":{"id":"D005455","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteins","uri":{"id":"D011506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vitalism","uri":{"id":"D014799","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"World Health Organization","uri":{"id":"D014944","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biological Markers","uri":{"id":"D015415","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Denmark","uri":{"id":"D003718","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Follow-Up Studies","uri":{"id":"D005500","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nerve Tissue Proteins","uri":{"id":"D009419","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tumor Markers, Biological","uri":{"id":"D014408","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplastic Stem Cells","uri":{"id":"D014411","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival Rate","uri":{"id":"D015996","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"World Health Organization","uri":{"id":"D014944","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RNA-Binding Proteins","uri":{"id":"D016601","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissue Array Analysis","uri":{"id":"D046888","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Grading","uri":{"id":"D060787","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adult","Brain Neoplasms","Denmark","Female","Follow-Up Studies","Glioma","Humans","Male","Middle Aged","Neoplasm Grading","Neoplastic Stem Cells","Nerve Tissue Proteins","Prognosis","RNA-Binding Proteins","Survival Rate","Tissue Array Analysis","Tumor Markers, Biological","World Health Organization"]},"pmid":"24057325","title":"Prognostic value of Musashi-1 in gliomas.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: It is unclear whether patients undergoing trimodality therapy (TMT) should be screened or surveyed for brain metastases. METHODS: We retrospectively analyzed esophageal cancer (EC) patients who underwent TMT between the years 2000 and 2010. All were systematically staged and surveyed but none had screening or surveillance brain imaging. RESULTS: The median follow-up time for 518 patients was 29.3 months (range 1-149.2); all patients had adenocarcinoma of the esophagus. Of 188 (36.3%) patients who developed distant metastases, 20 (10.6% of 188 patients or 3.9% of 518 patients) had brain metastases. A higher baseline clinical stage (stage III or IVa) was associated with brain metastases. Most (90%) patients with brain metastases were diagnosed within 24 months of surgery. Sixteen patients had central nervous system symptoms at diagnosis. Twelve (60%) patients had solitary metastasis and 8 (40%) patients had multiple metastases. Although 17 patients received therapy for brain metastases, the median overall survival time of 20 patients was only 10.5 months (95% CI 6.6-14.0). CONCLUSION: After TMT, 3.9% of EC patients developed brain metastases and their prognosis was poor. Our data suggest that screening and/or surveillance for brain metastases in the EC population undergoing TMT is not warranted.","fulltextAvailable":false,"journal":"Oncology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Central Nervous System","uri":{"id":"D002490","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nervous System","uri":{"id":"D009420","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Esophageal Neoplasms","uri":{"id":"D004938","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neuroimaging","uri":{"id":"D059906","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adenocarcinoma","uri":{"id":"D000230","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Classification","uri":{"id":"D002965","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Data Collection","uri":{"id":"D003625","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Esophagitis","uri":{"id":"D004941","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Metastasis","uri":{"id":"D009362","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"General Surgery","uri":{"id":"D013502","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Incidence","uri":{"id":"D015994","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Esophagus","uri":{"id":"D004947","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Follow-Up Studies","uri":{"id":"D005500","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Retrospective Studies","uri":{"id":"D012189","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Incidence","uri":{"id":"D015994","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival Rate","uri":{"id":"D015996","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Esophagectomy","uri":{"id":"D016629","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Early Detection of Cancer","uri":{"id":"D055088","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Young Adult","uri":{"id":"D055815","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chemoradiotherapy","uri":{"id":"D059248","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adenocarcinoma","uri":{"id":"D000230","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Bridged Compounds","uri":{"id":"D001952","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Combined Modality Therapy","uri":{"id":"D003131","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Esophageal Neoplasms","uri":{"id":"D004938","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Fluorouracil","uri":{"id":"D005472","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Platinum Compounds","uri":{"id":"D017671","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dose Fractionation","uri":{"id":"D019583","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Taxoids","uri":{"id":"D043823","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adenocarcinoma","Adult","Aged","Brain Neoplasms","Bridged Compounds","Chemoradiotherapy","Combined Modality Therapy","Dose Fractionation","Early Detection of Cancer","Esophageal Neoplasms","Esophagectomy","Female","Fluorouracil","Follow-Up Studies","Humans","Incidence","Male","Middle Aged","Platinum Compounds","Retrospective Studies","Survival Rate","Taxoids","Young Adult"]},"pmid":"24051869","title":"Incidence of brain metastases after trimodality therapy in patients with esophageal or gastroesophageal cancer: implications for screening and surveillance.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Limited information is available to assist in the ante-mortem prediction of tumor type and grade for dogs with primary brain tumors. The objective of the current study was to identify magnetic resonance imaging (MRI) criteria related to the histopathological type and grade of gliomas in dogs. A convenience sample utilizing client-owned dogs (n=31) with gliomas was used. Medical records of dogs with intracranial lesions admitted to two veterinary referral hospitals were reviewed and cases with a complete brain MRI and definitive histopathological diagnosis were retrieved for analysis. Each MRI was independently interpreted by five investigators who were provided with standardized grading instructions and remained blinded to the histopathological diagnosis. Mild to no contrast enhancement, an absence of cystic structures (single or multiple), and a tumor location other than the thalamo-capsular region were independently associated with grade II tumors compared to higher grade tumors. In comparison to oligodendrogliomas, astrocytomas were independently associated with the presence of moderate to extensive peri-tumoral edema, a lack of ventricular distortion, and an isointense or hyper-intense T1W-signal. When clinical and MRI features indicate that a glioma is most likely, certain MRI criteria can be used to inform the level of suspicion for low tumor grade, particularly poor contrast enhancement. Information obtained from the MRI of such dogs can also assist in predicting an astrocytoma or an oligodendroglioma, but no single imaging characteristic allows for a particular tumor type to be ruled out.","fulltextAvailable":false,"journal":"Veterinary journal (London, England : 1997)","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals, Animal","uri":{"id":"D006762","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Magnetic Resonance Imaging","uri":{"id":"D008279","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medical Records","uri":{"id":"D008499","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Magnetic Resonance Spectroscopy","uri":{"id":"D009682","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Referral and Consultation","uri":{"id":"D012017","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Grading","uri":{"id":"D060787","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Edema","uri":{"id":"D004487","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitalization","uri":{"id":"D006760","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals","uri":{"id":"D006761","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oligodendroglioma","uri":{"id":"D009837","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Referral and Consultation","uri":{"id":"D012017","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Astrocytoma","uri":{"id":"D001254","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Personnel","uri":{"id":"D012108","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Magnetic Resonance Imaging","uri":{"id":"D008279","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dog Diseases","uri":{"id":"D004283","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dogs","uri":{"id":"D004285","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Grading","uri":{"id":"D060787","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Animals","Brain Neoplasms","Dog Diseases","Dogs","Female","Glioma","Magnetic Resonance Imaging","Male","Neoplasm Grading"]},"pmid":"24051197","title":"Canine intracranial gliomas: relationship between magnetic resonance imaging criteria and tumor type and grade.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: Recent studies have highlighted the heterogeneity of gliomas and demonstrated that molecular and genetic analysis could help in their classification and in the design of treatment protocols. In a previous study we have identified a 4-gene signature highly correlated with survival of glioma patients. The aim of this study is to confirm and extend these findings by investigating the expression of these genes at the protein level and their association with outcome of patients with high grade gliomas. METHODOLOGY/PRINCIPAL FINDINGS: Immunohistochemical staining for EDN/RB, HJURP, p60/CAF-1 and PDLI4 was studied on archive materials from 96 patients (64 glioblastomas and 32 grade III gliomas). The levels of all four proteins differed significantly between grade III and grade IV tumours. The levels of the EDN/RB, HJURP and p60/CAF-1 proteins were strongly associated with overall survival (p<0.001, p<0.001 and p=0.002, respectively), whereas the one of PDLI4 was not (P=0.11). A risk criterion defined as high levels of at least two of the EDN/RB, HJURP and p60/CAF-1 proteins accurately predicted the prognosis of patients. Multivariate analysis confirmed that this criterion was an independent negative prognostic marker (hazard ratio = 2.225; 95% CI, 1.248 to 3.966, p=0.007). CONCLUSIONS: The expression of the EDN/RB, HJURP, p60/CAF-1 and PDLI4 proteins is disrupted in high grade gliomas and increases in the levels of these proteins are closely linked to tumour aggressiveness and poor outcome.","fulltextAvailable":false,"journal":"PloS one","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Molecular Biology","uri":{"id":"D008967","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Multivariate Analysis","uri":{"id":"D015999","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Clinical Protocols","uri":{"id":"D002985","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Classification","uri":{"id":"D002965","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes","uri":{"id":"D005796","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Population Characteristics","uri":{"id":"D011154","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteins","uri":{"id":"D011506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Archives","uri":{"id":"D001109","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain","uri":{"id":"D001921","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunohistochemistry","uri":{"id":"D007150","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Staging","uri":{"id":"D009367","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tumor Markers, Biological","uri":{"id":"D014408","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Expression Regulation, Neoplastic","uri":{"id":"D015972","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"DNA-Binding Proteins","uri":{"id":"D004268","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Receptors, Endothelin","uri":{"id":"D017466","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chromatin Assembly Factor-1","uri":{"id":"D056504","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"LIM Domain Proteins","uri":{"id":"D060588","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Brain","Brain Neoplasms","Chromatin Assembly Factor-1","DNA-Binding Proteins","Gene Expression Regulation, Neoplastic","Glioblastoma","Glioma","Humans","Immunohistochemistry","LIM Domain Proteins","Neoplasm Staging","Prognosis","Receptors, Endothelin","Tumor Markers, Biological"]},"pmid":"24039914","title":"Prognostic significance of EDN/RB, HJURP, p60/CAF-1 and PDLI4, four new markers in high-grade gliomas.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"The unfolded protein response (UPR) is an endoplasmic reticulum (ER)-based cytoprotective mechanism acting to prevent pathologies accompanying protein aggregation. It is frequently active in tumors, but relatively unstudied in gliomas. We hypothesized that UPR stress effects on glioma cells might protect tumors from additional exogenous stress (ie, chemotherapeutics), postulating that protection was concurrent with altered tumor cell metabolism. Using human brain tumor cell lines, xenograft tumors, human samples and gene expression databases, we determined molecular features of glioma cell UPR induction/activation, and here report a detailed analysis of UPR transcriptional/translational/metabolic responses. Immunohistochemistry, Western and Northern blots identified elevated levels of UPR transcription factors and downstream ER chaperone targets in gliomas. Microarray profiling revealed distinct regulation of stress responses between xenograft tumors and parent cell lines, with gene ontology and network analyses linking gene expression to cell survival and metabolic processes. Human glioma samples were examined for levels of the ER chaperone GRP94 by immunohistochemistry and for other UPR components by Western blotting. Gene and protein expression data from patient gliomas correlated poor patient prognoses with increased expression of ER chaperones, UPR target genes, and metabolic enzymes (glycolysis and lipogenesis). NMR-based metabolomic studies revealed increased metabolic outputs in glucose uptake with elevated glycolytic activity as well as increased phospholipid turnover. Elevated levels of amino acids, antioxidants, and cholesterol were also evident upon UPR stress; in particular, recurrent tumors had overall higher lipid outputs and elevated specific UPR arms. Clonogenicity studies following temozolomide treatment of stressed or unstressed cells demonstrated UPR-induced chemoresistance. Our data characterize the UPR in glioma cells and human tumors, and link the UPR to chemoresistance possibly via enhanced metabolism. Given the role of the UPR in the balance between cell survival and apoptosis, targeting the UPR and/or controlling metabolic activity may prove beneficial for malignant glioma therapeutics.","fulltextAvailable":false,"journal":"PloS one","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Line, Tumor","uri":{"id":"D045744","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Amino Acids","uri":{"id":"D000596","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Line","uri":{"id":"D002460","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Survival","uri":{"id":"D002470","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Endoplasmic Reticulum","uri":{"id":"D004721","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Transcription Factors","uri":{"id":"D014157","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Expression","uri":{"id":"D015870","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Targeting","uri":{"id":"D018390","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biotransformation","uri":{"id":"D001711","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Metabolism","uri":{"id":"D008660","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteins","uri":{"id":"D011506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blotting, Northern","uri":{"id":"D015152","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blotting, Western","uri":{"id":"D015153","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Line, Tumor","uri":{"id":"D045744","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Unfolded Protein Response","uri":{"id":"D056811","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Protein Unfolding","uri":{"id":"D058767","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Ontology","uri":{"id":"D063990","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antioxidants","uri":{"id":"D000975","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cholesterol","uri":{"id":"D002784","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drive","uri":{"id":"D004328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Enzymes","uri":{"id":"D004798","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes","uri":{"id":"D005796","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glucose","uri":{"id":"D005947","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunohistochemistry","uri":{"id":"D007150","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lipids","uri":{"id":"D008055","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Metabolism","uri":{"id":"D008660","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Parents","uri":{"id":"D010290","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pathology","uri":{"id":"D010336","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phospholipids","uri":{"id":"D010743","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteins","uri":{"id":"D011506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Recurrence","uri":{"id":"D012008","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Transcription Factors","uri":{"id":"D014157","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Transplantation, Heterologous","uri":{"id":"D014183","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Apoptosis","uri":{"id":"D017209","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Metabolomics","uri":{"id":"D055432","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Metabolome","uri":{"id":"D055442","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Heterografts","uri":{"id":"D064593","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glycolysis","uri":{"id":"D006019","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lipogenesis","uri":{"id":"D050155","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Disease Models, Animal","uri":{"id":"D004195","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RNA, Messenger","uri":{"id":"D012333","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Transcription, Genetic","uri":{"id":"D014158","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Signal Transduction","uri":{"id":"D015398","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Expression Regulation, Neoplastic","uri":{"id":"D015972","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Resistance, Neoplasm","uri":{"id":"D019008","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Xenograft Model Antitumor Assays","uri":{"id":"D023041","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Line, Tumor","uri":{"id":"D045744","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice","uri":{"id":"D051379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dacarbazine","uri":{"id":"D003606","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Transcription Factors","uri":{"id":"D014157","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Molecular Chaperones","uri":{"id":"D018832","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antineoplastic Agents, Alkylating","uri":{"id":"D018906","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lipogenesis","uri":{"id":"D050155","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Regulatory Networks","uri":{"id":"D053263","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Unfolded Protein Response","uri":{"id":"D056811","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Endoplasmic Reticulum Stress","uri":{"id":"D059865","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Grading","uri":{"id":"D060787","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Animals","Antineoplastic Agents, Alkylating","Cell Line, Tumor","Dacarbazine","Disease Models, Animal","Drug Resistance, Neoplasm","Endoplasmic Reticulum Stress","Gene Expression Regulation, Neoplastic","Gene Regulatory Networks","Glioma","Humans","Lipogenesis","Mice","Molecular Chaperones","Neoplasm Grading","Prognosis","RNA, Messenger","Signal Transduction","Transcription Factors","Transcription, Genetic","Unfolded Protein Response","Xenograft Model Antitumor Assays"]},"pmid":"24039668","title":"Induction of the unfolded protein response drives enhanced metabolism and chemoresistance in glioma cells.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Recent studies suggest that the regulatory networks controlling the functions of stem cells during development may be abnormally active in human cancers. An embryonic stem cell (ESC) gene signature was found to correlate with a more undifferentiated phenotype of several human cancer types including gliomas, and associated with poor prognosis in breast cancer. In the present study, we used tissue microarrays of 80 low-grade (WHO Grade II) and 98 high-grade human gliomas (WHO Grades III and IV) to investigate the presence of the ESC-related proteins Nanog, Klf4, Oct4, Sox2 and c-Myc by immunohistochemistry. While similar patterns of co-expressed proteins between low- and high-grade gliomas were present, we found up-regulated protein levels of Nanog, Klf4, Oct4 and Sox2 in high-grade gliomas. Survival analysis by Kaplan-Meier analysis revealed a significant shorter survival in the subgroups of low-grade astrocytomas (n = 42) with high levels of Nanog protein (p = 0.0067) and of Klf4 protein (p = 0.0368), in high-grade astrocytomas (n = 85) with high levels of Nanog (p = 0.0042), Klf4 (p = 0.0447), and c-Myc (p = 0.0078) and in glioblastomas only (n = 71) with high levels of Nanog (p = 0.0422) and of c-Myc (p = 0.0256). In the multivariate model, Nanog was identified as an independent prognostic factor in the subgroups of low-grade astrocytomas (p = 0.0039), high-grade astrocytomas (p = 0.0124) and glioblastomas only (p = 0.0544), together with established clinical variables in these tumors. These findings provide further evidence for the joint regulatory pathways of ESC-related proteins in gliomas and identify Nanog as one of the key players in determining clinical outcome of human astrocytomas.","fulltextAvailable":false,"journal":"International journal of cancer. Journal international du cancer","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes, vif","uri":{"id":"D016341","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cardiomyopathy, Dilated","uri":{"id":"D002311","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Codon, Nonsense","uri":{"id":"D018389","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genetic Predisposition to Disease","uri":{"id":"D020022","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sampling Studies","uri":{"id":"D012494","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes, vif","uri":{"id":"D016341","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Frameshift Mutation","uri":{"id":"D016368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Troponin T","uri":{"id":"D020107","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lamin Type A","uri":{"id":"D034904","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Alleles","uri":{"id":"D000483","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Classification","uri":{"id":"D002965","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dilatation","uri":{"id":"D004106","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes","uri":{"id":"D005796","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ischemia","uri":{"id":"D007511","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mutation","uri":{"id":"D009154","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cardiomyopathies","uri":{"id":"D009202","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Population Characteristics","uri":{"id":"D011154","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Publishing","uri":{"id":"D011643","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Causality","uri":{"id":"D015984","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Alcoholism","uri":{"id":"D000437","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hypothyroidism","uri":{"id":"D007037","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Systole","uri":{"id":"D013599","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Troponin","uri":{"id":"D014336","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lamins","uri":{"id":"D034882","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged, 80 and over","uri":{"id":"D000369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Calcium-Binding Proteins","uri":{"id":"D002135","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cardiomyopathy, Dilated","uri":{"id":"D002311","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"DNA Mutational Analysis","uri":{"id":"D004252","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Frequency","uri":{"id":"D005787","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genetic Testing","uri":{"id":"D005820","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Case-Control Studies","uri":{"id":"D016022","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genetic Predisposition to Disease","uri":{"id":"D020022","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genetic Association Studies","uri":{"id":"D056726","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Promoter Regions, Genetic","uri":{"id":"D011401","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Quebec","uri":{"id":"D011792","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Frameshift Mutation","uri":{"id":"D016368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Codon, Nonsense","uri":{"id":"D018389","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Troponin T","uri":{"id":"D020107","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lamin Type A","uri":{"id":"D034904","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Exome","uri":{"id":"D059472","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Connectin","uri":{"id":"D064211","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adult","Aged","Aged, 80 and over","Astrocytoma","Brain Neoplasms","Embryonic Stem Cells","Female","Homeodomain Proteins","Humans","Immunohistochemistry","Isocitrate Dehydrogenase","Kruppel-Like Transcription Factors","Male","Middle Aged","Proto-Oncogene Proteins c-myc","Tissue Array Analysis"]},"pmid":"24037901","title":"A study of embryonic stem cell-related proteins in human astrocytomas: identification of Nanog as a predictor of survival.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVE: Increased amino acid transport in brain tumours is used for diagnostic purposes. It has been shown that the α-emitting radionuclide astatine-211 labeled to L-phenylalanine is taken up by glioblastoma cells. We here tested, if systemic treatment with 4-[211At]astatine-phenylalanine (At-Phe) has a beneficial effect on survival of rats with intracranial glioblastoma. ANIMALS, METHODS: The rat glioblastoma cell line BT4Ca was implanted into the prefrontal cortex of female BDIX rats by stereotaxic microinjection (10,000 cells/3 µl; n = 83). 3 days after implantation At-Phe or phosphate buffered saline were injected intravenously. A third group was treated twice, i.e., on day 3 and 10. Health condition was assessed each day by using a score system. Rats were sacrificed on days 6, 10, 13 and 17 after implantation, or when showing premortal health condition to measure tumour volume and necrosis. The proliferation index (PI) was assessed after immunohistochemical staining of Ki-67. RESULTS: Survival time of rats treated twice with At-Phe was significantly prolonged. Additionally, both At-Phe-treated groups remained significantly longer in a better health condition. Rats with poor health status had larger tumours than rats with fair health condition. Overall, irrespective of treatment the PI was reduced in rats with poor health condition. Necrosis was larger in rats treated twice with At-Phe. CONCLUSION: Intravenous treatment with At-Phe enhanced survival time of rats with intracranial glioblastomas and improved health condition. These results encourage studies using local treatment of intracranial glioblastoma with At-Phe, either by repeated local injection or by intracavital application after tumour resection.","fulltextAvailable":false,"journal":"Nuklearmedizin. Nuclear medicine","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Amino Acids","uri":{"id":"D000596","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Line","uri":{"id":"D002460","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Health Status","uri":{"id":"D006304","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Health Fairs","uri":{"id":"D006277","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prefrontal Cortex","uri":{"id":"D017397","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Amino Acid Transport Systems","uri":{"id":"D026905","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Abstracting and Indexing as Topic","uri":{"id":"D000043","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Necrosis","uri":{"id":"D009336","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phosphates","uri":{"id":"D010710","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Salinity","uri":{"id":"D054712","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Injections","uri":{"id":"D007267","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microinjections","uri":{"id":"D008845","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phenylalanine","uri":{"id":"D010649","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radioisotopes","uri":{"id":"D011868","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival Rate","uri":{"id":"D015996","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Treatment Outcome","uri":{"id":"D016896","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Line, Tumor","uri":{"id":"D045744","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rats","uri":{"id":"D051381","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Astatine","uri":{"id":"D001246","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brachytherapy","uri":{"id":"D001918","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dose-Response Relationship, Radiation","uri":{"id":"D004307","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phenylalanine","uri":{"id":"D010649","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiopharmaceuticals","uri":{"id":"D019275","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Animals","Astatine","Brachytherapy","Brain Neoplasms","Cell Line, Tumor","Dose-Response Relationship, Radiation","Female","Glioblastoma","Phenylalanine","Radiopharmaceuticals","Rats","Survival Rate","Treatment Outcome"]},"pmid":"24036694","title":"Systemic treatment with 4-211Atphenylalanine enhances survival of rats with intracranial glioblastoma.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Combined deletion of chromosomes 1p and 19q is a prognostic marker in oligodendroglial tumors. Recent studies in oligodendroglial tumors have unveiled recurrent mutations of CIC (homolog of Drosophila capicua) and FUBP1 (far upstream element binding protein 1) that are located on 19q13 and 1p31, respectively. However, the impact of CIC and FUBP1 mutations on their protein expressions has not been examined. The aims of this study were to correlate the expression patterns of CIC and FUBP1 with their mutation profiles and to evaluate the clinical relevance of these molecular markers in 55 oligodendroglial tumors diagnosed in 47 adult patients. Using direct sequencing, somatic mutations of CIC and FUBP1 were identified in 47% (22/47) and 16% (7/45) of oligodendroglial tumors, respectively. Immunohistochemical analysis revealed loss of CIC or FUBP1 protein expression in 36% (20/55) and 16% (9/55) of oligodendroglial tumors examined. Somatic mutation was significantly associated with absent protein expression for both genes (CIC, P=0.01; FUBP1, P=0.00001). Four tumors with undetectable CIC mutations exhibited absent CIC expression, suggesting that CIC inactivation could be mediated by mechanisms other than mutations and genomic loss. Univariate survival analysis revealed that 1p/19q codeletion was significantly associated with overall survival (P=0.05). Loss of CIC expression was significantly correlated with shorter progression-free survival (P=0.03), whereas CIC alteration (mutation or null expression) with worse overall survival (P=0.05). Absent FUBP1 expression was linked with unfavorable progression-free survival (P=0.02) and overall survival (P=0.01). In 16 tumors with 1p/19q codeletion, CIC mutation was associated with unfavorable survival (P=0.01). There was a correlation between lack of CIC or FUBP1 expression and poor progression-free survival (P=0.004; P=0.0003). No molecular markers showed association with survival in oligodendroglial tumors lacking 1p/19q codeletion. We conclude that absent CIC and FUBP1 expressions are potential markers of shorter time to recurrence and CIC mutation a potential marker of worse prognosis, especially in tumors carrying 1p/19q codeletion.","fulltextAvailable":false,"journal":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Multivariate Analysis","uri":{"id":"D015999","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nevi and Melanomas","uri":{"id":"D018326","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Multivariate Analysis","uri":{"id":"D015999","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival Analysis","uri":{"id":"D016019","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Intermediate Filaments","uri":{"id":"D007382","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunohistochemistry","uri":{"id":"D007150","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Melanocytes","uri":{"id":"D008544","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Melanoma","uri":{"id":"D008545","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Necrosis","uri":{"id":"D009336","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Metastasis","uri":{"id":"D009362","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nevus","uri":{"id":"D009506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissues","uri":{"id":"D014024","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ulcer","uri":{"id":"D014456","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nestin","uri":{"id":"D064231","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunohistochemistry","uri":{"id":"D007150","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Melanoma","uri":{"id":"D008545","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Skin Neoplasms","uri":{"id":"D012878","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tumor Markers, Biological","uri":{"id":"D014408","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissue Array Analysis","uri":{"id":"D046888","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Kaplan-Meier Estimate","uri":{"id":"D053208","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nestin","uri":{"id":"D064231","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adult","Brain Neoplasms","Chromosomes, Human, Pair 1","Chromosomes, Human, Pair 19","DNA Helicases","DNA Mutational Analysis","DNA-Binding Proteins","Disease-Free Survival","Female","Gene Expression Regulation, Neoplastic","Humans","Immunohistochemistry","In Situ Hybridization, Fluorescence","Kaplan-Meier Estimate","Male","Middle Aged","Mutation","Neoplasm Recurrence, Local","Oligodendroglioma","Prognosis","Proportional Hazards Models","Repressor Proteins","Tumor Markers, Biological"]},"pmid":"24030748","title":"Loss of CIC and FUBP1 expressions are potential markers of shorter time to recurrence in oligodendroglial tumors.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Brain metastases are common in patients with cancer and are associated with a poor prognosis. Optimal treatment requires an integrative multidisciplinary approach, and therapeutic options may include stereotactic radiosurgery, whole-brain radiation therapy, surgical resection, chemotherapy, and targeted agents. The goals of therapy are to prolong survival, preserve neurologic function, and palliate symptoms. This article outlines the various therapeutic modalities, factors that guide treatment decisions, and medical management of frequently encountered complications of brain metastases.","fulltextAvailable":false,"journal":"Journal of the National Comprehensive Cancer Network : JNCCN","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiosurgery","uri":{"id":"D016634","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Therapy","uri":{"id":"D004358","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Metastasis","uri":{"id":"D009362","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiation","uri":{"id":"D011827","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Complicity","uri":{"id":"D028661","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiosurgery","uri":{"id":"D016634","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Combined Modality Therapy","uri":{"id":"D003131","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiotherapy","uri":{"id":"D011878","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiosurgery","uri":{"id":"D016634","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Brain Neoplasms","Combined Modality Therapy","Humans","Radiosurgery","Radiotherapy"]},"pmid":"24029127","title":"Clinical discussion and review of the management of brain metastases.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: Intraoperative ultrasound for intracranial neurosurgery was largely abandoned in the 1980s due to poor image resolution. Despite many technological advances in ultrasound since then, the use of this imaging modality in contemporary practice remains limited. Our aim was to evaluate the utility of modern intraoperative ultrasound in the resection of a wide variety of intracranial pathologies. METHODS: A total of 105 patients who underwent intracranial lesion resection in a contiguous fashion were prospectively included in the study. Ultrasound images acquired intraoperatively were used to stratify lesions into one of four grades (grades 0-3) on the basis of their ultrasonic echogenicity and border visibility. RESULTS: Forty-two out of 105 lesions (40 %) were clearly identifiable and had a clear border with normal tissue (grade 3). Fifty-five of 105 lesions (52 %) were clearly identifiable but had no clear border with normal tissue (grade 2). Eight of 105 lesions (8 %) were difficult to identify and had no clear border with normal tissue (grade 1). None (0 %) of the lesions could not be identified (grade 0). High-grade gliomas, cerebral metastases, meningiomas, ependymomas, and haemangioblastomas all demonstrated a median ultrasonic visibility grade of 2 or greater. Low-grade astrocytomas and oligodendrogliomas demonstrated a median ultrasonic visibility grade of 2 or less. CONCLUSION: Intraoperative ultrasound can be of tremendous benefit in allowing the surgeon to appraise the location, extent, and local environment of their target lesion, as well as to reduce the risk of preventable complications. We believe that our grading system will provide a useful adjunct to the neurosurgeon when deciding for which lesions intraoperative ultrasound would be useful.","fulltextAvailable":false,"journal":"Acta neurochirurgica","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ultrasonography","uri":{"id":"D014463","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Environment","uri":{"id":"D004777","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Meningioma","uri":{"id":"D008579","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Metastasis","uri":{"id":"D009362","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oligodendroglioma","uri":{"id":"D009837","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pathology","uri":{"id":"D010336","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissues","uri":{"id":"D014024","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Complicity","uri":{"id":"D028661","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Astrocytoma","uri":{"id":"D001254","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ependymoma","uri":{"id":"D004806","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neurosurgery","uri":{"id":"D009493","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ultrasonics","uri":{"id":"D014465","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prospective Studies","uri":{"id":"D011446","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neurosurgical Procedures","uri":{"id":"D019635","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neuronavigation","uri":{"id":"D038361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Grading","uri":{"id":"D060787","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Brain Neoplasms","Glioma","Humans","Neoplasm Grading","Neuronavigation","Neurosurgical Procedures","Prospective Studies"]},"pmid":"24026229","title":"A practical grading system of ultrasonographic visibility for intracerebral lesions.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"RAB38 is a new member of the RAB small G protein family that regulates intracellular vesicle trafficking. RAB38 is expressed in melanocytes and it has been shown that a point mutation in the postulated GTP-binding domain of RAB38 is the gene responsible for human Hermansky-Pudlak syndrome. However, the prognostic and molecular features of tumors with RAB38 expression is still unclear, as well as glioma. Whole genome mRNA expression microarray data on 220 glioma samples from the Chinese glioma genome atlas (CGGA) database (http://www.cgga.org.cn) was applied as discovery set. Each grade of glioma patients was analyzed by the Kaplan-Meier method. To determine the protein expression levels of RAB38, further 82 glioma tissues were stained by immunohistochemistry. Three additional datasets (TCGA, GSE16011 and Rembrandt) were obtained as validation sets. The functional annotation of RAB38 was analyzed by Gene ontology (GO) analysis and Gene set variation analysis (GSVA) in 89 glioblastomas (GBMs). High RAB38 expression was mainly increased in high-grade gliomas, and high RAB38 expression also conferred high mortality of glioma in the CGGA cohort. RAB38 showed a mesenchymal subtype, G3 subtype and isocitrate dehydrogenase 1 (IDH1) wild-type preference. GO and GSVA analysis showed that RAB38 was significantly correlated with migration. These results were validated in other 3 datasets. The expression levels of RAB38 were significantly associated with grade progression as well as prognosis in gliomas. RAB38 is an important prognostic biomarker and potential therapeutic target in gliomas.","fulltextAvailable":false,"journal":"Oncology reports","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Coloring Agents","uri":{"id":"D004396","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Isocitrate Dehydrogenase","uri":{"id":"D007521","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"GTP-Binding Proteins","uri":{"id":"D019204","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Point Mutation","uri":{"id":"D017354","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Monomeric GTP-Binding Proteins","uri":{"id":"D020559","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hermanski-Pudlak Syndrome","uri":{"id":"D022861","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Ontology","uri":{"id":"D063990","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Emigration and Immigration","uri":{"id":"D004641","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes","uri":{"id":"D005796","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunohistochemistry","uri":{"id":"D007150","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Isocitrates","uri":{"id":"D007523","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Melanocytes","uri":{"id":"D008544","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mesoderm","uri":{"id":"D008648","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mortality","uri":{"id":"D009026","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mutation","uri":{"id":"D009154","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oxidoreductases","uri":{"id":"D010088","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteins","uri":{"id":"D011506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RNA, Messenger","uri":{"id":"D012333","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Syndrome","uri":{"id":"D013577","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissues","uri":{"id":"D014024","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biological Markers","uri":{"id":"D015415","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genome","uri":{"id":"D016678","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genomics","uri":{"id":"D023281","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Asian Continental Ancestry Group","uri":{"id":"D044466","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Movement","uri":{"id":"D002465","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tumor Markers, Biological","uri":{"id":"D014408","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Expression Regulation, Neoplastic","uri":{"id":"D015972","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Disease Progression","uri":{"id":"D018450","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oligonucleotide Array Sequence Analysis","uri":{"id":"D020411","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"rab GTP-Binding Proteins","uri":{"id":"D020691","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hermanski-Pudlak Syndrome","uri":{"id":"D022861","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Kaplan-Meier Estimate","uri":{"id":"D053208","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adult","Brain Neoplasms","Cell Movement","Disease Progression","Female","Gene Expression Regulation, Neoplastic","Glioma","Hermanski-Pudlak Syndrome","Humans","Kaplan-Meier Estimate","Male","Middle Aged","Oligonucleotide Array Sequence Analysis","Prognosis","Tumor Markers, Biological","rab GTP-Binding Proteins"]},"pmid":"24026199","title":"RAB38 confers a poor prognosis, associated with malignant progression and subtype preference in glioma.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: Pancreatic cancer is an aggressive disease which metastasizes readily. The presence of brain metastases from pancreatic cancer is rare and it carries a poor prognosis. Our approach to treating these lesions stresses extensive use of stereotactic radiosurgery (SRS), whereas other reports focus on surgical resection. CASE REPORT: Information regarding the patient's clinical history was extracted from a retrospective review of the medical records and imaging studies. The patient survived seven years after his primary diagnosis of pancreatic cancer, and 36 months after diagnosis of metastatic disease to the brain. In addition to surgical resection and the use of multiple chemotherapeutic agents, the patient received six separate radiosurgery treatments. CONCLUSION: We present a case of brain metastasis from pancreatic cancer that is remarkable for an unusually long survivorship and discuss the utility of SRS along with a multimodality treatment approach for dealing with these cases.","fulltextAvailable":false,"journal":"Anticancer research","meshAnnotations":{"@type":"java.util.ArrayList"},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adenocarcinoma","Aged","Antineoplastic Combined Chemotherapy Protocols","Brain Neoplasms","Humans","Liver Neoplasms","Magnetic Resonance Imaging","Male","Pancreatic Neoplasms","Radiosurgery","Survival Analysis"]},"pmid":"24023326","title":"Stereotactic radiosurgery plays a critical role in enhancing long-term survival in a patient with pancreatic cancer metastatic to the brain.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Large cell neuroendocrine carcinoma (LCNEC) has an especially poor prognosis, and an effective therapeutic strategy has yet to be established. We have previously shown that the expressions of tropomyosin-related kinase B (TRKB) and brain-derived neurotrophic factor (BDNF) are high in LCNEC and that TRKB/BDNF signaling is involved in the proliferation, tumorigenesis, and invasive nature of LCNEC. Therefore, TRKB/BDNF signaling may offer a potential therapeutic target for LCNEC treatment. In the present study, we evaluated whether the TRKB tyrosine kinase inhibitor, k252a, has effects on tumor regression and relapse prevention on LCNEC, using a murine xenograft model. The LCNEC cell line and NCI-H810 cells were subcutaneously implanted into the flanks or intrathoracically injected into the bilateral pleural cavities of BALB/c nude mice. k252a significantly inhibited tumor volume, expression of matrix metalloproteinases and the formation of pleural dissemination by LCNEC. These results suggest that k252a has potential for tumor regression and relapse prevention in LCNEC. Since many patients with LCNEC suffer through the use of ineffective therapeutic strategies, a clinical trial using the TRKB inhibitor for LCNEC is urgently required.","fulltextAvailable":false,"journal":"Anticancer research","meshAnnotations":{"@type":"java.util.ArrayList"},"meshHeading":{"@type":"java.util.ArrayList","@items":["Animals","Brain-Derived Neurotrophic Factor","Carbazoles","Carcinoma, Large Cell","Carcinoma, Neuroendocrine","Cell Line, Tumor","Female","Humans","Indole Alkaloids","Lung Neoplasms","Male","Mice","Mice, Inbred BALB C","Protein Kinase Inhibitors","Protein Kinases","Recurrence"]},"pmid":"24023298","title":"Tropomyosin-related kinase B inhibitor has potential for tumor regression and relapse prevention in pulmonary large cell neuroendocrine carcinoma.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Anaplastic lymphoma kinase (ALK) rearranged non-small-cell lung cancer (NSCLC) is highly responsive to crizotinib, an oral ATP-competitive selective inhibitor of ALK. However, crizotinib exhibits extremely poor blood-brain barrier penetration; therefore, it is considered to play a limited role in the treatment of brain metastases. We present a case of a 50-year-old man with a diagnosis of ALK-rearranged NSCLC with brain metastasis and malignant pleural effusion. Despite the several systemic chemotherapy regimens and whole brain radiotherapy, brain metastasis was refractory; therefore, crizotinib was initiated. A CT scan showed a slight reduction in the brain metastasis and no change in intrathoracic disease 17 weeks after initiating crizotinib. Moreover, CT obtained 12 months after crizotinib treatment revealed brain metastasis without progression. To our knowledge, the present case is the second report of crizotinib-responsive brain metastases due to echinoderm microtubule-associated protein-like 4-ALK (EML4-ALK)-rearranged NSCLC.","fulltextAvailable":false,"journal":"BMJ case reports","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aftercare","uri":{"id":"D000359","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lung Neoplasms","uri":{"id":"D008175","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blood-Brain Barrier","uri":{"id":"D001812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pleural Effusion","uri":{"id":"D010996","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pleural Effusion, Malignant","uri":{"id":"D016066","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Therapy","uri":{"id":"D004358","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Exhibits as Topic","uri":{"id":"D005085","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lung","uri":{"id":"D008168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lymphoma","uri":{"id":"D008223","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Metastasis","uri":{"id":"D009362","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phosphotransferases","uri":{"id":"D010770","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radiotherapy","uri":{"id":"D011878","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Knowledge","uri":{"id":"D019359","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Penetrance","uri":{"id":"D019683","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Treatment Outcome","uri":{"id":"D016896","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carcinoma, Non-Small-Cell Lung","uri":{"id":"D002289","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lung Neoplasms","uri":{"id":"D008175","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pyrazoles","uri":{"id":"D011720","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pyridines","uri":{"id":"D011725","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oncogene Proteins, Fusion","uri":{"id":"D015514","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Disease-Free Survival","uri":{"id":"D018572","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Receptor Protein-Tyrosine Kinases","uri":{"id":"D020794","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Protein Kinase Inhibitors","uri":{"id":"D047428","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Brain Neoplasms","Carcinoma, Non-Small-Cell Lung","Disease-Free Survival","Humans","Lung Neoplasms","Male","Middle Aged","Oncogene Proteins, Fusion","Protein Kinase Inhibitors","Pyrazoles","Pyridines","Receptor Protein-Tyrosine Kinases","Treatment Outcome"]},"pmid":"24022905","title":"Long-lasting response to crizotinib in brain metastases due to EML4-ALK-rearranged non-small-cell lung cancer.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"PURPOSE: Brain metastases (BM), a common occurrence in non-small cell lung cancer (NSCLC), usually lead to a poor prognosis. Recently, the selection of treatment modalities for BM has modestly improved patient survival and quality of life. Treatment choice is largely based on the number of BM, the presence of BM-related symptoms, and performance status. Therefore, early BM detection is crucial. In this study, we aimed to elucidate the factors associated with BM and identify subgroups of patients at higher risk for BM. METHODS AND PATIENTS: The medical records of 596 consecutive patients with stage I-IV NSCLC were reviewed between January 2006 and November 2011. A multivariate logistic regression (MLR) model was used to identify factors associated with BM. RESULTS: Among 482 eligible stage IIIB/IV NSCLC patients, 173 (36%) experienced BM during their disease course. On MLR analysis, female gender, age < 60 years and adenocarcinoma were associated with BM (OR = 1.71, 95% CI = 1.06-2.75, P = 0.028; OR = 2.11, 95% CI = 1.38-3.22, P = 0.001; and OR = 2.39, 95% CI = 1.16-4.92, P = 0.018, respectively). The actuarial incidence of BM varied widely from 14% to 59% in different subgroups; younger patients with adenocarcinoma tended to experience BM more than older patients with squamous cell carcinoma (OR = 6.88, 95% CI = 2.97-15.94, P < 0.001). Furthermore, the incidence of BM correlated closely with survival after NSCLC diagnosis, and it was 42%, 54% and 64% in patients who survived more than 3, 12 and 24 months, respectively. Notably, the number of BM, the size of the largest BM and the proportion of multiple BM, defined as more than 4 metastatic tumors in brain, were significantly different in NSCLC patients with and without BM-related symptoms or signs (4.0 ± 2.1 vs 2.7 ± 1.9, P < 0.001; 2.6 ± 1.5 vs 1.3 ± 1.0 CM, P < 0.001, and 50% vs 21%, P < 0.001, respectively). CONCLUSION: We found that subgroups of NSCLC patients characterized by younger age, female gender and adenocarcinoma are at higher risks for BM. These findings might be helpful to detect BM earlier and facilitate the design of clinical trials aiming at their prevention.","fulltextAvailable":false,"journal":"Lung cancer (Amsterdam, Netherlands)","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carcinoma, Squamous Cell","uri":{"id":"D002294","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carcinoma, Squamous Cell","uri":{"id":"D002294","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lung Neoplasms","uri":{"id":"D008175","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medical Records","uri":{"id":"D008499","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Quality of Life","uri":{"id":"D011788","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Logistic Models","uri":{"id":"D016015","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patient Selection","uri":{"id":"D018579","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carcinoma, Non-Small-Cell Lung","uri":{"id":"D002289","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Signs and Symptoms","uri":{"id":"D012816","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adenocarcinoma","uri":{"id":"D000230","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carcinoma","uri":{"id":"D002277","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lung","uri":{"id":"D008168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Metastasis","uri":{"id":"D009362","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Organization and Administration","uri":{"id":"D009934","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Incidence","uri":{"id":"D015994","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Life","uri":{"id":"D019369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Age Factors","uri":{"id":"D000367","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Staging","uri":{"id":"D009367","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Risk Factors","uri":{"id":"D012307","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carcinoma, Non-Small-Cell Lung","uri":{"id":"D002289","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lung Neoplasms","uri":{"id":"D008175","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adult","Age Factors","Aged","Brain Neoplasms","Carcinoma, Non-Small-Cell Lung","Female","Humans","Lung Neoplasms","Male","Middle Aged","Neoplasm Staging","Risk Factors"]},"pmid":"24018025","title":"Identification of subgroup patients with stage IIIB/IV non-small cell lung cancer at higher risk for brain metastases.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: Glioblastomas are the most aggressive primary brain tumors in humans. Microglia/brain macrophage accumulation in and around the tumor correlates with malignancy and poor clinical prognosis of these tumors. We have previously shown that microglia promote glioma expansion through upregulation of membrane type 1 matrix metalloprotease (MT1-MMP). This upregulation depends on signaling via the Toll-like receptor (TLR) adaptor molecule myeloid differentiation primary response gene 88 (MyD88). METHODS: Using in vitro, ex vivo, and in vivo techniques, we identified TLR2 as the main TLR controlling microglial MT1-MMP expression and promoting microglia-assisted glioma expansion. RESULTS: The implantation of mouse GL261 glioma cells into TLR2 knockout mice resulted in significantly smaller tumors, reduced MT1-MMP expression, and enhanced survival rates compared with wild-type control mice. Tumor expansion studied in organotypic brain slices depended on both parenchymal TLR2 expression and the presence of microglia. Glioma-derived soluble factors and synthetic TLR2 specific ligands induced MT1-MMP expression in microglia from wild-type mice, but no such change in MT1-MMP gene expression was observed in microglia from TLR2 knockout mice. We also found evidence that TLR1 and TLR6 cofunction with TLR2 as heterodimers in regulating MT1-MMP expression in vitro. CONCLUSIONS: Our results thus show that activation of TLR2 along with TLRs 1 and/or 6 converts microglia into a glioma supportive phenotype.","fulltextAvailable":false,"journal":"Neuro-oncology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Expression","uri":{"id":"D015870","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival Rate","uri":{"id":"D015996","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice, Knockout","uri":{"id":"D018345","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Toll-Like Receptors","uri":{"id":"D051193","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Toll-Like Receptor 2","uri":{"id":"D051195","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes","uri":{"id":"D005796","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ligands","uri":{"id":"D008024","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Macrophages","uri":{"id":"D008264","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Membranes","uri":{"id":"D008566","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phenotype","uri":{"id":"D010641","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Up-Regulation","uri":{"id":"D015854","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice","uri":{"id":"D051379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microglia","uri":{"id":"D017628","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Metalloproteases","uri":{"id":"D045726","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Matrix Metalloproteinase 14","uri":{"id":"D053511","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain","uri":{"id":"D001921","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice, Inbred C57BL","uri":{"id":"D008810","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival Rate","uri":{"id":"D015996","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice, Knockout","uri":{"id":"D018345","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mice","uri":{"id":"D051379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Macrophage Activation","uri":{"id":"D008262","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microglia","uri":{"id":"D017628","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Toll-Like Receptor 1","uri":{"id":"D051194","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Toll-Like Receptor 2","uri":{"id":"D051195","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Toll-Like Receptor 6","uri":{"id":"D051216","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Kaplan-Meier Estimate","uri":{"id":"D053208","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Matrix Metalloproteinase 14","uri":{"id":"D053511","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Animals","Brain","Brain Neoplasms","Female","Glioblastoma","Kaplan-Meier Estimate","Macrophage Activation","Matrix Metalloproteinase 14","Mice","Mice, Inbred C57BL","Mice, Knockout","Microglia","Survival Rate","Toll-Like Receptor 1","Toll-Like Receptor 2","Toll-Like Receptor 6"]},"pmid":"24014382","title":"Toll-like receptor 2 mediates microglia/brain macrophage MT1-MMP expression and glioma expansion.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Astrocytomas are common malignant intracranial tumors that comprise the majority of adult primary central nervous system tumors. MicroRNAs (miRNAs) are small, non-coding RNAs (20-24 nucleotides) that post-transcriptionally modulate gene expression by negatively regulating the stability or translational efficiency of their target mRNAs. In our previous studies, we found that the downregulation of miR-106a-5p in astrocytomas is associated with poor prognosis. However, its specific gene target(s) and underlying functional mechanism(s) in astrocytomas remain unclear. In this study, we used mRNA microarray experiments to measure global mRNA expression in the presence of increased or decreased miR-106a-5p levels. We then performed bioinformatics analysis based on multiple target prediction algorithms to obtain candidate target genes that were further validated by computational predictions, western blot analysis, quantitative real-time PCR, and the luciferase reporter assay. Fas-activated serine/threonine kinase (FASTK) was identified as a direct target of miR-106a-5p. In human astrocytomas, miR-106a-5p is downregulated and negatively associated with clinical staging, whereas FASTK is upregulated and positively associated with advanced clinical stages, at both the protein and mRNA levels. Furthermore, Kaplan-Meier analysis revealed that the reduced expression of miR-106a-5p or the increased expression of FASTK is significantly associated with poor survival outcome. These results further supported the finding that FASTK is a direct target gene of miR-106a-5p. Next, we explored the function of miR-106a-5p and FASTK during astrocytoma progression. Through gain-of-function and loss-of-function studies, we demonstrated that miR-106a-5p can significantly inhibit cell proliferation and migration and can promote cell apoptosis in vitro. The knockdown of FASTK induced similar effects on astrocytoma cells as those induced by the overexpression of miR-106a-5p. These observations suggest that miR-106a-5p functions as a tumor suppressor during the development of astrocytomas by targeting FASTK.","fulltextAvailable":false,"journal":"PloS one","meshAnnotations":{"@type":"java.util.ArrayList"},"meshHeading":{"@type":"java.util.ArrayList","@items":["3' Untranslated Regions","Apoptosis","Astrocytoma","Base Sequence","Binding Sites","Brain Neoplasms","Cell Line, Tumor","Cell Movement","Cell Proliferation","Cell Survival","Female","Gene Expression Regulation, Neoplastic","Genes, Tumor Suppressor","Humans","Kaplan-Meier Estimate","Male","MicroRNAs","Middle Aged","Oligonucleotide Array Sequence Analysis","Protein-Serine-Threonine Kinases","RNA Interference","Transcriptome"]},"pmid":"24013584","title":"miR-106a-5p inhibits the proliferation and migration of astrocytoma cells and promotes apoptosis by targeting FASTK.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Glioblastoma (GBM) is the highest-grade glioma in astrocytoma. Patients often have poor prognosis due to therapeutic resistance and tumor recurrence. Identification of the genetic factors of GBM could be important contribution to early prevention of this disease. We genotyped 17 tag single-nucleotide polymorphisms (tSNPs) from nine genes in this study, including 72 cases and 302 controls. SNP genotyping was conducted using Sequenom MassARRAY RS1000. Statistical analysis of the association between tSNPs and GBM was performed using the χ (2) test and SNPStats software. The rs3829382 in FLT3 was associated with increased odds of developing GBM using the χ (2) test. When we analyzed tSNPs under different inheritance models, we found rs9642393 in EGFR increased odds of developing GBM in the dominant model. After stratification by gender, we found that rs12645561 in NEIL3 and rs2291427 in ALOX5 were associated with developing GBM. Polymorphisms within FLT3, EGFR, NEIL3, and ALOX5 may contribute to the occurrence of GBM in the Han Chinese population. However, the functional significance of these polymorphisms needs further investigation.","fulltextAvailable":false,"journal":"Medical oncology (Northwood, London, England)","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes","uri":{"id":"D005796","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genotype","uri":{"id":"D005838","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Recurrence","uri":{"id":"D012008","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Software","uri":{"id":"D012984","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Wills","uri":{"id":"D014918","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Asian Continental Ancestry Group","uri":{"id":"D044466","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Astrocytoma","uri":{"id":"D001254","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genotype","uri":{"id":"D005838","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genetic Predisposition to Disease","uri":{"id":"D020022","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Polymorphism, Single Nucleotide","uri":{"id":"D020641","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Asian Continental Ancestry Group","uri":{"id":"D044466","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arachidonate 5-Lipoxygenase","uri":{"id":"D001094","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioblastoma","uri":{"id":"D005909","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"N-Glycosyl Hydrolases","uri":{"id":"D009699","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Receptor, Epidermal Growth Factor","uri":{"id":"D011958","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"fms-Like Tyrosine Kinase 3","uri":{"id":"D051941","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adult","Arachidonate 5-Lipoxygenase","Asian Continental Ancestry Group","Brain Neoplasms","Female","Genetic Predisposition to Disease","Genotype","Glioblastoma","Humans","Male","Middle Aged","N-Glycosyl Hydrolases","Polymorphism, Single Nucleotide","Receptor, Epidermal Growth Factor","fms-Like Tyrosine Kinase 3"]},"pmid":"24005813","title":"Association of polymorphisms in FLT3, EGFR, ALOX5, and NEIL3 with glioblastoma in the Han Chinese population.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"The pathological grading system for human gliomas is usually used to evaluate the prognosis of glioma patients. However, some glioma patients with similar grades have obvious discrepancies in survival. It is therefore necessary to identify some new certain tumor biomarkers that are more suitable for the prognostic assessment of gliomas than the grading system. The 58-kD microspherule protein (MSP58) is an evolutionarily conserved nuclear protein and plays an important role in the regulation of cell proliferation and malignant transformation. However, whether MSP58 can be used as a biomarker to evaluate the malignancy and the prognosis of glioma patients is unknown. In the present study, we performed immunohistochemical analysis to evaluate MSP58 protein expression in 158 specimens of human gliomas and 34 normal control brain tissues. Compared with the control tissues, MSP58 expression was not only significantly higher in the glioma tissues (P < 0.05), but also increased with the increasing pathological grade (P < 0.001). Furthermore, the Kaplan-Meier analysis showed that high expression of MSP58 could predict poor survival in glioma patients (P < 0.001). In the multivariate analysis, high expression of MSP58 was also an independent unfavorable prognostic factor for the overall survival in glioma patients (P < 0.001, hazard ratio, 8.177, 95% CI 2.571-26.008). In conclusion, the increased expression of MSP58 is correlated with a higher malignant grade and poor prognosis in glioma patients. MSP58 is valuable both as an indicator of the malignancy of gliomas and as a prognostic factor for the clinical outcome of glioma patients.","fulltextAvailable":false,"journal":"Medical oncology (Northwood, London, England)","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Multivariate Analysis","uri":{"id":"D015999","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Proliferation","uri":{"id":"D049109","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nuclear Proteins","uri":{"id":"D009687","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Kaplan-Meier Estimate","uri":{"id":"D053208","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteins","uri":{"id":"D011506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Survival","uri":{"id":"D013534","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissues","uri":{"id":"D014024","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biological Markers","uri":{"id":"D015415","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Neoplasms","uri":{"id":"D001932","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nuclear Proteins","uri":{"id":"D009687","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prognosis","uri":{"id":"D011379","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tumor Markers, Biological","uri":{"id":"D014408","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Multivariate Analysis","uri":{"id":"D015999","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glioma","uri":{"id":"D005910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"RNA-Binding Proteins","uri":{"id":"D016601","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Kaplan-Meier Estimate","uri":{"id":"D053208","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Brain Neoplasms","Female","Glioma","Humans","Kaplan-Meier Estimate","Male","Middle Aged","Multivariate Analysis","Nuclear Proteins","Prognosis","RNA-Binding Proteins","Tumor Markers, Biological"]},"pmid":"23996240","title":"Increased expression of the 58-kD microspherule protein (MSP58) is correlated with poor prognosis in glioma patients.","year":"2013"}